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Sarcomas
Sarcomas are a group of solid malignant tumours of mesenchymal origin. They comprise 
more than 70 histological subtypes[1]; approximately 80% of sarcomas originate in soft 
tissue, the remainder in bone. They have considerable heterogeneity with respect to age 
of onset, anatomic location, speed of progression, and outcome (Figure 1). Together, they 
are a typical example of rare cancers (incidence <6 per 100,000 per year), accounting for 
approximately 1-2% of all malignant neoplasms in adults, with an estimated incidence of 
4-5 per 100.000 per year[2, 3]. However, the incidence of several subtypes is even below 
1 per 100,000/year.
Figure 1: sarcoma subtypes
Adapted from www.news-medical.net
For localised disease, surgery is the standard treatment of all patients with STS[4]. The 
typical wide excision is preceded or followed by radiotherapy in case of high grade, deep, 
or >5cm lesions. Hyperthermic limb perfusion may be an option prior to limb-preserving 
surgery. (Neo-)adjuvant chemotherapy is not standard in adult-type STS but could be 
discussed with patients in case of either marginally resectable tumours or in patients with 
tumours at high-risk of developing distant metastases.
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Treatment of BS differs per subtype. These subtypes have distinct patterns of incidence. 
The most common subtypes are osteosarcoma, Ewing sarcoma, and chondrosarcoma[5]. 
Osteosarcoma and Ewing sarcoma have a higher incidence among adolescents, whereas 
chondrosarcomas are more common in older age[3]. 
Conventional osteosarcomas are always high-grade and metastasise frequently. They are 
curatively treated with extensive (neo-)adjuvant combination chemotherapy in addition 
to surgery[6]. Patients with metastases at diagnosis are treated with curative intent 
following the same principles, but responses are less durable and patients have a worse 
prognosis. 
Ewing sarcomas are high-grade tumours, treated with neo-adjuvant combination 
chemotherapy, followed by local therapy (preferably surgery), and adjuvant 
chemotherapy[6]. Radiotherapy should be considered in cases of inadequate surgical 
margins or poor histological response to neo-adjuvant chemotherapy. Primary 
radiotherapy is applied as local therapy in case of unresectable tumour locations. Patients 
with primary metastases are treated with the same approach. Whole-lung irradiation 
can be considered in patients with lung metastases,  the role of local therapy for other 
metastases is unclear. There is no clear benefit from high dose chemotherapy followed 
autologous stem-cell rescue compared to standard chemotherapy with whole-lung 
irradiation in patients with pulmonary or pleural metastases[7]. 
Most chondrosarcomas are low-grade and can be treated with surgery or radiotherapy[6]. 
High-grade chondrosarcomas should be excised with wide margins, if this cannot be 
achieved with limb salvage, amputation should be considered. Several less common 
subtypes, such as mesenchymal chondrosarcoma, may be more chemotherapy sensitive.
For most patients with secondary metastatic disease, regardless of subtype, curative 
therapy is no longer possible. In general, standard therapy for metastatic STS and BS is 
chemotherapy[4, 6], but in selected cases of oligometastatic disease, local therapy such 
as surgery, radiotherapy or radiofrequency ablation, of metastases can be considered. The 
feasibility and benefit of such treatment depends on the number and site of metastases, 
the interval since primary diagnosis, and complaints caused by the tumour. 
Survival rates of patients with sarcomas vary widely. In the Netherlands, 5-year survival 
rates were 60% for high-grade BS, 93% for low-grade BS, 46% for high-grade STS, and 81% 
for low-grade STS between 2017-2018[8]. There is a large variability across histological 
subtypes: in an American database consisting of 78527 patients with sarcoma, the lowest 
5-year cause specific survival, all grades combined, for STS was found in angiosarcoma 
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(53.8%), and the highest in dermatofibrosarcoma (99.2%)[5]. For BS, 5-year cause specific 
survival was lowest in Ewing sarcoma (64%), and highest in chondrosarcoma (81.9%)[5]. 
Despite efforts to improve survival outcomes of sarcoma patients with novel imaging and 
treatment strategies, only limited progress has been made. Another approach to improve 
outcomes is to improve the diagnostic pathway. Due to the rarity of the disease and the 
heterogenous presentation, the diagnostic pathway may be difficult and prolonged, 
resulting in higher disease stage at diagnosis. This is a common problem among rare 
cancers and unfortunately, sarcoma patients are no exception: 7% of BS and 14% of STS 
patients have metastases at diagnoses, with a large variance among subtypes, e.g. 42% of 
Ewing sarcomas are metastasized at diagnoses[8]. This thesis focusses on the diagnostic 
pathway of sarcoma patients and tries to identify its effect on outcomes and ways for 
improvement.
Diagnosing sarcoma
Previous research has shown that the sarcoma diagnostic pathway is variable and long in 
a high proportion of patients[9]. Its length varies from several weeks to several years, and 
patients can follow different referral routes to diagnosis. 
To understand the diagnostic pathway, it is important to use a standardized framework 
with clear definitions. In this thesis, we will use the model first described by Olesen et 
al[10, 11], which we have adapted to fit the sarcoma diagnostic pathway, as shown in 
Figure 2. The time from first symptom until histological diagnosis, is defined as the total 
interval. This is further divided into a patient and diagnostic interval. The diagnostic 
interval encompasses the primary care, secondary care, and tertiary care interval. A long 
total interval may be caused by several factors. First, diagnosis may be delayed due to 
a prolonged time to presentation by the patient, a time interval known as the patient 
interval. Second, referral by general practitioner to secondary or tertiary care may take 
long due to unfamiliarity with sarcomas and heterogeneity of its symptoms. This time 
interval is known as the primary care interval. Third, the final diagnosis may be delayed due 
to low awareness among non-sarcoma specialists, delays for imaging, biopsy, and biopsy 
reporting, leading to late referral to a sarcoma centre from the secondary care hospital. 
This interval, the secondary care interval, encompasses the time from referral by the GP 
until referral from a secondary care specialist to a sarcoma centre. Fourth, the tertiary care 
interval, the time from referral to a sarcoma centre until definitive (pathological) diagnosis, 
can be long because histological diagnosis can be complex, and histology often needs to 
be reviewed in an expert panel or additional molecular investigations need to be done, 
dependent on the trajectory within the secondary care interval.
14   |   Chapter 1
Figure 2: time intervals in the route from first symptom until diagnosis[9]
Factors contributing to the total interval length
Several factors are thought to influence the total interval length. These can be divided 
into patient factors (e.g. socio-demographic characteristics and co-morbidities), tumour 
factors (e.g. histology and location), and healthcare system factors (e.g. access and referral 
pathways). 
These factors can be different for different sarcoma histologies and age groups. Until 
now, published literature has been mainly retrospective and among small groups of 
patients, generating contradicting results[9]. For sarcoma, it is especially interesting to 
study different age groups as it accounts for about 10% of all invasive cancers among 
adolescents and young adults (AYAs), and only 1-2% of all malignancies among adults[12]. 
Although survival for AYA cancers have paralleled those of childhood cancers since the 
year 2000[13], this improvement is less distinct for sarcomas[14]. The distribution of 
different histologic sarcoma subtypes is linked to age; several “paediatric sarcomas” have 
a (second) peak during adolescence, such as rhabdomyosarcomas, Ewing sarcomas 
and osteosarcomas[15]. Synovial sarcomas have a peak incidence in patients aged 30-
35. The different biological and clinical behaviour of these sarcomas, along with age-
specific characteristics of AYA patients, such as developmental, physical, psychosocial and 
economic issues (e.g. becoming financially independent, infertility issues, care for small 
children), may contribute to different diagnostic pathways of this group as compared to 
older adults. Although the diagnostic pathway and its contributing factors have been 
studied among children, and teenagers and adolescents (aged 15-25), it has not been 
described in detail for patients aged 25-39[16-20].   
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Healthcare system factors have been difficult to study, as there is a lack of studies 
comparing different healthcare systems. In order to improve outcomes, many countries 
have introduced some form of centralization of diagnosis and treatment for patients 
with sarcoma. Patients diagnosed at sarcoma centres and discussed in multidisciplinary 
teams, receive the correct diagnosis and treatment more often than those diagnosed 
elsewhere[21]. In a study among 1463 French and Italian patients diagnosed with sarcoma, 
more than 40% of histological diagnoses were modified by the expert pathologist[21]. 
The major discrepancies were related to histological grade, type, and subtype. A 
second study, including 12528 STS patients compared those who were presented in a 
multidisciplinary meeting before and after initiation of treatment[22]. The former group 
had worse prognostic characteristics, but there was a better compliance to clinical 
guidelines, resulting in better relapse-free survival than those who were presented in 
the multidisciplinary team after treatment initiation. The same study group has shown 
that sarcoma patients receiving their surgical treatment in a sarcoma centre, have better 
overall survival than those operated on in non-reference centres[23]. 
Until now, there is no published data in which diagnostic pathways of two or more 
healthcare systems have been directly compared. It would be ideal to study comparable 
healthcare systems with differences in organization of sarcoma care. This would contribute 
to identification of healthcare system factors influencing total interval length specifically 
for sarcoma care, as well as identify cultural and geographical factors which may influence 
total interval length. 
Effect of total interval length on outcomes for sarcoma 
patients
The cumulative effect of events leading to delays in each interval component, may 
jeopardize outcome and prognosis[24]. In several cancers there is an association between 
shorter times to diagnosis and more favourable outcomes, such as breast- , colorectal-, head 
and neck-, testicular cancer, and melanoma[25]. In sarcomas, the most investigated effect 
of a long total interval is that of increased size of the lesion, leading to a lower chance of 
uncomplicated complete resection, greater risk of amputation, and potential for developing 
metastases[26]. Data on the effect of the total interval on survival in sarcoma is lacking.
Traditionally, clinicians have been interested in clinical outcomes. Patient-reported 
outcomes (PROs) are other important and powerful tools to inform clinicians, as well 
as patients themselves and policy-makers. PROs are reports of the status of a patient’s 
health condition, directly reported by the patient. Several patient-reported outcome 
measures (PROMs) exist; these are questionnaires patients complete on their health. 
Health-related quality of life (HRQoL) is such a measure and encompasses the patient’s 
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subjective experience of his health status, encompassing physical, psychological, and 
social functioning[27]. Integration of PROMs in standard care has been shown to improve 
short-term outcomes and overall survival among patients with metastatic cancer[28]. 
Only few studies have investigated the association between total interval length and 
patient-reported outcomes. In lung and colorectal cancer no association was found, 
among endometrial and ovarian cancer patients a shorter time to diagnosis lead to better 
HRQoL and patient satisfaction[25]. To our knowledge, there is no published data about 
the effect of total interval length on HRQoL of sarcoma patients. Furthermore, which cut-
off point for interval length should be applied in terms of effect on clinical outcomes, 
such as survival, and patient-reported outcomes, such as HRQoL, is unknown. Moreover, 
whether there will be a clear and similar cut-off for both outcomes, survival and HRQoL, 
in sarcomas is uncertain.
Apart from studying the effect of total interval length on outcomes during treatment and 
shortly thereafter, it is important to study long-term effects of total interval length. With a 
growing incidence of sarcoma, the number of sarcoma survivors increases. Currently, there 
are an estimated 280,000 sarcoma survivors in Europe[3]. Survivorship focusses on the 
health and well-being of a person with cancer from the time of diagnosis, until the end of 
life[29]. It includes issues related to follow-up care (including regular health and wellness 
check-ups), late effects of treatment, cancer recurrence, second cancers, and quality of 
life. For sarcoma survivors, the diversity of clinical presentations, variation in treatments, 
demographic and other factors, makes it difficult to describe survivorship issues that are 
applicable to all sarcoma survivors. There is a lack of studies looking at long-term effects, 
such as its influence on HRQoL, of a long total interval among adult sarcoma survivors.
1
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Outline of this thesis
The aim of this thesis is to gain insight in diagnostic pathways of adult sarcoma patients, to identify 
risk groups for prolonged diagnostic pathways, and investigate the impact of the diagnostic 
pathway with respect to clinical and patient-reported outcomes for diagnostic pathway length.
In this thesis we will discuss data from Dutch and English patients. Approximately 1200 
and 5000 people are diagnosed with sarcoma each year in The Netherlands and England, 
respectively[30, 31]. In both countries, general practitioners (GP) have an important role 
as healthcare gatekeepers. Their healthcare sector is largely funded by the government 
from general taxation, and a smaller amount from insurance contributions and fees paid 
by its user. However, most services, such as GP care, are free at the point of use. In general, 
people consult their GP who then decides whether referral is needed and determines the 
acuteness and location of the referral. In the UK, privately insured patients can also self-
refer to a hospital without seeing a GP. In both countries, patients suspected of sarcoma 
are usually referred by their general practitioner for further analysis to a hospital, where 
a medical specialist refers onwards to a sarcoma centre in case of an actual sarcoma. In 
the Netherlands, this is formally organized for patients with bone sarcoma, for patients 
with soft tissue sarcoma this is recommended, but not mandatory. In the United Kingdom, 
care for all sarcoma patients has formally been centralized. These comparable healthcare 
systems with differences in organization of sarcoma care are thus a good fit to compare 
diagnostic pathways. 
We started by conducting a systematic review, which is described in chapter 2. It gives 
an overview of what was already known about the total interval of sarcoma patients by 
quantifying its length, identifying contributing factors, and determining the impact on 
patients’ outcome in terms of clinical and patient-reported outcome.
In order to study the diagnostic pathway in more detail and identify bottlenecks as viewed 
by patients, we conducted interviews among Dutch and English patients with sarcoma. 
This qualitative study, described in Chapter 3, illustrates the diagnostic pathway as 
experienced by sarcoma patients, and its impact on HRQoL and care satisfaction.
The results of the review and qualitative study were a prelude to three studies described 
in this thesis. First, we conducted a cross-sectional cohort study among a Dutch sarcoma 
survivorship population, known as the SURVSARC study. Second, we studied the 
diagnostic pathway of English young adults aged 25-39, to identify factors associated 
with a prolonged pathway. Third, we describe the design of a longitudinal, prospective, 
international study, known as the QUEST study. 
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Chapter 4 and chapter 5 describe results of the SURVSARC study. For this cross-sectional 
study, patients diagnosed with sarcoma 2-10 years ago in one of six Dutch participating 
sarcoma centres were asked to complete a questionnaire on diagnostic pathway, 
treatment, and outcome measures such as HRQoL. In chapter 4 we report interval lengths 
of sarcoma survivors and identify factors associated with prolonged intervals. The effect 
of these interval lengths on current HRQoL of sarcoma survivors is described in chapter 5. 
We also examine the impact of diagnostic pathway length on patients’ subjective feeling 
of its impact on HRQoL, and study to what extent this subjective feeling is of influence 
on HRQoL. Lastly, we describe the results of a qualitative analysis of why some patients 
perceive a negative influence of diagnostic pathway length on their HRQoL. 
In chapter 6 we describe the results of English young adults diagnosed with cancer in the 
past five years, who were treated at one of the six participating Trusts. Since the incidence 
of sarcoma is relatively high among AYAs, and care for these patients is challenged by 
age-specific needs, comparing sarcoma patients with other cancer AYA patients may be 
contributing to gaining insight in the sarcoma-specific diagnostic pathway for this age 
group. Apart from a quantitative analysis of the diagnostic pathway, in this chapter we 
present suggestions to improve the diagnostic pathway for young adults made by the 
study population. These open field answers were qualitatively analysed and the results 
are presented in chapter 6. 
The third study is the QUEST study (QUality of life and Experiences of Sarcoma Trajectories). 
In chapter 7 we describe its design. It is a longitudinal, prospective, international study we 
developed and has recruited patients from 2018-2020. Participants with a new diagnosis 
of sarcoma, treated in one of five sarcoma centres in the Netherlands or three centres 
in England, were asked to complete questionnaires at time of diagnosis and during a 
follow-up period of two years. The study aims to quantify total interval, identify factors 
associated with interval length, and determine the association between total interval and 
HRQoL, stage and tumour size at diagnosis, progression-free survival, and overall survival. 
We hope this will lead to the identification of risk groups and points of action to optimize 
their total interval. Furthermore, identifying a clinically relevant cut-off point for short and 
long intervals, which could differ between subtypes, will guide policy makers, healthcare 
providers, and patients to improve referral pathways.
Chapter 8 provides a summary of the results and discusses the practical implications of 
the findings in this thesis and future research perspectives. 
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Abstract
Background
Sarcomas are rare and heterogeneous mesenchymal tumours of soft tissue or bone, 
making them prone to late diagnosis. In other malignancies, early diagnosis has an impact 
on stage of disease, complexity of therapeutic procedures, survival and health-related 
quality of life (HRQoL). Little is known about what length of diagnostic interval should be 
considered as delay in patients with bone (BS) or soft tissue sarcomas (STS). 
Objectives
To quantify total interval(defined as time from first symptom to histologic diagnosis) and 
its components, identify contributing factors to its length and determine the impact on 
patients’ outcome in terms of mortality and HRQoL. 
Methods
A systematic review was conducted according to PRISMA guidelines. 
Results
Seventy-six articles out of 2,310 met the predefined inclusion criteria. Total intervals, 
varied broadly;  9-120.4 weeks for BS and 4.3-614.9 weeks for STS. Older age and no initial 
radiologic examinations were contributing factors for a long interval in BS, while in STS 
results were conflicting. The impact of length of total interval on clinical outcomes in 
terms of survival and morbidity remains ambiguous; no clear relation could be identified 
for both BS and STS. No study examined the impact on HRQoL. 
Conclusion
The length of total interval is variable in BS as well as STS. Its effect on outcomes is 
contradictory. There is no definition of a clinically relevant cut-off point that discriminates 
between a short or long total interval
2
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Introduction
Sarcomas are a rare group of solid malignant mesenchymal tumours, which comprise 
more than 70 histological subtypes. They have considerable heterogeneity with respect 
to age of onset, anatomic location, tempo of progression and outcome. Approximately 
80% of sarcomas originate in soft tissue, the remainder in bone. Sarcomas form a typical 
example of rare cancers, with an estimated European incidence averaging 4-5 per 100 
000 per year[1]. Patients with rare cancers have a higher mortality rate than those with 
common cancers because of delays to accurate diagnosis and subsequent suboptimal or 
inadequate treatment, fewer developments in novel therapies and reduced opportunities 
to participate in clinical trials[2]. 
Early and accurate diagnosis of cancer is important to optimise patient outcomes in terms 
of local disease control, overall survival and health-related quality of life (HRQoL)[3, 4]. 
The absence of a typical and uniform sarcoma presentation, the lack of public awareness, 
and the limited experience of primary and secondary healthcare professionals with 
sarcomas can result in a prolonged total interval and late referral to specialist sarcoma 
centres. The total interval is the time between first symptoms and ( preferably histological) 
diagnosis(Figure 1)[5]. To date, the impact of late referrals on sarcoma patient outcomes 
has been understudied and reports have been contradictory. 
Figure 1: time intervals in the route from first symptom until diagnosis 
Adapted from Olesen et al, 2009.
-Total interval: from first symptom to diagnosis; 
- Patient interval: from the date the patient first noticed a sarcoma related symptom until the first 
presentation to a doctor with this symptom;
-Diagnostic interval: from first presentation to a doctor until diagnosis;
- Primary care interval: from first presentation to a general practitioner (GP) until first referral to 
secondary care (if applicable) or to a specialist sarcoma centre; 
- Secondary care interval: from referral to secondary care until referral to tertiary care (a specialist 
sarcoma centre); 
-Tertiary care interval: from referral to  a specialist sarcoma centre until the date of (histological) diagnosis.
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To inform interventions that shorten the total interval, better insights are needed into the 
determinants of each component of the total interval, such as socio-demographic, clinical, 
psychological and healthcare factors. The aim of this systematic review is to examine 
the total interval of sarcoma patients by quantifying its length, identifying contributing 
factors, and determine the impact on patients’ outcome in terms of mortality and HRQoL. . 
Material and methods
Search strategy
We conducted a systematic review according to PRISMA guidelines[6]. The review is 
registered in PROSPERO under registration number CRD42017062492. 
A computerized search of the literature through Pubmed (1946-present), MEDLINE 
(1950-present), EMBASE (1974-present), Web of Science (1945-present) and Cochrane 
Library was carried out with the help of a librarian of the Radboudumc by two researchers 
(VS and OH) on February 28th 2019. The search strategy combined terms related to 
“sarcoma”, “delayed diagnosis”,  “early diagnosis” or “referral”. The search string is presented 
in supplementary material A. 
Selection criteria
Studies were included if they met the following criteria: (1) study participants had a proven 
diagnosis of sarcoma; (2) the total interval or any of its components as defined in Figure 
1 were available; (3) the full-text paper was available in English. Reviews were excluded 
because they did not contain original data and single case reports were excluded to limit 
selection bias. 
Definition 
The following definition was used: the total interval, defined as time between first 
symptoms and (histological) diagnosis, which includes both a patient and diagnostic 
interval; the latter can be further divided into a primary, secondary and tertiary care 
interval. The intervals and their associated time points are illustrated in Figure 1. This 
figure was adapted from Olesen et al[5, 7] by adding a tertiary interval , consistent with 
centralised sarcoma care pathways.
Data extraction and synthesis
Study design, inclusion period, study population, length of total interval and its 
components, and effect of total interval on outcomes, such as metastases at diagnosis, 
overall survival and HRQoL, were extracted from included articles. Factors influencing 
length of total interval or its components were extracted and organized as tumour 
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specific factors (e.g. histology), patient specific (e.g. age) or healthcare related (e.g. 
available imaging studies). Based on our clinical experience, previous reports and different 
healthcare providers treating these groups of patients, we expected to find different 
results for bone sarcoma (BS) and soft tissue sarcoma (STS) , and data was thus presented 
in separate tables. Due to the heterogeneity of inclusion criteria and methods, it was not 
possible to conduct a meta-analysis, so results were reported descriptively.
Results
Included articles
Our search yielded 2304 unique hits. The reference lists of relevant articles were searched 
for additional studies which resulted in 6 additional publications. VS and OH screened 
titles and abstracts of these 2 310 publications, 109 studies met the inclusion criteria. After 
careful independent full-text screening by VS and OH, 62 studies were included in this 
review. The flow chart of this selection procedure is presented in Figure 2.
Bone sarcomas
Length of total interval 
Thirty-four studies involving a total of 17 258 patients investigated the total interval in 
bone sarcoma (Table 1A)[8-41]; five of these studies prospectively collected follow-up 
data. A broad range in the length of the total interval was found, which varied from 9 to 
120.4 weeks. 
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Figure 2: Selection procedure
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Components of the total interval 
The impact of patient intervals was measured in 19 studies (mean 4.1 to 34.1 weeks), 
eight studies measured the primary care interval (mean 5 to 32.3 weeks), whereas the 
secondary (mean 2.3 to 7.1 weeks) and tertiary care intervals (mean 2 to 17.4 weeks) were 
measured in two and three studies respectively(Table1). 
Effect of tumour specific factors 
Several factors were studied as determinants of the length of the total interval. Interestingly, 
tumour specific factors such as tumour size or grade did not appear to influence the length 
of total interval[22, 26, 27, 41]. Patients with sarcomas located in the trunk were shown to 
have a longer interval than those who have sarcomas in the extremities (29 versus 14 
weeks; p<0.001) by Lawrenz et al. (n=1792)[41].
Tumour histology was found to be of influence on the total interval. Goedhart et al. 
performed a retrospective study among 102 patients with high-grade bone sarcoma 
and reported a significantly longer patient interval and secondary care interval for 
chondrosarcoma versus Ewing sarcoma and osteosarcoma[21], which resulted in a 
significantly longer total interval, with a mean of 98.3 weeks for chondrosarcoma, versus 
22.9 and 23.3 weeks for Ewing sarcoma and osteosarcoma respectively. 
Four other studies reported similar results on total intervals for Ewing sarcoma and 
osteosarcoma; all had a trend towards a longer diagnostic pathway for patients with Ewing 
sarcoma[12, 14, 26, 40]. In a study by Widhe et al. (n=106), the longer diagnostic pathway 
in Ewing sarcoma was a result of both a longer patient and primary care component[11], 
whereas a study by Sneppen et al. (n=124), reported a four times longer diagnostic interval 
for Ewing sarcoma than for osteosarcoma patients despite similar patient intervals[25]. 
Lawrenz et al. illustrated that intermediate-grade tumours had a longer diagnostic 
interval (52 weeks) compared with high-grade bone sarcomas (12 weeks; p<0.001)[41]. 
In contrast, a study focusing only on bone sarcoma of the foot (n=32) presented opposite 
results: a median total interval of 32.3 weeks for chondrosarcoma, versus 64.5 weeks and 
77.4 weeks for osteosarcoma and Ewing sarcoma respectively[15]. Another small study 
(n=6) reported that half of patients with osteosarcoma of the foot had a considerable 
patient delay, resulting in a mean total interval of 120.4 weeks[16]. 
Effect of patient specific factors 
Gender was not associated with the length of the total interval in four studies[12, 26, 
39, 40], however there was evidence that patient age was a factor. Six studies reported 
a significantly longer total interval for older teenagers, adolescents or adults  compared 
to younger children or (younger) teenagers   (<12 versus ≥12-22 years[11, 22]; <20 versus 
≥20-86 years[26]; <22 versus ≥ 22 years[27]; 0-14 versus 15-19 versus 20-29 years[40]; <12 
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versus ≥12 years[11]). Furthermore, Desandes et al. found young adults were more at risk 
for a longer total interval than patients in puberty (15-19 versus 20-24 years; 10.1 versus 
21.4 weeks respectively; p=0.04)[35]. Lawrenz et al.(n=1792) investigated age (mean 30.7 
years) as a continuous variable and reported every additional year of age was associated 
with a 1.3 week longer total interval(p<0.00)[41]. In contrast Guerra et al. (n=253) found 
no significant relationship between age (range 0-30 years) and the length of the total 
interval[14]. Younger et al. found no relationship between age and patient interval nor 
diagnostic interval[38]. 
The presenting symptom did not predict the length of the total interval in four studies[12, 
13, 22, 26]. Study results (n=4) on the influence of pain symptoms on the total interval are 
contradictory, with some studies suggesting a shortening of the interval, no influence, or 
even a longer total interval[12, 13, 22, 26]
Effect of healthcare system related factors
The influence of the year of first presentation was studied in five studies. None showed 
evidence of shortening total intervals over the past 30 to 50 years[10, 14, 22, 26, 41], 
despite advances in healthcare models including the introduction of cancer pathways 
and dedicated specialist sarcoma centres.
The location of first presentation to a healthcare professional was investigated among 
patients with Ewing sarcoma. The diagnostic interval was significantly longer when 
presenting to a general practitioner (GP) compared with the Accident & Emergency 
department (p=0.04)[11].
The influence of radiology and pathology investigations on the diagnostic interval were 
reported in two studies[10, 12]. When no imaging studies were ordered at the patient’s 
first contact with a healthcare professional, a longer diagnostic interval was observed. 
When imaging was incorrectly interpreted as normal, which was the case in 35% of 
patients with chondrosarcoma at non-specialist centres, this resulted in an even longer 
diagnostic interval (21 versus 9.5 months). At non-specialist centres, only 26% (n=39) of 
chondrosarcomas biopsied were correctly diagnosed as malignant, whilst at specialist 
sarcoma centres, 94% (n=34) were correctly diagnosed[10]. A descriptive study by 
Ashwood et al. highlighted how imaging studies performed prior to referral to a specialist 
centre often had to be repeated because they did not provide all the required information, 
and biopsies or surgeries performed by the referring teams often complicated the patient’s 
subsequent management[29]. 
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A qualitative study in Malaysia by Pan et al. (n=30) demonstrated the multifactorial nature 
of diagnostic delay, which was dependent on the patient perception of symptoms and 
complaints, the influence of traditional healers, and the proximity of health clinics[9]. A 
Brazilian study with 1257 bone sarcoma patients found differences in diagnostic intervals 
between geographic regions, possibly explained by the availability of CT scan equipment 
and the difference in number of hospital beds per region[40]. 
Relationship between total interval and outcomes
The influence of delay on clinical outcomes of bone sarcoma patients has been investi-
gated in 20 of the 34 included bone sarcoma studies(Table 1B)[10, 11, 15, 17-25, 27, 28, 
31, 33, 36, 37, 39, 41]. 
In twelve of these studies (n=7,414),  no significant association between length of the 
total interval (mean total interval between 8.7 and 50.1 weeks) and overall survival was 
found[11, 15, 19, 21, 22, 25, 27, 28, 33, 36, 37, 39]. However, one of these studies (n=1,702) 
found that patients with a longer total interval more often had metastatic disase at 
diagnosis than those with a short total interval[39].
One study of 965 high grade osteosarcomas of the extremities diagnosed between 1983-
1999, identified an inverse relationship between the total interval and the stage of disease 
[19]; the patient interval was significantly shorter in patients with metastatic disease 
compared to patients with localized disease (4.1 versus 6.0 weeks), ultimately resulting in 
a shorter total interval (9.0 versus 10.7 weeks). The total interval was significantly shorter 
in patients who later relapsed than in patients who remained free of disease after 5 years. 
However, this difference lost significance when patients were analysed according to 
disease stage at presentation. In a secondary analysis of this patient population, including 
patients diagnosed between 1980-1983 (n=1,071)[18], patients with a diagnostic interval 
<2 months were significantly more likely to have metastases at diagnosis than those with 
a longer interval (56.1% versus 45.2%; p<0.0009). 
Two other studies by the same research group in patients with Ewing sarcoma and Ewing 
sarcoma family of tumours (ESFT), both demonstrated that a diagnostic interval <2 
months was associated with an increased likelihood of metastases at diagnosis (Table 1B)
[17, 20], impact on overall survival was not reported. 
A study with 1,792 bone sarcoma patients showed that a longer duration of symptoms 
was associated with longer survival (HR 0.996, 95% confidence interval (CI) 0.994-0.998)
[41]. This continuous association was lost when patients were compared in categories(< 
or > 4 months; HR 0.935 95% CI 0.743-1.177). 
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In contrast, four studies with a combined number of 386 patients with chondrosarcoma, 
osteosarcoma and Ewing sarcoma, and mean total intervals between 10.7 and 35 weeks, 
reported a negative impact of a long total interval on stage and survival[10, 23, 24, 31].  
No study has reported on the association between length of the total interval on patient 
reported outcomes including HRQoL.  
Soft tissue sarcoma
Length of total interval
Thirty-six studies investigated the total interval for soft tissue sarcoma (Table 2A)[27, 30-35, 38, 
42-69]. A combined total of 16 845 patients were included and, reflecting soft tissue sarcoma 
(STS) heterogeneity, the total interval varied tremendously; between 4.3 to 614.9 weeks.
Components of the total interval
Eleven studies examined the length of one or more components of the total interval[30, 
38, 44, 47, 50-52, 54, 58, 59, 63]. Patient intervals varied between a median of 1.3 to 17.2 
weeks, the primary care interval lasted 0.1 to 13.3 weeks, the secondary care interval 
varied between 1.1 and 6.9 weeks and the tertiary care interval was 2.1 to 7.9 weeks. 
Effect of tumour specific factors 
Three studies found no relationship between tumour size and length of the total interval[27, 
54, 69], one study (n=575) in children and adolescents found that larger tumours were 
associated with a longer total interval (both for tumours <5 versus ≥5cm and <10 versus 
≥10cm)[67], whilst a study in adults (n=162) reported that smaller tumours (median 8cm) 
were associated with a longer total interval[47].
Five studies reporting on the influence of tumour localization have yielded contradictory 
results. Chotel et al. (n=33) reported that synovial sarcoma of the knee or elbow had a longer 
total interval than tumours at other sites[54] and Smolle et al. found synovial sarcomas 
located superficially had a longer interval than deeply located tumours (n=248; 2 years 
versus 12 months)[68]. However, two other studies found no relationship between tumour 
site and total interval[47, 69]. In children and adolescents, Ferrari et al. (n=575) reported 
a longer total interval for soft tissue sarcomas of the extremities compared to tumours at 
other sites[67]; the  authors attributed this difference to the underlying tumour histology, 
which for extremity tumours was more likely to consist of non-rhabdomyosarcomas and 
thus to encompass a broad spectrum of tumour biologies including low grade soft tissue 
sarcomas. There is limited data specifically exploring the relationship between tumour 
histology and total interval, but Nandra et al. (n=2 277) identifed that low grade sarcomas 
were associated with a longer total interval[27] . 
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Effect of patient specific factors 
Patient gender, level of education and measures of social deprevation were not associated 
with length of total interval[47, 67]. The effect of patient age was examined in five studies. 
Ferrari et al.(n=575) established that children over 10 years old had a longer total interval 
than those younger than 10 years old[67]. Desandes et al. (n=43) found the same result 
when comparing age groups 15-19 versus 20-24 years (15.4 versus 48.7 weeks; p=0.04)
[35]. Smolle et al. found no difference for patients with synovial sarcoma older or younger 
than 16 years old[68]. A large retrospective study of almost 5,000 sarcoma patients found 
no difference in total interval in patients older and younger than the median study age of 
57 years[27]. A Sarcoma UK survey (n=558) established no association between age and 
patient interval or total interval[38].
Two studies in children examined the effect of presenting symptoms on the total interval. 
The first (n=575) found no significant difference in the length of total interval between 
patients presenting with a swelling or with a specific symptom (e.g. urethral obstruction)
[67]. The second in 33 patients with synovial sarcoma, found the presence of a lump led to 
a shorter doctor interval, whilst a peri-articular location or presence of a joint contracture 
led to both a longer patient and a longer doctor interval[54].  
Effect of healthcare system related factors
The influence of the year of first presentation was studied in two publications, which did 
not find an improvement in total interval over the past 30 to 40 years[54, 67]. 
In a study of 162 STS patients surveyed in 2005, the median patient interval was just 
1.3 weeks, whilst the median primary care interval was 25.0 weeks[47]; if patients were 
reassured by the first medical professional they consulted (e.g. their general practitioner), 
it took twice as long to be referred on to an appropriate specialist centre. 
Another single centre study of 545 patients with suspected sarcoma referred to a specialist 
clinic in Denmark reported a median total interval of 25.1 weeks[59]; 102 patients 
(19%) had a sarcoma (88 soft tissue, 14 bone sarcoma), 68 patients (12%) had another 
malignancy[58]. Patients referred to the centre with prior investigations in their local 
hospital had a longer total interval than those with investigations in the sarcoma centre 
(median 13.3 versus 23.7 weeks). Synovial sarcoma patients with an unplanned resection 
had a longer diagnostic interval than those referred directly to a sarcoma centre (24 versus 
12 months; p=0.001)[68].
Relationship between total interval and patient outcomes
The influence of the length of total interval on clinical outcomes in soft tissue sarcoma 
patients has been reported in ten retrospective studies(Table 2B)[27, 43, 54, 61-63, 65, 
67-69]. 
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Five of these studies observed no effect on survival[54, 61, 65, 68, 69]. One study (n=2 277) 
reported that patients with soft tissue sarcoma treated between 1985 and 2010 with a 
longer total interval (26 vs 20 weeks) had a significantly improved survival rate, even when 
stratified by disease stage[27]. This pattern was consistent for all histological subtypes 
apart from rhabdomyosarcoma where survival was significantly better with a short total 
interval (n=34, 16 versus 52 weeks total interval). Furthermore, patients undergoing 
unplanned resections prior to specialist referral had a lower 1-year mortality rate than 
patients referred directly. These patients tended to have small, superficial, low grade 
tumours, which are associated with a better prognosis.  
Three studies reported that patients with a shorter total interval had improved overall 
survival rates[43, 63, 67]. Ferrari et al. analysed the risk of death for 575 children at 
different time intervals and found worse survival with increased diagnostic interval and 
with diagnostic intervals <1 month versus 1 – 3 months (hazard ratio 1.4 (95% CI  0.7-
2.6))  and <1 month versus >12 months (hazard ratio 3.6 (95% CI 1.7-8.0)) respectively[67]. 
Bandyopadhyay et al. (n=391) reported that the odds of death increased by 46% for every 
doubling of the diagnostic interval[43]. 
No study has investigated the influence of the length of the total interval on patient 
reported outcomes.  
Discussion
This is the first systematic review on the sarcoma total diagnostic interval. Analysis of 
the length of the total interval is complex, as it is influenced by many different factors. In 
sarcomas, assessment of the total interval is further challenged by the heterogeneity of 
the disease,the rarity of the group and  the presence of  70+ subtypes.
 
Focussing on the patient interval, it might be anticipated that patients who consult 
a doctor early have a reason for doing so (e.g. worrying, severe symptoms or evidence 
of rapid progression), which would result in a quicker referral for investigation and a 
shorter diagnostic interval[16, 21], and vice versa[12, 13, 26, 54]. However, some aspecific 
symptoms such as pain have given contradictory results[22, 26]. 
Both patient and doctor intervals might be influenced by the biological behaviour of 
the sarcoma. The usually indolent chondrosarcomas had a longer total interval than the 
more aggressive osteo- and Ewing sarcomas[12, 14, 21, 26], and non-rhabdomyosarcoma 
soft tissue sarcomas had a longer total interval than rhabdomyosarcomas or soft tissue 
ESFT[67]. 
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Furthermore, tumour location influences the length of the total interval, with atypical 
tumour presentations increasing the difficulties in diagnosis and prolonging the 
diagnostic interval. 
There are two main findings from studies of the primary and secondary care intervals. 
Firstly, if at initial presentation the assessing clinician is falsely re-assured or makes an 
incorrect diagnosis, the diagnostic interval is severely prolonged[47, 62]. Secondly, patients 
undergoing an unplanned resection prior to referral to a specialist centre have a lower 1-year 
mortality rate than those referred directly to a specialist centre[27]. This finding may be due 
to selection bias, as patients undergoing unplanned resections have smaller, superficial and 
lower grade tumours, which are known factors associated with a better prognosis.
The influence of the length of the total interval on clinical outcomes remains unclear. It 
might be predicted that sarcomas with more aggressive behaviour have a shorter total 
interval and worse survival outcomes, whilst sarcomas with indolent behaviour have a 
longer total interval and improved survival. Alternatively, it may be expected that shorter 
total intervals lead to earlier treatment and better outcomes. For STS, we found conflicting 
results, which is not surprising with over 70 histological subtypes with different clinical 
behaviours. Most bone sarcoma studies from our review not report an association 
between length of total interval and survival as well. Researchers have argued that this 
lack of an association, often reffered to as the ‘waiting-time paradox’, may be due to the 
fact that the studies have not been able to adjust for the aggressiveness of the tumour. 
To date, the influence of total interval on morbidity, HRQoL and other patient reported 
outcomes has not been assessed. Based on the available literature in other malignancies, 
improving the total interval will likely influence the level of patient satisfaction, fear and 
morbidity. The importance of these outcomes is demonstrated by Mesko et al. who studied 
factors most commonly causing litigation in sarcoma cases in the USA[70]. In 81% of cases 
a delay in diagnosis was part of the complaint, a further 7% were about misdiagnosis and 
11% about unnecessary amputation. Primary care doctors and orthopaedic specialists 
were most common defendants in delay in diagnosis cases. 
In neither bone or soft tissue sarcoma did our review identify a clear cut-off point for 
appropriate versus inappropriate length of total interval or its components. Apart from 
the contradictory results in terms of influence of the length of the interval on survival, 
several other factors make it difficult to draw firm conclusions. Firstly, the design of most 
studies was retrospective, increasing the chance of recall bias with regard to self-reported 
outcomes such as dates of first symptoms. Secondly, many studies included a small 
number of heterogeneous patients, which made them unsuitable for subtype analysis. 
Although we excluded case reports, we included case series because they reflect the sort 
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of research that has been done in this area, and show how heterogeneous the population 
is. Thirdly, the inclusion criteria of studies differed; some studies only considered those 
patients who reported a diagnostic delay, which made it impossible to compare this 
group to the entire sarcoma population. Furthermore, diagnostic delay was defined 
differently throughout the literature. One of the limitations of this review is that we had 
to work with these different definitions,which made comparisons difficult.  We propose 
for future reports that the date of pathologic diagnosis is used as the endpoint of the 
diagnostic interval. Furthermore, studies included in this review were conducted over the 
past 50 years. During this period, radiologic and histologic diagnostic techniques have 
evolved,treatment options have improved, and, in some countries,  diagnostic pathways 
with referrals of suspected lumps to centralised sarcoma services have developed, which 
may have influenced our results.
Centralised sarcoma care may improve diagnostic pathways and there is an increasing 
number of  (inter)national guidelines for the diagnosis and management of 
sarcomas[71-74]. Centralizing care at sarcoma centres with a multidisciplinary team 
improves the diagnostic interval because patients 1) do not lose time at local hospitals, 
2) receive appropriate imaging for tumour staging and 3) get a higher rate of correct pre-
operative pathologic diagnosis[10, 12, 29, 30, 50, 58, 75-79]. Improvement of these factors 
decrease tumour size and stage at diagnosis, resulting in an increase of the quality of 
surgery and improvement of survival outcomes in several of these studies[60, 75, 77-80].  . 
Best practices of different countries could be integrated to develop the optimal diagnostic 
pathway. In order for such guidelines to be successfully implemented, one needs strong 
political support with continuous attention to raise awareness and optimize the system 
by following a quality and control cycle[60]. 
Conclusion
This review confirms the complexity of the total interval to sarcoma diagnosis. Published 
studies give contradictory results in terms of determinants for a long total interval as well as 
its influence on outcomes. The impact of a long interval on HRQoL has not been studied. To 
present a clinically relevant cut-off point that discriminates between a short or long interval 
is thus impossible. Such a cut-off point , which can differ between histological subtypes, is 
necessary to make guidelines more evidence based, help to guide patients and support 
the sarcoma diagnostic process. Furthermore, to improve care we need to understand the 
impact of the total interval on HRQoL of patients diagnosed with a sarcoma. Future research 
should include relevant outcomes for patients , as well as focus on areas where a change in 
management could make a difference, such as in increased public awareness, education of 
primary and secondary healthcare providers and improved access to specialist centres. 
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Supplementary material A
Search: ((((((((“Sarcoma”[Mesh]) OR (“Bone Neoplasms”[Mesh:noexp]) OR (“Soft 
Tissue Neoplasms”[Mesh:noexp]) OR (“Gastrointestinal Stromal Tumors”[Mesh]) 
OR (Sarcoma*[tiab] OR Adenosarcoma*[tiab] OR Carcinosarcoma*[tiab] OR 
Chondrosarcoma*[tiab] OR Desmoplastic Small Round Cell[tiab] OR Endometrial 
Stromal[tiab] OR Fibrosarcoma*[tiab] OR Dermatofibrosarcoma*[tiab] OR 
Neurofibrosarcoma*[tiab] OR Hemangiosarcoma*[tiab] OR Malignant Fibrous 
Histiocytoma*[tiab] OR Leiomyosarcoma*[tiab] OR Liposarcoma*[tiab] OR 
Lymphangiosarcoma*[tiab] OR Mesodermal Mixed[tiab] OR Myosarcoma*[tiab] OR 
Rhabdomyosarcoma*[tiab] OR Myxosarcoma*[tiab] OR Osteosarcoma*[tiab] OR Ewing 
Sarcoma*[tiab] OR Phyllodes[tiab] OR Gastrointestinal Stromal[tiab])) AND ((((“Delayed 
Diagnosis”[Mesh])) OR (“Diagnostic Errors”[Mesh:noexp]) OR (“Early Diagnosis”[Mesh]) OR 
(((Delay*[tiab] OR late[tiab] OR Waiting time*[tiab]) AND (diagnos*[tiab] OR Referral*[tiab] 
OR Referal*[tiab] OR Journey*[tiab])))))) NOT “Case Reports”[Publication Type])) NOT 
((((((“Child”[Mesh]) OR “Infant”[Mesh])) OR Adolescent[mesh])) NOT “Adult”[Mesh]))))
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Supplementary material B
Section/topic # Checklist item Reported on page # 
TITLE 




Structured summary 2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number. 
2
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is 
already known. 
4
Objectives 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). 
4
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number. 
5
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale. 
5
Information sources 7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched. 
5
Search 8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated. 
Supplementary
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis). 
5
Data collection process 10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators. 
5
Data items 11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
5
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis. 
5/discussion
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference 
in means). 
5
Synthesis of results 14 Describe the methods of handling data and combining results 
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Section/topic 
# Checklist item Reported on page # 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, 
selective reporting within studies). 
Discussion
Additional analyses 16 Describe methods of additional analyses (e.g., 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified. 
n/a
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram. 
5
Study characteristics 18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations. 
6 and onwards tables 1-2
Risk of bias within studies 19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 12). 
n/a
Results of individual studies 20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot. 
6 onwards
Synthesis of results 21 Present the main results of the review. 6 onwards
Risk of bias across studies 22 Present results of any assessment of risk of bias across 
studies (see Item 15). 
Discussion
Additional analysis 23 Give results of additional analyses, if done (e.g., 




Summary of evidence 24 Summarize the main findings including the strength 
of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers). 
15
Limitations 25 Discuss limitations at study and outcome level (e.g., 
risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias). 
15
Conclusions 26 Provide a general interpretation of the results in the 




Funding 27 Describe sources of funding for the systematic review 
and other support (e.g., supply of data); role of 
funders for the systematic review. 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097 
For more information, visit: www.prisma-statement.org. 
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Abstract
Introduction
Sarcomas are rare tumours. Early diagnosis is challenging, but important for local control 
and potentially survival and quality of life(QoL). We investigated (1)the route to diagnosis 
(RtD) experienced by sarcoma patients, including factors contributing to the length of the 
RtD from patients’ perspective; (2)the impact of the RtD on QoL and care satisfaction; and 
(3)differences in aims 1-2 between English and Dutch patients.
Methods
Fifteen sarcoma patients from The Royal Marsden Hospital, United Kingdom, and Radboud 
University Medical Centre, The Netherlands, were interviewed, exploring RtD experiences. 
Interviews were analysed according to qualitative content analysis.
Results
The main themes were: patient interval, diagnostic interval, reflection on the RtD and 
recommendations for improvement. Patient interval was long if symptoms were attributed 
as benign, did not interfere with daily life or were expected to cease. An incorrect working 
diagnosis, ineffective process of additional investigations, long referral times and lack of 
a lead clinician lengthened the diagnostic interval. Long waiting times, false reassurance 
and inadequate information provision led to dissatisfaction and a high emotional burden. 
Factors for improvement included increasing awareness of patients and healthcare 
providers, empowering patients, and having a lead clinician.
Conclusion
The RtD of sarcoma patients is complex. Increasing awareness of patients and healthcare 
providers may contribute to shorten the RtD. 
3
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Introduction
Sarcomas are mesenchymal tumours which comprise more than 70 histological subtypes. 
They are heterogeneous in terms of age of onset, presentation, anatomic location, speed 
of progression and clinical outcome. Approximately 85% of sarcomas originate in soft 
tissue, the remainder in bone. Sarcomas have an estimated incidence averaging 4-5 per 
100,000 per year in Europe[4] and are a so-called rare cancer. Patients with rare cancers 
have a higher mortality rate than those with common cancers because of delays in accurate 
diagnosis, suboptimal or inadequate treatment, fewer opportunities to participate in 
clinical trials and less availability of novel agents[5].
Early and adequate diagnosis of sarcoma is challenging due to the heterogeneity in 
presentation and histology, but is important for local control, and potentially (health-
related) quality of life ((HR)QoL) and survival, as seen in other cancer diagnoses[6-11]. 
Different histological sarcoma subtypes vary in biological behaviour; some aggressive 
sarcomas cause severe symptoms at an early stage, leading to an early presentation and 
potentially faster diagnosis, but with a worse outcome than sarcomas that grow slow, 
causing symptoms with a long total interval. The total interval is the time between first 
symptoms and (preferably histological) diagnosis (Fig 1)[3]. 
Apart from cancer characteristics, patient and healthcare factors can be of influence on the 
length of the total interval[3, 12]. Until now, contradictory results have been found for the 
influence of patient characteristics[13]; data on comparison of healthcare systems is scarce 
for sarcomas. The healthcare system of The Netherlands(NL) and United Kingdom(UK) are 
comparable but differ regarding sarcoma referral pathways.
Patients in both countries have access to health services via a publicly funded healthcare 
system[14] and generally the general practitioner (GP) is the first healthcare provider(HCP) 
to be consulted, who refers to secondary or tertiary centres if appropriate. In the UK a 
minority of patients (11%) is privately insured giving them access to private hospitals 
via self-referrals, in NL patients may, if they can afford it, use certain diagnostic services 
provided in private clinics. Sarcoma care has been centralized in the UK, and although 
bone sarcoma centres exist in NL, care for patients with soft tissue sarcomas has not 
formally been centralized. 
The aim of this study is to investigate (1)the route to diagnosis(RtD) experienced by 
sarcoma patients, including factors contributing to the length of the total interval from 
the perspective of a patient; (2)the impact of the RtD length on QoL and care satisfaction; 
and (3)differences in aims 1-2 between English and Dutch patients.
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Fig 1: Definitions of the route to diagnosis for sarcoma patients 
This fig was adapted from Olesen et al and Walter et al[1-3]
•  Patient interval: from the date the patient first noticed a sarcoma related symptom until the first 
presentation to a doctor with this symptom;
   -  Appraisal: from noticing a sarcoma related symptom to deciding to seek the help of a healthcare 
provider (HCP);
   -  Help-seeking: from making the decision to consult a HCP until the actual appointment;
•  Diagnostic interval: from first presentation to a doctor until diagnosis;
   -  Primary care interval: from first presentation to a general practitioner (GP) until first referral to 
secondary (if applicable) or tertiary care, in this study the sarcoma centre (in which referral is the 
time point at which there is a transfer of responsibility from one HCP to another); 
   -  Secondary care interval: from referral to secondary care specialist until referral to tertiary care 
specialist; 
   -  Tertiary care interval: from referral to tertiary care specialist (sarcoma centre) until date of 
histological diagnosis; 
•  Total interval: from first symptom until histological diagnosis.
Methods
Conceptual framework
To study the RtD, a framework for research with clear definitions is needed. In this study 
we combined the widely used models of Olesen et al and Walter et al, as shown in Fig 1[1-
3]. The combined model identifies a patient interval, which can be divided between the 
process of appraisal and help-seeking, and a diagnostic interval, which can be divided 
into a primary, secondary, and tertiary care interval, the latter was added to fit the sarcoma 
referral pathway. The treatment interval was left out, as it is out of the scope of this 
study. The events marking the beginning and end of each interval can be found in Fig 
3
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1. The length of each interval can be influenced by patient, system and tumour factors, 
which will eventually influence clinical and patient-reported outcomes, represented by 
the outcomes column to the right. This theoretical framework will be used to describe 
patients’ experience of the sarcoma RtD. 
Study design and patient recruitment
We conducted semi-structured interviews between March and November 2017. Patients 
were eligible if they were (1)≥18 years; (2)diagnosed within the past 4 months in Radboud 
University Medical Centre (Radboudumc), NL, or the Royal Marsden NHS Foundation Trust, 
UK, with histological proven sarcoma and (3)could communicate in Dutch or English, 
respectively. Patients with significant cognitive impairment or mental health problems, as 
determined by their HCP, were excluded. 
At both sites, eligible patients were identified by their HCP or a member of the research 
team(VS) and supplied with an information letter. VS then contacted the patients to 
answer remaining questions and, if agreeing to participate, to set a time for the interview. 
All participants provided written informed consent before the interviews. Participants 
completed demographic and clinical questions prior to the interview. RtD, QoL, and care 
satisfaction were subjects within the interview, and not subject of the questionnaire.
In the UK the study was deemed exempt from full review and approval by a research ethics 
committee (Committee for Clinical Research, Royal Marsden NHS Foundation Trust), but 
was approved by the service evaluation committee of the Royal Marsden NHS Foundation 
Trust(SE669). In NL the study was approved by the medical ethical committee of the 
Radboudumc(2017-3229). 
Data collection, analysis and reporting
Patients completed a short questionnaire on sociodemographic data and dates of referral. 
Date of referral to the sarcoma centre and the date of histological diagnosis was confirmed 
from medical records. 
Semi-structured interviews were conducted by one member of the research team at both 
sites(VS), the interview schedule is provided in appendix 1. VS had no clinical relationship 
with the participants or the treating physician. The interviews were conducted at the 
hospital. Topics and questions were based on clinical experience and literature review[13, 
15-17], whilst emerging questions from interviews were discussed in the following 
interviews. The interviews were recorded and transcribed verbatim and anonymously. 
Data analysis was conducted by two coders(VS and OH) using ATLAS.ti 8.0. Data was 
analysed according to qualitative content analyses and were ordered into relevant code 
terms, and then categorised into themes by two researchers(VS and OH). Data answering 
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the first research question was organized according to our conceptual framework 
(directed approach)[18]. The second and third research question were answered by 
conventional content analyses, in which coding categories are derived directly from the 
data[18]. After analysing the data independently, the coders discussed and redefined until 
they reached consensus. Saturation was reached when no new themes were identified. 
The consolidated criteria for reporting qualitative research(COREQ) were used. Appendix 
2 provides an overview of translated quotes. 
Results
Participants 
Seven Dutch and eight English patients with a total interval varying between 10-145 weeks 
participated. All invited patients gave informed consent and participated in the study. 
Both patient and diagnostic interval contributed to a prolonged total interval: though the 
median patient interval was 4 weeks, it ranged from 0-119 weeks; the median diagnostic 
interval was 18 weeks with a range of 3-140 weeks. More details on these intervals and 
socio-demographic and clinical characteristics of the patients are presented in Table 1. 
The study participants reflect the heterogeneity of the sarcoma population.
Themes
The first research question is answered by the first two themes, which are organized 
according to our conceptual framework. The other two main themes, ‘reflection of 
diagnostic pathway’ and ‘recommendations for improvement of the diagnostic pathway’ 
give an answer to the second aim of this study, to describe the impact of RtD length on 
QoL and care satisfaction of sarcoma patients. The third research question is accounted for 
under all themes. Fig 2 shows a schematic representation of our main findings, quotes to 
support our results can be found in Table 2. 
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Figure 2: Schematic representation of main findings
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Table 2: Quotes
Theme Subtheme Quote
Patient interval Appraisal ‘Initially we thought it was a, like a bug bite’ (male, #11).
‘I stopped doing sport and waited without having any concerns’ (male, #1). 
‘I was made this appointment at a back-specialist clinic and again he [a 
physiotherapist] completely examined me and he quite 100% told me that you 
have got a class-3 classic sciatica. He just said, keep taking your medication, 
you’re on the best medication that you can get. [...] Well, with that I then 
continued’ (male, #13). 
Help-seeking ‘I waited until it started to affect my style of life. I do a manual job [...]. So, I carried 
on until basically it started to affect, you know, my daily work’ (male, #13).
‘Then last year around about Christmas time we noticed it getting much bigger 
and taking on a red, a reddish, sort of like a bruise. So, and it started becoming 
quite can I say noticeable. I couldn’t put my arm down properly and couldn’t sleep 
on that side. And it did start giving me pain’ (male, #11). 
‘At that moment the pain became worse, [...]it really hurt in the buttocks and the 
back of my legs. I thought, this really can’t be any good’ (female, #4). 
‘What made me decide to [make an appointment]? Because it wasn’t getting 
better. More frequent I expect and a lot of...soreness in the lower abdomen.’ 
(female, #9).
‘I was just getting scared because the pain, the pressure in the ribs, it wasn’t going 
away. And I did have coughs and things like that, then they went away, then a 
lot of mucus then they went away. But it just, you know, something wasn’t right’ 
(female, #12).
Diagnostic interval Diagnostic phase ‘” It’s a hematoma because you’ve obviously pulled a muscle and you know you’ve 
pulled a muscle and it looks much like a hematoma” they said. [...] You don’t like 
to dreadfulize, you don’t like to think what ifs. I had pulled muscles in the past and 
they have been painful, and I have had problems with back muscles in the past 
through dangerous sports, so I just assumed at the time that they were correct, it 
was a hematoma.’ (female, #14)
‘Waiting for 6 weeks for an MRI is actually extremely long I think. If I would have 
been aware that it might not be benign, I would not have agreed with that. But 
I wasn’t, so I just went on a holiday, spent the entire day in the sun and drank 
alcohol. I was extremely, extremely, extremely tired’ (male, #1).
‘The referral for that second opinion at the sarcoma centre had to go through the 
GP’ (male, #2). 
‘The GP never referred me to get a CAT-scan because they [the GP] said I was fit, 
healthy, non-smoker, never had any family condition or history of anything bad. 
I had no pre-existing conditions of anything and I took no medication at all, so 
they said that there was no reason for a CAT-scan. [...] So, they stopped there and 
every time I went back they thought it was musculoskeletal’ (female, #12).
‘[...] and then a biopsy 3 times. They punctured 3 times, so they would have 
enough, but they hadn’t because it turned out they were still in doubt between a 
chondrosarcoma and an osteosarcoma. After that I got a biopsy under general 
anaesthesia and that showed it was an osteosarcoma, but low grade. [...] Then I 
had an operation, which went well, but they found other, more aggressive, cells, 
which is why I had to come here [medical oncology department] eventually’ 
(male, #1).
‘They had to send the tissue sample to another hospital because they weren’t sure, 
I think that’s when they pushed back the appointment and then when they had 
it confirmed at the hospital they brought it [the appointment] forward’ (female, 
#10).
‘But it wasn’t the same doctor. The first time I saw, I had seen my own doctor but 
the second time it was another doctor’ (male, #13)
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Theme Subtheme Quote
‘So, my GP looked and investigated me but did not know what it was, so he sent 
me for an ultrasound that same afternoon’ (female, #5). 
‘The doctor said: “if I had not seen you on Sunday and I had not seen the 
difference between Sunday and Friday, then I probably would not even have 
referred you to the hospital”’ (male, #7). 
Effect of 
centralisation
‘Yes, I had to get used to the travel distance. […] The travel costs, it was my 
savings I used. You can ask something back from the insurance company, that is 
nice, but in the beginning it did cost a bit more money’ (male, #1).  
Reflection on 
diagnostic pathway
Care satisfaction ‘[Getting the diagnosis took] roughly 4 months. If I look back at those dates, 
perhaps two or three weeks might have been saved by a referral being sent on as 
soon as I was seen as opposed to me phoning up to see if that had gone. So, apart 
from that I can’t really, fault anybody or the process of the system.’ (female, #8). 
‘I’m very angry. I’m not saying that they ... [pause], it could’ve been done better. 
[..] For me to get where I am now I don’t think it would’ve [been necessary]’ (male, 
#13). 
‘Well I suppose if I had been a private patient, I would have been seen and all this 
would have happened maybe half the time or maybe less. So on looking at the 
NHS I’m being realistic and thinking they have done the best they can.’ (female, 
#8).
‘But...it’s a case, when they’re all available. They are very, very pushed. I think 
there’s too many patients in our practice anyway.’ (female, #9).
Impact of receiving 
the diagnosis
‘I entered the room and he said: “I have not got good news for you”. I then 
thought: “wow”. It was like a rollercoaster. I had gone alone.  I was startled, 
absolutely. No, I really did not see it coming. It came out of nowhere.’ (male, #1). 
‘Everybody said the chances of it being anything suspicious were absolutely 
minute, so I had no reason to feel concerned at all. To be told...actually that’s 
not what you thought it was. Alright, okay where do we go now? [..] I was just 
so surprised after everything being...”yes, yes everything looks good, everything 
looks good”. Then bang... [..] They don’t know how to express too much sympathy.’ 
(female, #10)
Impact of delay on 
medical outcomes 
and quality of life
‘Yes, I understand it does influence my prognosis’ (male, #2). 
‘It was difficult from the moment of the result at the hospital until the scans. 
Especially after the scans I was wondering: “is it somewhere else, how bad is it?” I 
thought I was dying.’ (male, #1). 
‘I suppose the most difficult part was not knowing, or waiting, knowing that in all 
these investigations would obviously help towards the diagnosis and just waiting 




of the diagnostic 
pathway
‘Be persistent for what you want [to know]. If you don’t know [what’s going on] 
and you want to know then you just have to be persistent about it’ (female, #9).
‘Everything could have gone faster if people had been more aware that this could 
be sarcoma’ (male, #1). 
‘A patient should at the moment of getting complaints of peeing or whatever take 
it seriously straight away’ (female, #3).
‘The key is to start with your general practitioner’ (female, #5). 
‘Possibly my doctor himself should have pushed slightly more rather than saying: 
yes, that’s fine, you can leave it until after your holidays, [the GP] should’ve 
possibly said: “no, let’s fix it beforehand”’ (female, #14).
Table 2: Continued
70   |   Chapter 3
Theme 1: Patient interval: appraisal and help-seeking 
Appraisal
Three factors were identified that contributed to a long phase of appraisal. First, many 
patients had an alternative, benign explanation for their symptoms. In some cases, this 
alternative explanation was not something a patient would need to seek the help of a 
HCP for (e.g. a bug bite), while in other cases the symptom was normalised by the patient 
as being part of life (e.g. old age). Second, if the symptoms did not interfere with daily life, 
most patients did not feel the urge to seek help. The process of help-seeking was often 
delayed further due to other life priorities (e.g. a holiday), stopping with activities that 
became difficult due to symptoms (e.g. gardening), and treatment from a paramedical 
HCP which decreased complaints temporarily. Third, many patients expected their 
complaint to cease by itself. 
Help-seeking
The main trigger of help-seeking was interference of the symptoms with daily life. If 
symptoms lasted or became worse, this was an extra reason to seek help. There were no 
delays in making an appointment with an HCP. There were no remarkable differences in 
the patient interval between NL or the UK. 
Theme 2: Diagnostic interval: diagnostic phase and effect of centralisation
Diagnostic phase
Once the patient seeks help from a HCP, he or she enters the diagnostic phase. This phase 
was found to be lengthened by six factors, which could send patients back to the process 
of appraisal. 
First, the HCP often had a “working diagnosis” for which wait-and-see management was 
legitimate. However, a lack of follow-up to ensure resolution of symptoms attributed to a 
long diagnostic phase.
Second, the process of additional investigations was prolonged: (1)performing 
investigations was often postponed, (2)passive waiting time for imaging studies and 
biopsies, (3)long time between investigations and receiving results, and (4)absence of 
subsequent investigations if results were inconclusive or (false) negative.    
Third, referrals took a long time due to: (1)referrals to the wrong specialist, (2)second 
opinions needed to go through the GP, or (3)long waiting times for an appointment at the 
sarcoma centre. 
Fourth, if the course of disease progression was different than expected, often the working 
diagnosis was not adjusted, and no new investigations were ordered. 
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Fifth, if a biopsy was performed it took a long time to get a diagnosis due to the rarity of 
the disease, heterogeneity and difficulty to diagnose, more tissue needed or necessity to 
send the material to a sarcoma pathologist. 
Sixth, the lack of a lead clinician lengthened the diagnostic process, e.g. when a patient 
was repeatedly referred to a different specialist at another hospital, or if follow-up 
consultations did not take place with the same doctor. This was more evident in English 
than in Dutch interviews, whereas the other causes were mentioned by both groups of 
patients.
Similarly, the reverse of these factors led to a short diagnostic interval. Especially 
investigations done within a short time frame, smooth referrals, awareness of the patient 
that something was wrong and having one lead clinician facilitated fast diagnosis. 
Effect of centralisation
Many patients acknowledged centralisation of sarcoma care had been difficult in terms of 
travel distance, arranging transport, the necessity to take longer time off from work, and 
paying travel expenses from their own savings, especially in the UK. Although travelling to 
a sarcoma centre or being admitted away from home felt as an effort, it was not a barrier 
for them to visit a sarcoma centre as they believed they received better care. 
Theme 3: Reflection on diagnostic pathway: satisfaction with care and 
impact of delay
Care satisfaction
Patients were satisfied about the received care if (1)HCPs kept their promises, (2)
information provision was satisfactory, and (3)patients felt they were taken seriously. 
The absolute length of the diagnostic interval was mostly not of influence on the level of 
satisfaction with care, but the (subjectively) experienced length was important. 
Patients were unsatisfied if (1)there were long waiting times, (2)they felt their symptoms 
were ignored, (3)they were falsely reassured, and (4)information provision was inadequate. 
In the UK patients felt that their doctors were busy, and the system was pushed, therefore 
not faulting their doctor but the system they needed to work in. They thought this caused 
GP’s to be less proactiveand thought waiting times were longer due to the National Health 
Service(NHS) and would have been shorter if they were privately insured. This was not 
applicable to Dutch patients.  
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Impact of receiving the diagnosis
Most patients who experienced a long diagnostic interval felt shocked when they received 
the diagnosis. Those who experienced a short diagnostic interval were more concerned 
about their loved ones than themselves. 
Impact of delay on medical outcomes and quality of life
Only one patient thought a long diagnostic interval influenced his clinical outcomes. 
However, the emotional burden with feelings of anxiety, fear of dying, and anger was 
mentioned by most patients. The impact of a long interval on quality of life was largest 
when patients had not expected a malignant diagnosis. They also experienced the period 
in which they knew they had a malignancy but had to wait for the definite diagnosis as 
difficult. 
Theme 4: Recommendations for improvement of the diagnostic pathway
Patients gave advice regarding improvements of the diagnostic pathway. First, awareness 
of both the patient and HCP was described as a requisite for an efficient diagnostic pathway. 
Awareness leads to investigations being done in a shorter time frame due to persistence of 
patients or recognized necessity for investigations by the HCP. Second, patients indicated 
they can be empowered by receiving copies of referral letters. Third, each patient should 
have a lead clinician, who tracks results of investigations until a diagnosis has been made. 
Many patients emphasized the importance of the role of the gatekeeper, most often the 
GP. If the gatekeeper ordered the right investigations or referred them to the correct 
specialist most RtD’s went smoothly. If the gatekeeper reassured them, referred to the 
wrong specialist, or postponed investigations or referrals, then patients lingered for a long 
time. These recommendations were the same among Dutch and English patients. 
Discussion
This study investigated the RtD as experienced by sarcoma patients, its effect on QoL and 
care satisfaction and differences between English and Dutch patients. We found the RtD 
to be variable and many sarcoma patients encounter difficulties during the process. The 
total interval of our patients varied from 10 to 145 weeks, this large variability is concurrent 
with the literature[13].
Our study identified four main themes: patient interval, diagnostic interval, reflection on 
diagnostic pathway and recommendations for improvement of the diagnostic pathway; 
fig 2 shows a schematic summary of our main findings. 
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Factors influencing the length of the patient interval were alternative explanations for 
symptoms, interference with daily life, expectations about prolongation of symptoms and 
waiting time for appointments. The diagnostic interval was lengthened if the working 
diagnosis was inaccurate or not adjusted, the process of investigations and receiving 
their results was inefficient, there was a lack of a head clinician, or there were long referral 
times. These associations are in concurrence with existent cancer literature, which has 
shown that key concepts for length of patient and diagnostic interval were recognition 
and interpretation of symptoms, the impact on everyday life by symptoms, experiences 
of generalist health care, entry into secondary care, repeated cycles of healthcare seeking 
and appraisal without resolution and lack of follow-up of persisting symptoms[15-17, 19, 
20]. As shown in our study, the role of the GP or subsequent lead clinician is important for 
referral times and promptness of successive additional investigations.
Sarcoma care is centralized in sarcoma expert centres in many countries, it is generally 
accepted that this improves diagnosis and subsequent treatment[4, 5]. We explored the 
effect of centralisation on patients’ experiences of the diagnostic pathway. For nearly all 
included patients, travelling to a sarcoma centre was time consuming and costly, but not 
withstanding them from going there to receive the best possible care. 
Although the diagnostic interval was perceived more negative by English patients, care 
satisfaction was equal amongst Dutch and English participants. An interesting finding is 
that the absolute duration of the diagnostic interval was not of influence on care satisfaction 
as reported by our participants. They were unsatisfied with passive waiting time, being 
ignored or falsely reassured, and if information provision was inadequate. The reverse of 
these factors improved their level of care satisfaction. To the best of our knowledge, the 
influence of RtD on care satisfaction has not been measured. However, there is a lot of 
literature and policy reports measuring RtD length including anecdotal evidence that the 
large number of prolonged time to diagnosis will lead to lower care satisfaction[13, 21, 
22]. The European patient advocacy group (SPAEN) has written a position paper in which 
the first priority challenge is earlier accurate diagnosis[23]. This underlines the importance 
of a fast RtD for patients. Delays to diagnosis have also been shown to be the main cause 
of sarcoma litigation[24, 25].   General cancer literature has shown contradictory results 
about the relation between care satisfaction and experienced RtD; a qualitative study 
with 26 patients with anal cancer showed most patients were satisfied with received 
care, unless they experienced passive waiting time[26]. However, another study in 353 
women with gynaecological cancer reported a longer diagnostic interval led to lower care 
satisfaction[10], and a study in 904 cancer patients showed patients had less confidence in 
GPs after being diagnosed with a doctor delay [27]. Upon receiving the diagnosis patients 
with a long interval felt shocked, those with a shorter interval were mainly worried about 
their family. 
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Research about the effect of the length of total on clinical and patient-reported outcomes 
is mostly retrospective and shows contradictory results[13]. However, a long total interval 
could cause significant psychological morbidity[9]. Participants in our study confirm that 
waiting time causes psychological distress. Yet, only one patient considered his delayed 
diagnosis to influence his clinical outcome. This is an additional rationale to investigate 
the effect of the length of diagnostic interval on both clinical as well as patient-reported 
outcomes. 
The fourth theme, recommendation for improvement of the diagnostic pathway, provided 
us with information consistent with existing cancer literature but now from a patients’ 
perspective: the main recommendations were to increase awareness amongst patients 
and HCPs, to empower patients, and to have one lead clinician[12, 15, 20]. 
This study has given us insight in the patients’ perspective of the diagnostic pathway. 
Nevertheless, several limitations should be considered. First, although qualitative study 
methods are ideal to gain insight in what is important and why, this is a descriptive study 
and results can therefore not be generalized to all sarcoma patients. The RtD is influenced 
by healthcare systems, culture and organization of care and therefore these results cannot 
be generalized to sarcoma patients outside NL or the UK. In our analyses, the same factors 
facilitating and prolonging time to diagnosis emerged from all interviews. In that respect, 
we concluded we reached data saturation and did not add any more participants. However, 
due to the heterogeneity of the disease, depending on subtype and location, patients 
will encounter many different specialist in the RtD. As shown in this study, this results 
in many different pathways and  we cannot say we explored all possible cases. Second, 
one of the aims of our study was to examine the effect of the RtD on QoL. However, the 
impact on QoL was not a main issue in our interviews. To investigate whether QoL is truly 
not impacted by length of the total interval, quantitative research is needed. Third, we 
left the treatment interval out of the scope of our study. Outcomes may be influenced by 
this time interval, and some patients had just heard their diagnosis whereas others had 
already started treatment, which may have influenced their responses. Fourth, patient 
interval dates were patient-reported and therefore possibly inaccurate. To limit recall bias, 
we included and interviewed patients within four months after diagnosis, in our clinical 
experience patients remember many details about their RtD, we therefore think this bias 
is limited. 
Until now, the conceptual framework used to describe the RtD was a theoretical model 
representing methodological recommendations. Our study described the patient 
experience of sarcoma diagnosis and for the first time confirms that this patient experience 
fits the model. This is an important finding, because understanding the RtD from both the 
patient and clinical perspective is necessary to improve the diagnostic pathway. 
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Our study confirms the research model as presented in fig 1 is useful for sarcoma patients 
and can be used in future research to report uniformly on the subject. The fig could be 
given more detail specifically for sarcoma patients, e.g. contributing events could be 
complemented with patient awareness and empowerment for patient factors, direct 
access to investigations and having a lead clinician are important system factors and care 
satisfaction is influenced by passive waiting times. However, to make these findings more 
robust and to study the effect of total interval on outcomes, more research is needed. This 
qualitative study was used to identify factors important to patients, to use in our design 
of a large quantitative and prospective longitudinal study, currently a trial in progress 
(the ‘QUEST’ study, NCT03441906). This study will allow us to quantify total interval 
and its components, provide insight in factors contributing to its length, and study the 
relationship between its length and clinical as well as patient-reported outcomes. If the 
sample is large enough, we may be able to distinguish these features for specific sarcoma 
subtypes. Hopefully it will allow us to give a more detailed insight in what is specific in 
the RtD for sarcoma patients, compared to other malignancies. The present study has 
contributed to understanding patients’ experiences during the diagnostic process and 
has enabled us to design a study in which the patients’ perspectives are involved.
Conclusion
This study confirmed RtD for sarcoma patients is variable and found several patient and 
system factors influencing its length for English and Dutch patients, and described its 
effect on care satisfaction. The total interval could be reduced by increasing awareness 
amongst patients and HCPs, having an efficient pathway for investigations and referrals 
and working with a lead clinician. Centralisation of care is costly and time consuming, but 
not a barrier for receiving care. The patients’ experience of the RtD could be improved by 
reducing passive waiting time and providing adequate information. Quantitative research 
is needed to confirm these findings and study the impact of RtD on clinical and patient-
reported outcomes. 
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S1 Appendix 1 interview schedule
Introductory question
Can you briefly give me the outlines of what happened when you experienced your first symptoms 
until the moment the diagnosis of sarcoma was made?
Core questions
If you think back at the period in which you first noticed your symptoms, what was your explanation 
for having those symptoms? 
If appropriate: What do you think delayed you going to a doctor? 
What made you go to the doctor (in the end), and what happened when you did? 
During the diagnostic pathway, did finance or travel distance, including taking days off work etc, 
play a role in the decisions you made? How? 
How did you feel about the diagnosis itself? 
Looking back at the entire pathway, which period do you feel was the most difficult in a psychological 
way? Why? 
What do you think the effect of the length of the diagnostic pathway is / has been? 
Looking back, would you have done anything differently? 
Are you satisfied with the care you have received? Why (not)?
Closing question
Have you got recommendations on how to improve the diagnostic pathway?
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S2 Appendix 2 translated quotes
Translated quote Original quote
‘I actually had some problems with peeing for some time. You 
just put it aside as being: ‘you get older, so you may need to 
go to the bathroom more quickly or just drink more’ (female, 
#3).
Eigenlijk had ik bepaalde klachten met plassen al langer. 
Alleen dat zet je dan weg als zijnde: je wordt ook ouder, dus 
misschien moet je sneller naar de wc of je drinkt gewoon 
wat meer.
‘I stopped doing sport and waited without having any 
concerns’ (male, #1).
Ik ben gestopt met sporten en gewoon even afgewacht 
zonder enige onrust.
‘Waiting for 6 weeks for an MRI is actually extremely long I 
think. If I would have been aware that it might not be benign, 
I would not have agreed with that. But I wasn’t, so I just went 
on a holiday.’ (male, #1).
6 weken wachten op een MRI is ook eigenlijk extreem lang 
vind ik. Als ik mezelf er al van bewust was dat het niet goed 
zou kunnen zijn, dan was ik daar niet akkoord mee gegaan. 
Dat was ik dus niet, ik ben gewoon op vakantie geweest.
‘The referral for that second opinion at the sarcoma centre 
had to go through the GP’ (male, #2). 
Die verwijzing voor die second opinion hier naar het 
Radboud moest via de huisarts.
‘They biopsied 3 times so they would have enough, but they 
hadn’t because it turned out they were still in doubt between 
a chondrosarcoma and an osteosarcoma. After that I got a 
biopsy under general anaesthesia and that showed it was an 
osteosarcoma, but low grade. [...] Then I had an operation, 
which went well, but they found other, more aggressive, cells, 
which is why I had to come here eventually’ (male, #1).
‘Ze deden dat [biopteren] extra 3 keer want dan zouden ze 
genoeg hebben, maar ook dat was niet genoeg, omdat ze 
toen aan het twijfelen waren tussen een chondrosarcoom 
en een osteosarcoom. Daarna kreeg ik een biopt onder 
narcose en die liet zien dat het een osteosarcoom was, maar 
laaggradig. […]De operatie gedaan, dat was wel gelukkig 
goed gegaan, maar dan toch andere agressieve cellen 
gevonden, waardoor ik toch hier in het traject ben beland.
‘That MRI-centre is nearby and I just went there and said: “I 
want you to make an MRI of my leg”. They do that if you pay 
for it yourself’ (male, #2). 
Dat MRI-centrum zit in Elst en daar ben ik gewoon 
langsgegaan en gezegd: ‘ik wil dat er een MRI van mijn been 
gemaakt wordt’. Dat kan als je het zelf betaalt.
‘So, my GP looked and investigated me but did not know 
what it was, so he sent me for an ultrasound that same 
afternoon’ (female, #5). 
Dus hij heeft gekeken en onderzocht en vond het eigenlijk 
ook maar, ja, kon het ook niet thuis brengen, dus hij heeft me 
eigenlijk gelijk ’s middags voor een echo gestuurd
‘The doctor said: “if I had not seen you on Sunday and I had 
not seen the difference between Sunday and Friday, then I 
probably would not even have referred you to the hospital”’ 
(male, #7). 
De dokter heeft ook zelf gezegd van: had ik jou die zondag 
niet gezien en het verschil niet gezien tussen zondag 
en vrijdag, dan had ik je waarschijnlijk vrijdag niet eens 
doorgestuurd naar het ziekenhuis.
‘Yes, I had to get used to the travel distance. […] The travel 
costs, it was my savings I used. You can ask something 
back from the insurance company, that is nice, but in the 
beginning it did cost a bit more money’ (male, #1).  
Ja, die reisafstand was in het begin wel even wennen. […]Het 
is een buffertje wat je op gaat maken voor ons. Je kunt ook 
een gedeelte terugvragen bij CZ, dus dat is ook wel fijn, maar 
op dat moment kost het wel wat meer geld.
‘I entered the room and he said: “I have not got good news 
for you”. I then thought: “wow”. It was like a rollercoaster. I had 
gone alone.  I was startled, absolutely. No, I really did not see 
it coming. It came out of nowhere.’ (male, #1). 
Ik kwam binnen en hij zei het al gelijk toen ik binnen was: ‘ik 
heb geen goed nieuws voor je’. Toen was ik echt van: wow. 
Dan kom je in het circus, eigenlijk een achtbaan. Ik was ook 
alleen gegaan. Het was wel schrikken, absoluut.
‘Yes, I understand it does influence my prognosis’ (male, #2). Ja, dat begrijp ik volgens mij dat het mijn prognose 
beïnvloedt.
‘It was difficult from the moment of the result at the hospital 
until the scans. Especially after the scans I was wondering: 
“is it somewhere else, how bad is it?” I thought I was dying.’ 
(male, #1). 
Het was gewoon zwaar van het moment in het ziekenhuis 
bij de uitslag tot na de scans. Vooral na die scans dat jij je 
afvraagt: zit het nog ergens anders, hoe ernstig is het. Ik 
dacht wel dat ik doodging.
‘Everything could have gone faster if people had been more 
aware that this could be sarcoma’ (male, #1).
Alles had sneller kunnen gaan als mensen zich meer bewust 
zouden zijn dat dit een sarcoom kan zijn.
‘The key is to start with your general practitioner’ (female, #5). De kern is toch dat je bij je huisarts begint.
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Abstract
Background
Sarcoma patients are hypothesized to experience a prolonged route to cancer diagnosis. 
This route, the total interval, can be divided into a patient (time from symptom to doctor 
consultation) and diagnostic interval (time from first consultation to diagnosis). We 
investigated these intervals of sarcoma survivors and identified factors associated with 
prolonged intervals.
Methods
We conducted a cross-sectional study among adult sarcoma patients, 2-10 years after 
diagnosis. Patients completed a questionnaire on their total interval, which was linked 
to clinical data from the Netherlands Cancer Registry. Descriptive statistics were used 
to describe intervals. Based on Dutch clinical guidelines, a diagnostic interval ≥1 month 
was considered prolonged, an interval ≥3 months as very long. Multivariable regression 
analyses investigated associations between patient and tumor characteristics, and interval 
length. 
Results
1099 participants were included (response rate 58%); 60% reported a patient interval ≥1 
month and 36% ≥3 months. Risk factors for a very long patient interval were sarcoma of 
skin, pelvis, liposarcoma or rhabdomyosarcoma. Stage III disease was associated with a 
shorter patient interval. Diagnostic interval length was ≥1 month in 55%, ≥3 months in 
28%; risk factors for a very long diagnostic interval were being female, aged <70, or having 
a synovial sarcoma or chordoma. 
Conclusion
Patient and diagnostic interval length were prolonged in a substantial proportion of this 
sarcoma survivorship population. Factors associated with length of patient or diagnostic 
interval differed. Creating awareness among (especially young) patients to consult a 
doctor and awareness among doctors to consider a sarcoma diagnosis will contribute to 
optimization of the total interval.
Keywords: sarcoma, survivorship, diagnostic interval, patient interval, diagnostic 
pathway, cancer diagnosis, delay to diagnosis
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Introduction
Sarcomas are a group of solid malignant mesenchymal tumors, with more than 70 
histological subtypes[1]. They have considerable heterogeneity with respect to age 
of onset, anatomic location, speed of progression, and outcome. Approximately 80% 
of sarcomas originate in soft tissue(STS) and 20% in bone(BS). Sarcomas form a typical 
example of rare cancer, with an estimated incidence of 4-5 per 100 000 per year[2]. 
Patients with rare cancers have a higher mortality rate than those with common cancers. 
Delayed diagnostic pathways, lack of expert pathologists, absence of rare tumour-specific 
multidisciplinary meetings, cancer-specific therapies and clinical trials often preclude rare 
cancer patients from receiving proper, timely diagnosis and care[3].
Sarcoma patients may experience long intervals to diagnosis, and the time to diagnosis 
has been measured frequently[4]. Total intervals for BS were 9-120.4 weeks, and 4.3-614.9 
weeks for STS. However, these studies often describe small cohorts and are heterogeneous 
regarding inclusion criteria and study designs. Several theoretical models exist to describe 
time to cancer diagnosis. For research purposes it is important to work with a standardised 
framework with clear definitions of each event and time interval within the diagnostic 
pathay. In this paper we use the influential model developed by Olesen et al[5]. The time 
to diagnosis, the time between first symptoms and (histological) diagnosis, is known as 
the total interval, which can be divided into a patient and diagnostic interval[5, 6]. 
The current interest in a prolonged interval in general is mainly based on the assumption 
that early diagnosis will lead to better survival. As research on diagnostic intervals mainly 
focusses on patients newly diagnosed with sarcoma, no data are available on survivors 
and their recall from the total interval. In other cancer diagnosis, prolonged total intervals 
lead to worse outcomes[7]. This knowledge led to optimization the diagnostic pathway 
for several types, e.g. by introducing fast referral pathways or performing multiple 
additional investigations on one day. It is therefore important to identify risk groups for a 
prolonged interval, in order to study whether these strategies would improve outcomes 
for sarcoma patients as well. We aim to describe the total interval and its components of 
sarcoma survivors, and to identify patient and tumor characteristics to define risk groups 
for prolonged intervals. 
Methods
Study design and participants
This population-based cross-sectional study included sarcoma survivors aged ≥18, 
registered in the Netherlands Cancer Registry (NCR), and diagnosed with sarcoma 
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between 1-1-2008 and 31-12-2016 at one of the six participating sarcoma expertise 
centers (Radboudumc Nijmegen, The Netherlands Cancer Institute Amsterdam, 
University Medical Center Groningen, Leiden University Medical Centre, Erasmus MC 
Cancer Institute Rotterdam, Maastricht University Medical Centre), regardless of their 
current disease status(Appendix 1 includes the selected morphology codes derived 
from ICD-O[8]). Exclusion criteria were cognitive impairment, too ill (judged by their (ex-) 
treating physician) or deceased at time of the study, unverifiable address, or inability to 
read and write in Dutch. Patients with desmoid fibromatosis, grade 1 chondrosarcoma, 
atypical lipomatous tumors or giant-cell tumors were excluded due to the indolent clinical 
behavior and less aggressive treatment strategies for these histological subtypes. In 
addition, patients with gastrointestinal stromal tumors were excluded. The NCR compiles 
data of all individuals newly diagnosed with cancer in the Netherlands[9]. Data registration 
is done by employees of the Netherlands Comprehensive Cancer Organization (IKNL) and 
includes patient and tumor characteristics. The main pathology source is the Nationwide 
Network and Registry of Histo- and Cytopathology in the Netherlands (PALGA)[10]. 
Ethical approval was given by the medical ethical committee of Radboud University 
Medical Centre (2017-3944). According to Dutch law, approval of one ethical committee 
for questionnaire research is valid for all participating centres. The study was registered in 
the Dutch Trial Registry (NTR-7253). 
Recruitment and data collection
Eligible patients received a letter from their (ex-)treating physician explaining the purpose 
of the study. Patients provided informed consent to participate and agreed to linkage of 
questionnaire data with their clinical data in the NCR. Data collection was conducted from 
October 2018 till June 2019 within PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long-term Evaluation of Survivorship; www.profilesregistry.nl). PROFILES 
is a data management system for the study of the physical and psychosocial impact of 
cancer and its treatment. Questionnaires could be completed online or upon request by 
pencil-and-paper. Paper questionnaires were returned and then scanned to digitalize the 
data. Further details of the data collection method have been described previously[11]. 
Responders were compared to non-responders: patient and clinical characteristics 
registered in the NCR were anonymously compared on group-level
Study measures
While the study was primarily designed to examine HRQoL among sarcoma survivors, 
compared to an age- and sex-matched normative population (https://www.trialregister.
nl/trial/7048; NTR-7253), the current study is a secondary analysis and aims to describe the 
total interval and its components of sarcoma survivors, and to identify patient and tumor 
characteristics to define risk groups for prolonged intervals. Questions on patient and 
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diagnostic interval were designed by the study group to match time intervals and events 
as defined in our adapted version of the standardized definitions proposed by Olesenet 
al[5, 6], as published before[4]. The diagnostic interval can be further divided into a primary 
care, secondary care, and tertiary care interval.  All interval lengths were categorical and 
patient-reported (<2 weeks, 2 weeks-1month, 1-3 months, 3-6 months, 6-12 months, >12 
months). A panel of patients gave feedback on relevance, comprehensibility, length of the 
questionnaire, and design of the questions. 
Socio-demographic and clinical characteristics 
Patient and tumor characteristics hypothesized to be of influence on total interval length 
were selected. Clinical data were derived from the NCR, which routinely collects data on 
patient and tumor characteristics including gender, age, socio-economic status (SES), date 
of diagnosis, histological subtype, tumor grade, localization and stage at diagnosis. Not 
all sarcomas are graded at diagnosis, where possible we added a grade according to the 
guideline at the time of the study[1]. Participants with missing grades were not excluded 
from further analyses. To report on clinically relevant subgroups, participants were divided 
into age categories at time of diagnosis (18-39; 40-70; ≥70 years). Time since diagnosis was 
calculated by subtracting date of questionnaire completion from the date of diagnosis. 
Participants were divided into categories (<2; 2-5; ≥5 years since diagnosis). SES was 
derived from zip codes, and is based on education, income and employment status[12]. 
Marital status, educational level, employment status, and number of comorbidities were 
measured at the time of questionnaire completion and are therefore not included in the 
analysis. 
Statistical analyses
Characteristics of responders were compared to those of non-responders using χ2 statistics 
for categorical variables and t-tests for continuous variables. Descriptive statistics were 
used to describe the study population, their total interval and its components. Categorical 
variables are presented as numbers or percentages, for continuous variables means and 
standard deviations are reported. 
The study population was grouped by patient and diagnostic interval length. Intervals 
were dichotomized into <1 month versus ≥1 month, based upon previous literature and 
considering that campaigns about awareness of cancer symptoms usually use a cut-off of 
three weeks or longer for duration of new symptoms[13-15]. For the diagnostic interval 
the Dutch SONCOS guideline (Stichting ONCologische Samenwerking; foundation for 
multidisciplinary oncological collaboration) states that a period of four weeks between 
referral by the GP and diagnosis is acceptable[16]. In order to identify risk factors for patients 
with a very long patient or diagnostic interval, the same analysis were alsof performed 
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with a cut-off point of 3 months, based on previous cancer interval literature[14, 15, 17]. 
Missing items were assumed to be missing at random. Only available data were analyzed. 
We performed multivariable logistic regression analyses, using a forced entry method. We 
built four models for four dependant variables: patient interval ≥1 month and ≥3 months, 
and diagnostic interval ≥1 month and ≥3 months. Based on a literature review, gender, age 
at diagnosis, SES, histology, stage, grade, and localization were selected as independent 
variables[4]. In case of multicollinearity we tried both factors in different models. The factor 
which resulted in the best model was chosen for further analysis. The calibration of final 
models was tested using Hosmer-Lemeshow goodness-of-fit test. Odds ratios(OR) and 95% 
confidence intervals(95%CI) are reported. All statistical analyses were performed using IBM 
SPSS 25.0; two-sided p-values <0.05 were considered statistically significant. 
Results
A total number of 1887 (ex-)sarcoma patients were approached to participate in our study. 
1099 (58%) of these provided informed consent and completed the questionnaire. Figure 
1 presents the flow chart. 
Responders versus non-responders
Comparative analysis of responders and non-responders found no differences in gender, 
time since diagnosis, and sarcoma subtype (BS versus STS)(Table 1). Non-responders 
were diagnosed at a younger age (50.2 versus 55.1 years, p<0.01), and had a lower SES 
(all p<0.05). Furthermore, their sarcomas were less often localized retroperitoneally, but 
more often in the skin or gynecological organs, and dermatofibrosarcoma protuberans 
occurred more frequently(all p<0.01).
Characteristics of participants
More than half of participants were male (54%) with a mean age at diagnosis of 55(Table 
1). Mean time since diagnosis was 67 months, 76% had a soft tissue sarcoma, 47% were 
localized in the extremities. Only 2% had stage IV (distant metastases) disease at diagnosis.
Length of the components of total interval
Figure 2 shows the proportion of participants and their patient and diagnostic interval. 
The patient interval (n=982) lasted ≥1 month in 60%. Many patients waited longer than 
3 months (36%), or even 12 months (15%) before consulting a doctor, 10% of patients 
could not remember their patient interval length. The diagnostic interval (n=1035) lasted 
≥1 month in 55%, and for 28% it took ≥3 months with 9% of patients  ≥12 months; 5% of 
patients couldn’t remember. 
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Figure 1:  Flow chart
The diagnostic interval can be separated in a primary (n=899), secondary (n=964), and 
tertiary (n=984) care interval. Half of the patients got referred within 1 week (28%) or 1-2 
weeks (23%) by their GP. Those who were not referred promptly had a very long primary 
care interval, of 2 weeks to 1 month (18%), 1-3 months (15%), 3-6 months (6%), 6-12 months 
(4%), or ≥12 months (7%). Twelve percent reported consultation of a diff erent doctor fi rst, 
whereas 4% couldn’t remember their primary care interval length. The secondary care 
interval was <1 month in 64%, 1-3 months in 23%. Only a small proportion of patients 
had a longer interval of 3-6 months (7%), 6-12 months (3%), or ≥12 months (3%). Within 
the tertiary care interval, we saw a similar trend: 85% got diagnosed <1 month, 35% even 
within one week, and 30% in 1-2 weeks. Those who took longer, usually took 1-3 months 
(12%) with only a few participants who reported 3-6 months (2%), 6-12 months (1%), or 
≥12 months (1%)(Figure 2). Patients couldn’t remember the length of their secondary and 
tertiary care interval in 8 and 9%, respectively. 
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Because of rounding, percentages may not add up to 100%.*Differences in continuous variables 
have been examined with the unpaired t-test. For differences in categorical variables,  χ2 statistics 
have been used. NA: not available for non-responders analysis.  
A diagnostic interval ≥3 months was caused by lengthening of all components. Participants 
with a diagnostic interval ≥3 months (28%), had a primary care interval of ≥3 months in 
50%, for secondary care and tertiary care this was 38% and 9%, respectively, versus 17%, 
13%, and 4% for all participants. 
Association between patient interval length and patient and tumor 
characteristics
Multivariabele analyses showed an association between age and patient interval ≥1 
month: patients aged ≥70 at diagnosis were less likely to have a patient interval ≥1month 
(Table 2). This relationship lost its significance at a cut-off of 3 months. Histology, stage, 
and localization were associated with a patient interval ≥3 months.
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Figure 2: Percentages of participants per interval length
Association between diagnostic interval length and patient and tumor 
characteristics
Multivariable analysis showed an association between age at diagnosis and diagnostic 
interval ≥1month: patients aged ≥70 were less likely to have a long diagnostic 
interval(Table2). This association remained significant at a cut-off of 3 months. Gender 
was associated with a diagnostic interval ≥3 months as well: females were more likely to 
experience a long diagnostic interval. 
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Table 2: Multiple regression analysis of association between patient and diagnostic interval 















OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Gender
•  Male
•  Female 1.2 0.9-1.6 1.0 0.7-1.3 1.3 1.0-1.7 1.4* 1.1-2.0
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The first category is the reference category; *p<0.05; MPNST: malignant peripheral nerve sheath 
tumor. **n=2 for multivariable analysis, therefore unreliable OR (>10.000) and 95% (0.0-infinite). 
***n=7 for multivariable analysis, therefore unreliable OR. Chi-square of model for patient interval 
≥1 month: 73.111 (p=0.000); ≥3 months 84.146 (p=0.000); diagnostic interval ≥1 month 55.122 
(p=0.003); ≥3 months 57.271 (p=0.002).
92   |   Chapter 4
Discussion
In this cross-sectional survivorship study, we described the total interval of adult sarcoma 
patients as reported by the sarcoma survivors and identified factors associated with 
patient and diagnostic interval length. To our knowledge our study is the largest to report 
on the route to diagnosis of adult sarcoma patients.
We found the length of the total interval of adult sarcoma patients to be highly variable 
due to different patient and diagnostic intervals, which is in line with existing literature. 
The patient interval was long (≥1 month) in 60%, and very long (≥3 months) in 36%. 
The hypothesis that low stage, indolent sarcomas do not trigger patients to seek help, is 
supported by our findings and due to our survivorship patient selection. Tumors located 
in the pelvis often cause npn-specific symptoms causing patients to delay a visit to their 
GP. Stage III tumors often grow rapidly, causing patients to seek help as soon as they 
experience symptoms. Similar results were found in a British adult sarcoma study[17]. A 
review amongst other cancer patients, with mostly retrospective data, found contradictory 
results: older age was associated with patient delay for breast cancer, whereas there was 
inconclusive evidence or no impact on patient interval length in upper gastro-intestinal, 
gynecological, colorectal, urological, and lung cancer[18]. Similar to findings in our study, 
gender and SES were not associated with patient interval length in most cancers, although 
patients with a lower SES who had upper gastro-intestinal or urological cancer waited 
longer.
The diagnostic interval was long (≥1 month) in 55%, and very long (≥3 months) in 28%. 
A long diagnostic interval was not based on one specific component, but remarkably on 
all its components (primary, secondary, and tertiary care interval). These are important 
findings because improving the patient, diagnostic and referral pathway could thus 
be highly profitable in reducing the total interval length. It is difficult to compare our 
findings with other sarcoma studies, as in general those studies included mainly children. 
However, the trend of younger patients having longer diagnostic intervals was also seen 
in a British adult sarcoma study[17] and is generally seen amongst other cancer subtypes 
such as breast, upper gastro-intestinal, and pancreatic carcinoma, although results are 
contradictory for several other cancer types in different studies[18, 19]. Furthermore, the 
latter study by Din et al only included patients aged ≥40 and these results are thus not 
directly comparable. 
In our study, the secondary care interval lasted less than 4 weeks in 57%, however, it lasted 
more than a month for 33% of patients. According to Dutch guidelines, the secondary 
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interval should not last more than 4 weeks[16] unless a patient is being referred to a 
different healthcare facility, such as a sarcoma centre, when an additional three weeks 
may be added to the interval. An important number of patients does thus not receive 
a diagnosis within this time limit. The tertiary care interval was <1 month for 78% of 
patients. This proportion may be overestimated due to a group of patients diagnosed with 
sarcoma at the referring hospital, and who thus received their diagnosis before or at the 
first appointment (e.g. within a week: 32%). 
The question arises whether the proportion of prolonged intervals found in our study 
is due to healthcare system factors. The Dutch curative healthcare sector is financed by 
taxes and obligatory personal healthcare insurances, with which care by a GP does not 
result in additional costs for the patient. Almost all citizens are registered with a particular 
GP, which they need to consult to be referred for hospital care. In the Netherlands, there 
is no private sector for sarcoma care. Literature on whether healthcare system factors 
influence total interval length is scarce and studies with direct comparisons are lacking. 
Future research should ideally have an international design, which enables the evaluation 
of the contribution of healthcare system factors on total interval length.  
Our study had a response rate of 58%, which is high considering decreasing response 
rates in cross-sectional surveys[20-23]. Although non-responders were slightly younger 
and had a lower SES than responders, they showed an equal distribution of gender, time 
since diagnosis, and rate of BS versus STS and we therefore assume that our study is 
representative for all sarcoma patients with a 2-10-year survival after diagnosis. However, 
due to the survivorship nature of the study, there is a selection bias in which elderly with 
significant co-morbidities, primary metastatic patients and patients with low literacy are 
probably underrepresented in this cohort[24]. Another part of this selection bias is that 
we invited patients diagnosed or treated at six sarcoma centers and may have missed 
patients treated in regional hospitals, who probably had more superficial and low-grade 
sarcomas.
A second limitation is that our data were patient-reported and subject to recall bias. 
However, when given the choice to indicate whether they could or could not remember 
the time intervals, 90% and 95% of patients indicated they still remembered their patient 
and diagnostic interval length, respectively. Furthermore, time since diagnosis was not 
associated with either length of patient or diagnostic interval(data not shown). A generally 
consistent research finding is that as the recall time increases, the ability to recall events, 
begins to degrade[25]. However, significant events, such as a cancer diagnosis, are less 
likely to be forgotten[25]. Furthermore, estimation of duration of an event is extremely 
stable[26]. To minimize the effect of recall bias in our study, patients had to report duration 
of intervals instead of exact dates, questions were anchored to a life event (cancer 
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diagnosis), history had to be recalled in a chronological fashion, and comprehensibility of 
questions was checked by patient.
Further research is needed to understand the exact reasons and consequences of long 
diagnostic intervals. Our study group currently conducts a prospective, longitudinal, 
international study called QUEST: “QUality of life and Experiences of Sarcoma Trajectories”, 
to investigate the total interval in more detail and to link its length to both clinical and 
patient-reported outcomes(clinical trials record 2017-3881). The international design 
of this study allows for comparison of healthcare system factors, as well as patient and 
tumor characteristics. Its prospective design enables us to include all patients, including 
those with incurable disease and aggressive subtypes. Furthermore, understanding of 
the consequences of long diagnostic intervals will enable the sarcoma community to 
develop strategies to reduce diagnostic delay, including creating awareness among the 
general population and doctors (such as the ‘golf ball campaign’) and expert and fast 
comprehensive diagnostics at sarcoma centers.
Conclusion
The time to diagnosis of adult sarcoma patients who have survived 2-10 years after 
diagnosis is highly variable, and both patient and diagnostic interval contribute to a long 
total interval. More than half of our participants had a patient and diagnostic interval 
of ≥1 month or even ≥3 months in about a third of cases. Risk factors for a very long 
patient interval were sarcomas in the skin or pelvis, whereas having a liposarcoma, 
myxofibrosarcoma, rhabdomyosarcoma or other STS, and stage III disease lead to a shorter 
interval. Risk factors for a very long diagnostic interval were being female or aged 18-69. 
As the effect of a prolonged interval on outcomes remains unclear in terms of morbidity, 
HRQoL, and survival, we should prioritize in depth analysis of all contributing factors in 
patients and healthcare systems which are responsible for diagnostic delays. Analyzing 
this will result in recommendations which enable optimization of the total diagnostic 
trajectory for sarcoma patients.
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Abstract
Background
Sarcoma patients often experience a long time to diagnosis, known as the total interval. 
This interval can be divided into a patient (time from symptom to doctor consultation) 
and diagnostic interval (time from first consultation to diagnosis). In other cancers, a long 
total interval has been associated with worse outcomes, but its effect on health-related 
quality of life (HRQoL) has never been investigated among sarcoma patients. This study 
investigates the association between (1)actual time to diagnosis and HRQoL; (2)perceived 
impact of diagnostic interval length and HRQoL; (3)actual length and perceived impact of 
length on HRQoL of sarcoma survivors.
Methods
A cross-sectional study was performed among sarcoma patients aged ≥18, diagnosed 
2-10 years ago in the Netherlands. Participants completed a questionnaire on HRQoL, 
time to diagnosis, perceived impact of diagnostic interval on HRQoL, and coping. 
Results
1099 participants were included (response rate 58%). The mean time since diagnosis 
was 67.4 months. More than half reported a patient (60%) or diagnostic interval (55%) 
≥1 month. A third (31%) perceived a negative impact of their diagnostic interval length 
on HRQoL.  Patient or diagnostic interval length were not associated with HRQoL. In 
contrast, participants perceiving a negative impact (32%) had lower HRQoL scores than 
those perceiving a positive (11%) or no impact (58%)(p=0.000). This association remained 
significant in a multivariable model, in which maladaptive coping strategies and tumour 
characteristics were also found to be associated with HRQoL. Participants perceiving a 
negative impact of length of diagnostic interval related this to high psychological distress 
levels, more physical disabilities, and worse prognosis. 
Conclusion
The perceived impact of diagnostic interval length was associated with HRQoL of sarcoma 
survivors, whereas actual length was not associated with HRQoL. Maladaptive coping 
strategies were independently associated with HRQoL. This offers opportunities for early 
intervention to improve HRQoL.
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Introduction
Sarcomas are mesenchymal tumours, with considerable heterogeneity regarding age of 
onset, anatomic location, histological subtype, and outcome. These solid tumours consist 
of more than 100 histologic subtypes which originate in soft tissue (STS; 80%) or bone (BS; 
20%). Sarcomas are typical examples of rare cancers (less than 6 individuals in 100,000/
year), and have an estimated incidence of 4-5 per 100.000 per year[1]. Patients with rare 
cancer have worse outcomes than patients with common cancers: in The Netherlands 
the 5-year survival rate of all subtypes of STS and BS taken together is 58% and 49%, 
respectively, which is lower than 5-year survival rates for all cancers diagnosed in The 
Netherlands (65%)[2]. Given the rarity and heterogeneity of the disease, sarcomas are 
often not recognized by healthcare providers, leading to delayed diagnostic pathways. 
Also, the diagnostic process can be complex, leading to a prolonged diagnostic time in 
expert centres. Furthermore, a lack of expert pathologists, absence of tumour-specific 
multidisciplinary teams, cancer-specific therapies and clinical trials often preclude 
patients with rare cancer from receiving a proper, timely diagnosis and adequate care[3]. 
Historically, evaluation of oncologic care has focused on clinical outcomes, such as 
treatment-related toxicities and overall survival. Currently, more attention is being given 
to patient-reported outcomes, such as health-related quality of life (HRQoL). HRQoL 
refers to the impact of disease and treatment on domains of physical, psychological, and 
social functioning[4]. In other malignancies, prolonged time to cancer diagnosis has been 
associated with worse HRQoL[5]. The association between time to diagnosis and HRQoL 
has never been investigated quantitatively among sarcoma patients, but qualitative 
reports indicate that time to diagnosis influences patients’ physical and psychosocial well-
being[6, 7]. This may not only influence HRQoL on the short-term but may also influence 
HRQoL among sarcoma survivors. 
Although survival rates of sarcoma patients lag those of common cancer patients, there 
are an estimated 280.000 sarcoma survivors in Europe[1] who require supportive and 
rehabilitation services. To improve these services, we need to understand care experiences 
and needs of sarcoma survivors. Survivorship care focusses on the health and well-being 
of a person with cancer from the time of diagnosis until the end of life[8], including issues 
related to follow-up care (e.g. regular health and wellness check-ups), late effects of 
treatment, cancer recurrence, second cancers, and HRQoL. 
This study investigates the association between actual time to diagnosis and HRQoL in 
a group of adult sarcoma survivors. Furthermore, the perceived impact of diagnostic 
interval length on HRQoL, both quantitative as well as qualitative, and the independent 
association of time to diagnosis and other variables on HRQoL are investigated.  
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Methods
Study design and participants
This cross-sectional cohort study included Dutch sarcoma patients aged ≥18, registered 
in the Netherlands Cancer Registry (NCR), and diagnosed between 1-1-2008 and 31-
12-2016 at one of the participating sarcoma expertise centres (Radboud University 
Medical Centre Nijmegen, Antoni van Leeuwenhoek Amsterdam-The Netherlands Cancer 
Institute, University Medical Centre Groningen, Leiden University Medical Centre, Erasmus 
MC Cancer Institute Rotterdam, Maastricht University Medical Centre). Participants had 
to be able to complete Dutch questionnaires by themselves. Patients with desmoid 
fibromatosis, grade 1 chondrosarcoma, atypical lipomatous tumour, giant-cell tumours, 
or gastro-intestinal stromal tumour were excluded due to their indolent clinical behaviour 
or different treatment strategies compared to other sarcomas. Ethical approval was given 
by the medical ethical committee of Radboud University Medical Centre (2017-3944) and 
the study was registered in the Dutch Trial Registry (NTR-7253). 
Recruitment and data collection
Eligible patients received a letter from their (ex-)treating physician explaining the purpose 
of the study. After providing informed consent, patients could complete questionnaires 
either online or by pencil-and-paper. Further details of this method have been described 
previously [9, 10]. 
Study measures
While this study was primarily designed to examine HRQoL among sarcoma survivors 
compared to an age- and sex-matched normative population (https://www.trialregister.nl/
trial/7048; NTR-7253), the current study is a preplanned, secondary analysis investigating 
the association between time to diagnosis and HRQoL.
Time to diagnosis
Time to diagnosis is often referred to as the total interval. The total interval, describing 
time from first symptom until (histological) diagnosis, can be divided into a patient 
and diagnostic interval[6, 11, 12]. These encompass time from first symptom until first 
presentation to a doctor (patient interval), and time from this first presentation until 
pathologic diagnosis (diagnostic interval). The diagnostic interval can be further divided 
into a primary care, secondary care, and tertiary care interval. 
Questions on patient and diagnostic interval length were designed by the study group, 
all intervals were patient-reported, and answers were categorical. The study population 
was grouped by length of the patient and diagnostic interval, with a cut-off point of 1 
month, based on previous literature[13-16]. Many countries quantify four weeks or one 
month for the diagnostic interval as appropriate and also the Dutch SONCOS guideline 
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(Stichting ONCologische Samenwerking; foundation for multidisciplinary oncological 
collaboration) accepts a period of four weeks between referral by the GP and histological 
cancer diagnosis[17].
Health-related quality of life: EORTC QLQ-C30
HRQoL was measured by the European Organization for Research and Treatment for 
Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30). This self-administered 30-item 
questionnaire has been validated to measure HRQoL in cancer patients[18]. It consists 
of a global health status, five functional scales, three symptom scales, and several single 
items assessing additional symptoms and perceived financial impact of the disease. The 
global health status is the patient’s rating of his overall health and quality of life during 
the past week; the functional scales assess physical, cognitive, role, social, and emotional 
functioning. Global QoL and the functioning scales were used in our analyses. After linear 
transformation of the raw scores, all scores range from 0 to 100; a higher score represents 
a better global health status or level of functioning[19]. Apart from a quantitative score, 
one can examine clinical relevance using the guidelines of Cocks et al; they distinguish 
four effect sizes: trivial, small, medium, or large[20]. Each scale has its own threshold 
between size classes. A guideline for the interpretation of the clinical impact of emotional 
functioning is missing, therefore the cut-off points of role functioning were used, as this is 
the most conservative scale and this method has been described previously[21].
Perceived impact of diagnostic interval length on HRQoL
This was assessed by a single question: ‘Do you think your HRQoL was influenced by your 
diagnostic interval length?’, and the option for patients to explain their multiple-choice 
answer (yes, negatively; yes, positively; or no) in an open text field. 
Socio-demographic and tumour characteristics
Tumour characteristics were available from the NCR, which routinely collects data of 
all individuals newly diagnosed with cancer. These include date of diagnosis, histology, 
tumour grade, localisation, and stage at diagnosis, as well as several patient characteristics 
such as age at diagnosis, gender and socio-economic status(SES). Patients were grouped 
into clinically relevant subgroups based on age (18-39; 40-69; ≥70 years old). SES was 
derived from zip codes, and is based on education, income and employment status[22]. 
Date of participation was subtracted from date of diagnosis to calculate time since 
diagnosis. The treatment modalities were patient-reported and include all treatments 
patients have had since their primary diagnosis. 
Coping
Coping, the way an individual conducts oneself to decrease the effect of a stressful 
situation[23], was assessed using the Illness Cognition Questionnaire for chronic diseases 
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(ICQ)[24]. This 18-item questionnaire consists of three cognition subscales of six items rated 
on a 4-point Likert scale: helplessness as a way of emphasizing the aversive meaning of the 
disease; acceptance as a way to diminish the aversive meaning; and perceived benefits as 
a way of adding a positive meaning to the disease[24]. Total subscale scores could range 
from 6 to 24, with higher scores on helplessness, and lower scores on acceptance and 
disease benefits indicate maladaptive coping strategies. Adaptive coping means that 
one evaluates the situation, actively seeks for help, considers all thinkable solutions and 
actively tries to solve the problem, while maladaptive coping means one will try to move 
away from the stressful event, indicating that the problem will not be solved.
Statistical analyses
Descriptive statistics were used to describe the study population. Categorical variables 
are presented as numbers and percentages, for continuous variables, means and standard 
deviations are reported. 
To investigate the association between patient and diagnostic interval length, perceived 
impact of length of diagnostic interval and HRQoL (global health status and all five 
functioning scales), a series of one-way analysis of variance (ANOVA) were conducted, 
with a cut-off point of 1 month. 
The independent association between interval length, perceived impact of diagnostic 
interval on HRQoL, and patient and tumour characteristics and coping strategies were 
tested using multivariable linear regression analyses (for global health status and all five 
functioning scales). 
Open field answers given by patients who described a negative impact of their diagnostic 
interval length on HRQoL were analysed by two investigators (VS and OH) using inductive 
coding, followed by axial coding to define main themes. Quotes to illustrate the results 
were selected.
Missing items in the multi-item domains of the EORTC-QLQ-C30 were imputed with simple 
mean imputation, according to the guidelines of the EORTC Quality of Life Group[19]. After 
imputation of these values an available cases analysis was performed. All other missing 
data were assumed to be missing at random, and only available data were analysed. All 
statistical analyses were performed using IBM SPSS 25.0; two-sided p-values of <0.05 were 
considered statistically significant.
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Results
Participants
We included 1099 of 1887 invited sarcoma patients (response rate 58%). The flow-chart 
and characteristics of responders have been published before[9]. Responders were 
diagnosed at a mean age of 54.6 years, 54% were male, mean time since diagnosis was 
67.4 months, 76% were diagnosed with STS and 47% of sarcomas were located in the 
extremities (Table 1).
 
Health-related quality of life by patient and diagnostic interval length
The patient interval lasted ≥1 month in 60% (n=589). The diagnostic interval lasted ≥1 
month in 55% (n=569). No statistical differences in HRQoL were found for the different 
patient and diagnostic interval groups (Figure 1A). 
Influence of perceived impact of diagnostic interval on HRQoL
More than half of participants (58%, n=620) thought their HRQoL was not influenced 
by their diagnostic interval length, whilst 31% (n=337) and 11% (n=115) thought their 
HRQoL was influenced negatively or positively by their diagnostic interval length. 
In all domains, patients with a perceived negative impact of diagnostic interval length on 
HRQoL scored significantly lower compared to the patients with no or a positive perceived 
impact. (Figure 1B). All these differences showed a small clinically relevant difference 
as well, both between the groups who perceived a negative impact versus the group 
experiencing a positive impact or no impact. There was no difference between the group 
experiencing a positive impact and those experiencing no impact.   
Independent association of patient interval and patient and tumour 
characteristics on HRQoL
Global health status was independently associated with perceived impact of diagnostic 
interval length on HRQoL (Table 2). Participants perceiving a positive or no impact, had 
a higher global health status than those perceiving a negative impact. Furthermore, 
participants with a lower global health status score showed maladaptive coping strategies, 
with higher scores on helplessness and lower scores on acceptance and disease benefits. 
Several tumour characteristics were associated with global health status. 
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Age at diagnosis in years: Mean (SD) 54.6 (15.4)







Coping: mean (SD) 
•  Helplessness
•  Acceptance




Time since diagnosis in months: Mean (SD) 67.4 (30.4)
Location n (%)
•  Extremities 











•  Synovial sarcoma
•  Vascular sarcoma





•  Ewing sarcoma


















•  Low grade
•  Intermediate or high grade
614 (60)
407 (40)
Metastases at diagnosis n (%)




Treatment modalities n (%)
•  Surgery 
•  Surgery and radiotherapy 
•  Surgery and chemotherapy 





The n of an individual cell may be smaller due to missing values. Participants who had only undergone 
radiotherapy, chemotherapy or a combination of the two were excluded from this analysis, due to 
their small group size and unreliable analysis.
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Figure 1A: Mean scores on HRQoL
Figure 1B: Mean HRQoL scores by impact of diagnostic interval on HRQoL
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Table 2: Standardized betas of multivariable linear regression analysis evaluating the 










































































































































































































































































#STS = soft tissue sarcoma; BS = bone sarcoma; dfsp = dermatofibrosarcoma; myxofibros. = 
myxofibrosarcoma; leiomyos. = leiomyosarcoma; rhabdomyos. = rhabdomyosarcoma; mpnst = 
malignant peripheral nerve sheath tumour; chondros. = chondrosarcoma. ^CHx = chemotherapy; 
RTx = radiotherapy. *= p<0.05. ** p<0.01. 
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Similar results were found for the functioning scales (Table 2). Coping strategies, and 
especially the helplessness scale, was negatively associated with all functioning scales. 
The perceived impact of the diagnostic interval length on HRQoL showed a similar trend 
for all functioning scales but was only significant for the difference between the no impact 
group and the negative impact group on the emotional and social functioning scale. Age 
was associated with all functioning scales, and gender, SES, and time since diagnosis were 
associated with physical functioning. 
Independent association of diagnostic interval and patient and tumour 
characteristics on HRQoL
Although diagnostic interval length was not associated with global health status, the 
perceived impact of diagnostic interval length remained significantly associated (Table 3). 
Participants perceiving a positive or no impact have a higher global health status. Those 
with maladaptive coping strategies had lower global health status scores. Both location 
and histology were associated with global health status in the model including patient 
interval length.
Table 3: Standardized betas of multivariable linear regression analysis evaluating the 































































































































































































































































































#STS = soft tissue sarcoma; BS = bone sarcoma; dfsp = dermatofibrosarcoma; myxofibros. = 
myxofibrosarcoma; leiomyos. = leiomyosarcoma; rhabdomyos. = rhabdomyosarcoma; mpnst = 
malignant peripheral nerve sheath tumour; chondros. = chondrosarcoma. ^CHx = chemotherapy; 
RTx = radiotherapy. *= p<0.05. ** p<0.01. 
On the functioning scales coping strategies, especially the helplessness and acceptance 
scales, remained independently associated. Age at diagnosis, gender, SES, and a longer 
time since diagnosis remained associated as well. 
Considerations of patients who perceive a negative impact of their diag-
nostic interval length on HRQoL; qualitative analyses
We identified three main themes: psychological distress, physical inability, and influence 
on prognosis. Of the patients who commented on why their HRQoL was influenced 
negatively by their diagnostic interval length (n=298), 52% said this was due to 
psychological distress: an increase of insecurity, fear, and stress. 73% of these participants 
had a diagnostic interval length ≥1 month, 39% ≥3 months. They experienced these 
emotions not only during the diagnostic trajectory, but also in their current lives. They 
feared recurrence of disease, metastases or death. 
Table 3: Continued
5
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 ‘Fear, you don’t know when and where it recurs. You continuously monitor your body.’
 ‘Heavy psychological stress during the diagnostic trajectory.’ 
Many (41%) reported more physical inability due to longer lasting complaints, growth 
of the tumour and consequently more elaborate treatment, such as larger operations, 
the addition of radiotherapy or chemotherapy. 81% of these participants reported a 
diagnostic interval ≥1 month, and 63% ≥3 months. Some (7%) thought it influenced their 
prognosis and thought metastases or disease recurrence could have been avoided with 
an earlier diagnosis and would have possibly led to a curative treatment. Of these, 86% 
experienced a diagnostic interval ≥1 month and 36% ≥3 months.  
  ‘A lot of pain longer than necessary. Surgical intervention was not possible anymore 
due to the long diagnostic trajectory.’
  ‘Then they would not have to cut it out this far, so I would have fewer complaints 
now.’
  ‘Yes, because if there had been an earlier intervention, then the sarcoma would not 
have been this large and I would not have had metastases.’
 ‘Due to not tackling it immediately it came back twice.’
Discussion
In this cross-sectional cohort study among a large sarcoma survivorship population, we 
found that patient and diagnostic interval length were not associated with HRQoL scores, 
but the perceived impact of diagnostic interval length on HRQoL was associated with 
HRQoL scores. 
There have been no published studies looking at the effect of patient and diagnostic 
interval length on HRQoL among cancer survivors. However, in a systematic review about 
the effect of total interval length on outcomes of symptomatic cancer just after diagnosis, 
Neal et al found that earlier diagnosis of cancer will likely improve HRQoL[5]. 
Although patient and diagnostic interval length were not associated with HRQoL scores, 
we found perceived impact of diagnostic interval length on HRQoL to be independently 
associated with global health status and several HRQoL functioning scales. Participants 
perceiving a negative impact had lower HRQoL scores than those perceiving a positive 
or no impact. Furthermore, participants with lower HRQoL scores used maladaptive 
coping strategies. Participants perceiving a negative impact of their diagnostic interval 
on their HRQoL, showed higher scores on the subscale helplessness, and lower scores 
on the acceptance and disease benefits scales (data not shown). Both perceived impact 
and coping remained independently associated in our multivariable model. The question 
remains why perceived impact remains associated, this may be due to actual time to 
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diagnosis, or other patient or tumour characteristics. Coping strategy was also found to 
be a significant predictor of HRQoL among other malignancies[25-27]. The use of coping 
strategies can vary between patients, and over time or between situations[23]. Although 
probably not sarcoma specific and solely related to the diagnostic interval length, our 
results indicate that supportive services focussing on developing adaptive coping 
strategies, may positively influence patients’ HRQoL.
Our finding that the perceived impact of diagnostic interval length on HRQoL is associated 
with HRQoL scores, is further supported by the qualitative analysis of open text field 
answers, in which many patients perceiving a negative impact describe psychological 
distress, more physical disabilities, and a worse prognosis due to their diagnostic interval 
length. It is worrying that 2-10 years after diagnosis, patients still report this psychological 
and physical burden. We are not aware of previous studies examining patients’ perception 
of diagnostic interval length and HRQoL. However, our findings are supported by two 
British and two Danish studies, who which reported that cancer patients diagnosed 
through fast-track referrals, were less likely to be dissatisfied with length of waiting times 
and more likely to be satisfied with their subsequent cancer care, compared with those 
referred electively[28-31].
To our knowledge, this is the only study that has investigated the influence of patient and 
diagnostic interval length and perceived impact of diagnostic interval length on HRQoL 
among adult sarcoma survivors. The overall completeness of variables in our analysis 
sample was high. 
Our study has several limitations. First, although we invited all patients diagnosed with 
sarcoma in The Netherlands between 2008-2016, there is a selection bias with probably 
an overrepresentation of patients with high health literacy. Furthermore, due to the 
survivorship nature of the study, there is a natural selection of patients with a favourable 
prognosis, less aggressive histological subtypes, and low co-morbidity. Second, our interval 
length data are subject to recall bias. However, 90% and 95% of patients indicated they still 
remembered their patient and diagnostic interval length. In general, significant events, 
such as cancer diagnosis, are not likely to be forgotten[32]. Furthermore, estimation of 
duration of an event is extremely stable[33]. Third, one may argue that a cut-ff of 1 month 
for diagnostic interval length for sarcomas is too short. However, a sensitivity analyses with 
a cut-off of 3 months, did not show different results. Last, one of the biggest challenges 
when measuring patient-reported outcomes is what instrument assesses HRQoL or other 
relevant topics best among the study population. Given the qualitative results of our data, 
the EORT-QLQ-C30 may be too generic to measure the impact of total interval length 
on HRQoL of sarcoma survivors. In future research, patient-reported outcome measures 
focussing on disability, distress, or recurrence may better capture this relationship. 
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Our study has resulted in more understanding of the survivorship experience. Perceived 
impact of the diagnostic interval and coping strategies have a long-lasting effect on global 
HRQoL and all functional scales, it thus seems important to keep the diagnostic trajectory 
and perception thereof as short as possible. 
Since the perceived effect of diagnostic interval length still causes physical and 
psychological disabilities amongst patients 2-10 years after diagnosis, improvement of 
services, treatment and rehabilitation programs may contribute to improving HRQoL 
of sarcoma patients. Patients with maladaptive coping strategies are at risk of lower 
HRQoL. Sarcoma care could be improved if healthcare providers acknowledge patients’ 
frustrations regarding their diagnostic pathway and have eye for their coping strategies. 
If necessary, supportive care focussing on coping strategies could be given early in the 
treatment pathway. 
Conclusion
The perceived impact of diagnostic interval length was associated with HRQoL of sarcoma 
survivors, whereas actual length was not associated with HRQoL. Maladaptive coping 
strategies were independently associated with HRQoL. This offers opportunities for early 
intervention to improve HRQoL.
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Abstract
Purpose
Teenagers and young adults (TYAs; aged 13-24) experience prolonged intervals to 
cancer diagnosis. Insight into diagnostic intervals in young adults (YAs; aged 25-39) and 
subgroups at risk for long intervals is lacking. We investigated the diagnostic pathway of 
YA cancer patients, examined patient and tumor characteristics associated with its length, 
and compared the patient interval length of our sample with a TYA cohort. 
Methods
In this cross-sectional survey YAs diagnosed with cancer in the UK in the past five years 
completed a questionnaire describing their patient (time from first symptom to first 
doctor consultation) and healthcare interval (from first consultation until consultation 
with a cancer specialist), sociodemographic, and clinical characteristics. Associations 
between characteristics and interval length were examined and compared with previously 
published data in TYAs. 
Results
Among 341 YAs the patient interval lasted ≥2 weeks, ≥1 month, and ≥3 months in 60%, 
42%, and 21%, respectively, compared to 48%, 27%, and 12% in the TYA group. The 
healthcare interval lasted ≥2 weeks, ≥1 month, and ≥3 months in 62%, 40%, and 17% 
of YA patients, respectively. YAs with melanoma or cervical cancer were most likely to 
experience long intervals, whereas YAs with breast cancer and leukemia were most likely 
to experience short intervals.
Conclusion
Most YAs were not seen by a cancer specialist within 2 weeks of GP consultation. Interval 
lengths in YAs were associated with cancer diagnosis. Patient intervals were longer among 
YAs than among TYAs. Our study highlights long diagnostic pathways among YAs and calls 
for more awareness among healthcare professionals about malignancies in this age group.
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Introduction
Cancer in adolescence and young adulthood (AYA), defined as patients aged 15-39 at 
cancer diagnosis, is uncommon, accounting for 5% of all cancer diagnoses[1]. Leukemia, 
lymphoma, testicular cancer, and thyroid cancer are the most common cancers among 15 
to 24 year olds, while breast cancer and melanoma are most common among 25-39 year 
olds[2]. 
AYA cancer patients face unique developmental, physical, and psychosocial issues 
that make adjustment to their disease and health-maintenance challenging[3]. AYAs 
describe unsatisfactory care experiences such as lack of recognition of their autonomy by 
healthcare providers (HCPs), lack of peer support, and inappropriate care environments[4, 
5]. To address these issues, the United Kingdom (UK) has rapidly expanded the availability 
of dedicated services for teenagers and young adults (TYA) ages 13 to 24. In contrast, no 
age-specific care services are available for young adult (YA) cancer patients aged 25 to 39 
years. 
Historically, progress in survival for AYAs has lagged behind both children and older 
adults, at least partly due to a prolonged diagnostic pathway[6-8]. Recently, we and 
others showed this gap in survival has closed for most, but not all tumors[9, 10]. Early 
diagnosis of cancer is key to facilitate the start of treatment and can improve psychosocial 
and clinical outcomes[11-13]. The cause of prolonged diagnosis among AYA is likely to 
be multifactorial[14, 15], and may include a lack of awareness amongst AYAs and HCPs, 
heterogenous and non-specific symptoms, and the rarity of cancer at this age. Reducing 
time to diagnosis is a key area for improving cancer care in the National Health Service[16]. 
The BRIGHTLIGHT study, assessing specialist care for TYAs with cancer in England[17], is 
the largest study among TYA patients looking at diagnostic timeliness[15]. In this study, 
over a quarter of participants (27%) waited more than one month to approach an HCP 
about symptoms[15]. 
Although age-specific guidelines to improve diagnostic timeliness in TYAs have been 
developed in the UK, for YAs, no specific guidance exists[18]. Information regarding YA’s 
diagnostic pathway is lacking and often obscured in studies of older adults where most 
patient are over age 50. As life-events and the distribution of cancer types among YAs are 
distinct compared to older adults, available evidence cannot be extrapolated to YAs. 
To improve healthcare services for YAs, we aim to describe the diagnostic pathway of 
patients aged 25-39 at diagnosis, identify factors associated with a prolonged pathway, 
compare the time from first symptom to doctor consultation in YAs with that in TYAs, and 
describe suggestions made by YAs to improve the diagnostic pathway. 
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Methods
Study design and participants
In this cross-sectional observational study, we invited all surviving patients diagnosed with 
cancer (ICD-10 codes C00-C97) aged 25-39 years treated at a participating trust (The Royal 
Marsden Hospital NHS Foundation Trust, East Suffolk and North Essex NHS Foundation 
Trust, University Hospital Southampton NHS Foundation Trust, Barts Health NHS Trust, 
Imperial College Healthcare NHS Trust, and East and North Hertfordshire NHS Trust). 
Patients were eligible if they were diagnosed in the last 5 years, able to communicate 
in English and could complete questionnaires independently. Patients with a previous 
cancer diagnosis were excluded.  
Ethical approval
The Royal Marsden and Institute of Cancer Research Joint Committee on Clinical Research 
reviewed and sponsored the study (CCR4648). The Research Ethics Committee and Health 
Research Authority in the UK approved the study nationally (17/LO/0219). 
Recruitment and data collection
Eligible patients received a letter from their treating physician explaining the purpose 
of the study. Patients provided informed consent before taking part. Data collection 
was conducted from May 2018 until March 2019 using PROFILES(www.profilesregistry.
nl), a web-based system designed to collect patient-reported outcomes in cancer trials. 
Questionnaires could be completed online or upon request by pencil-and-paper. 
Study measures
Whilst the study was primarily designed to examine unmet supportive care needs of YAs, 
this paper describes secondary analyses to explore the diagnostic pathway of participants. 
Demographic and clinical variables
The questionnaire package contained socio-demographic items, including age at 
diagnosis, gender, ethnicity, relationship status, educational level, and gross income per 
annum. Patients also self-reported clinical data including tumor type and comorbidities.
Diagnostic pathway
The questionnaire package included a number of items about the diagnostic pathway, 
including items developed by the BRIGHTLIGHT group to assess the diagnostic pathway 
of TYAs[15, 19]. We explored the patient and healthcare intervals and the number of 
pre-diagnosis consultations as a surrogate marker of diagnostic timeliness (Figure 1). 
The patient interval, as defined previously[20], encompasses the time between the first 
symptom and first consultation with a HCP. The healthcare interval is the time from the 
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first HCP consultation until the first consultation with a cancer specialist. Interval items 
had categorical response options of under 1 week, 1-2 weeks, 2-4 weeks, 1-3 months, 3-6 
months, 6-12 months, more than 12 months or ‘I don’t know’. The number of pre-diagnosis 
consultations was measured with response options 0, 1, 2-3, ‘4 times or more’. 
º spoke to: “On a scale of 1 to 10, do you think your symptoms or concerns were taken 
seriously the first time you spoke to a doctor?”. A single free-text question asked for 
patient opinions on appropriate ways to reduce the time from symptom presentation to 
diagnosis. 
Statistical analysis
Descriptive statistics were reported for participants’ demographic and clinical data, patient 
and healthcare interval lengths, the number of consultations and whether patients felt 
they were taken seriously. Mean and standard deviation are reported for continuous 
variables. Frequency and percentage are reported for categorical variables. For patient 
and healthcare intervals, we dichotomized interval lengths at three separate thresholds: 
<2 weeks versus ≥2 weeks, <1 month versus ≥1 month, and <3 months versus ≥3 months. 
We performed univariate logistic regression analyses to detect associations between 
categorical independent variables and the length of the patient and healthcare intervals 
dichotomized at 1 month following previous studies[15, 21]. Odd ratios (OR) and 
95%-confidence intervals (95% CI) are presented. Independent samples t-tests were 
performed for continuous variables. We did not perform multivariable analysis because 
there were too few observations in each cancer type.
Figure 1 Diagnostic pathway
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The number of pre-referral consultations is an indicator of diagnostic timeliness as 
patients experiencing more pre-referral consultations have longer intervals from 
symptom presentation to diagnosis[22]. We argue that two consultations are usually 
needed before referral, thus ≥4 consultations best reflect a prolonged interval. Therefore, 
we dichotomized diagnostic timeliness into <4 or ≥4 consultations. Fisher’s exact tests 
were performed to test associations between categorical variables and the number of 
consultations before diagnosis. 
To compare our results with TYA patient intervals, we used data published by the 
BRIGHTLIGHT study group[15]. We were unable to compare the healthcare interval or 
number of consultations, as definitions and cut-off points between the two cohorts 
differed. We grouped carcinomas and combined all germ-cell tumors to make direct 
comparisons with the BRIGHTLIGHT cohort. Groups with too few observations or not 
occurring in both cohorts were excluded from the analysis. We reported frequency and 
percentage of patient intervals in both groups and tested the differences using Χ2 tests. 
As we had no access to the raw data from the BRIGHTLIGHT study, tests were limited to 
univariate analysis. Associations between patient characteristics and age group were 
restricted to single levels of patient.  If the expected number within a cell was smaller than 
five, Fisher’s exact tests were performed. 
All missing data was assumed to be missing at random and only complete cases were 
analyzed. All statistical analyses were performed using IBM SPSS 25.0. Two-sided p-values 
of <0.05 were considered statistically significant.
Qualitative Analysis
We analyzed free-text responses using inductive coding followed by axial coding to group 
participants’ answers[23]. Two investigators independently coded the data (VS and OH). 
We describe the number of times each recommendation occurred. 
Results
Participants
Of the 1657 invited patients, 348 completed the questionnaire (response rate 21%); 341 
participants had complete healthcare interval data and were included in the analysis. 
The mean age was 33.3 years, 108 (32%) were male, and 288 (84%) were white (Table 
1A). Breast cancer and testicular cancer were the most common diagnoses. Mean time 
between diagnosis and questionnaire completion was 2.9 years (standard deviation 1.7). 
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Table 1A: Participant characteristics at time of survey 
All participants (N=341)
















•  Testicular cancer
•  Ovarian cancer
•  Melanoma
•  Thyroid cancer
•  Colorectal cancer















Patient interval length 
(n=307; non-exclusive)
•  >2 weeks
•  >1 month




Healthcare interval length 
(n=341; non-exclusive)
•  >2 weeks
•  >1 month











•  In a relationship







•  No education or primary school











gross income per annum
•  < £ 20 000
•  £ 20 000-30 000
















Patient interval data was completed by 307 participants. Seventy-eight percent first told 
a doctor about their symptoms, mostly their general practitioner (GP)(84%). A minority 
of patients were admitted as an emergency (4%) or were detected through screening 
(6%). Those detected through screening had breast (n=2) or cervical cancer (n=16). Half 
the participants with cervical cancer (n=16) were not detected through screening. The 
majority (68%) of patients felt they were taken seriously by the first doctor they spoke to. 
Although 94% of participants experienced symptoms, the majority (60%) waited longer 
than two weeks before consulting a doctor. In 42% and 21% of cases, participants waited 
longer than one and three months, respectively (Table 1A). Reasons for delaying included 
waiting to see whether symptoms would disappear spontaneously, thinking there was 
no need to go to the doctor, being too busy, and not wanting to bother the doctor 
unnecessarily. Patients with melanoma and cervical cancer had significantly higher odds 
of experiencing a patient interval greater than one month compared to those with breast 
cancer (Figure 2A). Gender, age, and ethnicity were not associated with patient interval 
length (Table 1B). 
Figure 2A: Odds ratios of patient interval ≥1 month by diagnosis
Table 1A: Continued
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Table 1B: Participant characteristics by interval length
Patient interval (N=307) Healthcare interval (N=341)
<1 month ≥1 month <1 month >1 month
Mean (SD) Mean (SD) P-value# Mean (SD) Mean (SD) P-value#
Age at diagnosis in years 33.5 (4.3) 33.2 (4.4) 0.6 33.7 (4.2) 32.7 (4.3) 0.03
N (%) N (%) OR (95% CI) N (%) N (%) OR (95% CI)




































•  Testicular cancer
•  Ovarian cancer
•  Melanoma
•  Thyroid cancer
•  Colorectal cancer


















































































#Independent samples t-test; NA = not applicable; ^p<0.0;. OR = odds ratio; CI = confidence interval
Figure 2B: Odds ratios of healthcare interval ≥1 month by diagnosis
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Healthcare interval
Most patients (62%) had a healthcare interval ≥2 weeks. Forty percent of patient intervals 
were ≥1 month and 17% ≥3 months (Table 1A).  Compared to breast cancer, all other 
cancer types except for leukemia and testicular cancer had significantly higher odds 
of experiencing a healthcare interval ≥1 month (Figure 2B). Gender, ethnicity and the 
presence of a symptom were not associated with healthcare interval length. Patients 
with an interval ≥1 month were significantly younger than patients with an interval <1 
month(Table 1B). 
Before receiving a diagnosis, 90% of patients spoke to their GP, 14% to an A&E doctor, 61% 
to a hospital doctor not in A&E, 9% to a walk-in center clinician, 2% to a polyclinic doctor, 
and 12% to another doctor. A considerable number of participants (13%) spoke to their 
GP or a hospital doctor other than in A&E (12%) ≥4 times before diagnosis (Figure 2C).
Figure 2C: Number of pre-diagnosis consultations
The number of consultations, regardless of location, was not associated with age, gender, 
or symptom presence (Table 1C). Cancer type was associated with >4 GP consultations 
and >4 hospital doctor consultations. Participants diagnosed with leukemia, sarcoma, 
ovarian cancer, thyroid cancer, colorectal cancer, and “other diagnoses” most often 
had >4 GP consultations. Participants diagnosed with leukemia, lymphoma, sarcoma, 
testicular cancer, ovarian cancer, and “other diagnoses” most often had >4 hospital doctor 
consultations. 
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Table 1C: Participant characteristics with 4 or more pre-diagnosis consultations 
≥4 GP consultations ≥4 hospital consultations
Mean (SD) Mean (SD)
Age at diagnosis in years 32.3 (4.5)# 33.0 (4.3)#
N (%)~ p-value* N (%)~ p-value*
























•  Testicular cancer
•  Ovarian cancer
•  Melanoma
•  Thyroid cancer
•  Colorectal cancer




































~Percentages do not add up to 100% as data per column is arranged as proportion of patients with 
certain characteristics within a certain time interval. *Fisher’s exact test; ** X2 test. #Independent 
samples t-test showed no differences between age and number of consultations.
Comparison of findings with TYA population
The BRIGHTLIGHT cohort included 830 TYAs aged 12-24 at primary cancer diagnosis[15]. 
Their median age was 20 years, 55% were male, and 88% were white. Participants were 
diagnosed with lymphoma (32%), germ-cell tumors (19%), leukemia (13%), non-skin 
carcinomas (12%), bone cancer (10%), soft tissue sarcomas (6%), central nervous system 
neoplasms (4%), melanoma and skin carcinoma (4%), and unspecified (1%)(Table 2A). 
Complete patient interval data was reported for 748 TYAs. Compared to 341 YA participants, 
48% versus 60% had a patient interval ≥2 weeks, 27% versus 42% ≥1 month, and 12% 
versus 21% ≥3 months, for TYA versus YA patients, respectively (Figure 3). 
Among males, white respondents and patients with lymphoma, YAs were significantly 
more likely to have a patient interval ≥1 month than TYA participants (Table 2B). YAs were 
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also significantly more likely to have a >2 week patient interval compared to TYAs among 
males and white patients, though this association was not significant among cancer 
diagnosis groups (Supplementary material A). When dichotomized at three months, YAs 
were significantly more likely to have a longer patient interval than TYA participants among 
males, white patients, or those diagnosed with lymphoma or sarcoma (Supplementary 
material A). 
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•  Soft tissue sarcoma















TYA= teenagers and young adults; YA = young adults. 
Complete patient interval data was reported for 748 TYAs. Compared to 341 YA participants, 
48% versus 60% had a patient interval ≥2 weeks, 27% versus 42% ≥1 month, and 12% 
versus 21% ≥3 months, for TYA versus YA patients, respectively (Figure 3). 
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Figure 3: Proportion of participants by patient and interval length
Table 2B: Comparison of patient interval of TYA population with YA population
TYA (N=748) YA (N=307) TYA vs YA
<1 month >1 month <1 month >1 month >1 month
N (%) N (%) N (%) N (%) X2 p-value






























•  Soft tissue sarcoma

































TYA= teenagers and young adults; YA = young adults.
Suggestions for improving the diagnostic pathway
Many patients (39%) gave a total of 191 suggestions to improve the diagnostic pathway. 
Themes included raising awareness of cancer in YAs and taking young people seriously, 
communication, and reducing passive waiting times. Table 3 shows exemplary quotes.
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The majority (39%) of recommendations were about raising awareness among HCPs and 
YAs that age should not preclude cancer and taking YAs seriously (Table 3). Nearly a quarter 
(21%) suggested better communication, such as providing more information about 
investigations, not skirting around cancer suspicions, and not giving false reassurance. 
One in six (16%) thought the healthcare interval length could be reduced by shortening 
wait times for examinations, referrals and appointments, and sharing more information 
between institutions and departments. 
A small number of remarks were about the patient interval, recommending that YAs 
should not wait to contact their GP with abnormalities and be persistent about getting a 
diagnosis (9%). 
There were no major differences between groups, but participants with a healthcare 
interval ≥1 month more often remarked about raising awareness and being taken seriously 
(57%), and reducing waiting times for examinations, referrals, and appointments (50%). 
Table 3: Quotes supporting qualitative analyses
Raising awareness and taking young 
people seriously
“I didn’t come across many well-informed doctors before I was admitted to the ***. 
I think cancer was dismissed as a possible reason because I was relatively young 
and otherwise fit and healthy. No one took my tumor markers despite me having 
lumps/swelling. Perhaps my only suggestion is raising awareness with all doctors 
that age is not a reason to discount cancer if they can’t immediately identify the 
cause of a symptom. A blood test may have cut down my wait significantly.”
“I rarely felt like I was being listened to and taken seriously as an individual who 
knew their own body. The GP only took me seriously when I found that a pre-
existing lump in my breast had grown almost overnight, by which time it was too 
late. My sense was that the emergency/rapid response care was very good; but the 
preventative care and taking a holistic look at my symptoms in the early stages 
was completely overlooked.”
Communication “I didn’t realize they could tell you on the day that its cancerous, I thought you had 
to wait for the results, so I was very unprepared and alone (without my husband/
parent).”
“My consultant sent me for a fine needle aspiration but told me this was fairly 
routine. I was not told this was a test for cancer. I feel that I should have been given 
at least some mild warning of the possibility of cancer by the consultant.”   
Reducing passive waiting times “Reducing the wait between being referred to seeing a specialist or having tests. 
It’s a very stressful and scary time.”
“Share test results/scan info between trusts so tests do not have to repeated.”
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Discussion
In this study we investigated the diagnostic pathway of YA cancer patients, examined 
patient and tumor characteristics associated with the length of the diagnostic pathway, 
compared the patient interval length of our sample with a TYA cohort, and reported 
patients’ suggestions for improving the diagnostic pathway. 
Both patient and healthcare intervals were long among a substantial proportion of 
participants. Forty-two percent of participants had patient intervals ≥1 month and 
21% ≥3 months. Healthcare intervals were ≥1month for 40% and ≥3 months for 17% of 
participants. Gender and ethnicity were not associated with diagnostic intervals or number 
of consultations before diagnosis. Age was only associated with the healthcare interval, 
where age was slightly lower among patients with a >1 month interval. Remarkably, 
symptom presence at diagnosis did not influence healthcare interval length nor the 
number of GP or hospital doctor consultations. 
Subtype specific cancer diagnosis was associated with both patient and healthcare 
interval length and number of pre-diagnosis consultations. YAs with melanoma were 
most likely to wait ≥1 month before consulting a doctor, but never had ≥4 hospital doctor 
consultations, as expected with identifiable presenting symptoms (an itching or bleeding 
pigmented lesion) of this cancer. The finding that identifiable presenting symptoms may 
lead to a short patient interval is supported by a sub analyses of the BRIGHTLIGHT cohort, 
which shows 38% of participants with mole changes had a patient interval >1month[24]. 
YAs with cervical cancer were more likely to wait ≥1 month as well, and some had ≥4 
GP consultations. Notably, half of these patients were not detected through screening. 
However, in the NHS one in four women skip cervical screening, with the proportion 
increasing to one in three among those aged 25 to 29[25]. Unfortunately, our study did not 
ask cervical cancer patients not detected through screening whether they participated 
in the screening program. We therefore cannot conclude whether these were interval 
carcinomas occurring between two screening dates. 
In breast cancer, one might expect a short patient interval as breast cancer patients form 
a distinct group compared to other cancer patients, given the general knowledge about 
the disease and its symptoms in the population. However, a third waited more than one 
month before consulting a doctor. We hypothesize this may be due to YAs having busy lives 
and not recognizing symptoms as caused by malignancy. Two participants with breast 
cancer reported being diagnosed through screening, possibly in a screening program for 
a hereditary cancer syndrome. The standard NHS screening program for breast cancer 
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starts at age 50. Regarding the breast cancer healthcare interval, it is unsurprising that 
few participants had >4 GP (5%) or hospital (3%) consultations. 
The NICE two-week-wait rule (TWW) states patients with a suspicion of cancer should 
be referred to a specialist in two weeks and additional investigations, including biopsies, 
should be carried out on one day[26]. Therefore, one would expect the healthcare interval 
to be shorter than two weeks for most participants. However, the healthcare interval 
lasted ≥2 weeks in 43% of YAs, and ≥1 month in 16%. As expected, few had a healthcare 
interval ≥3 months (2%). It is known that younger patients present less often via the TWW, 
and more often via non-TWW referrals or in emergency presentations, however, this may 
not be directly correlated with the healthcare interval, as the majority of patients will be 
diagnosed through emergency presentation[27]. 
Participants with diagnoses other than breast cancer were more likely to experience a 
healthcare interval ≥1 month. The only exception was leukemia, though these patients 
had many pre-diagnosis GP and hospital consultations. The need to perform additional 
investigations in leukemia patients to confirm the diagnosis may explain the high 
number, but most of these investigations can be undertaken and interpreted relatively 
quickly. Alternatively, patients with leukemia often present as an emergency, although 
this percentage is higher in TYAs than YAs[27].
Comparison with existing literature is difficult, as studies focusing solely on YAs 25-
39 years of age are rare. This study enabled a direct comparison of YA and TYA patient 
intervals with findings from the BRIGHTLIGHT study. This showed that YAs in our study in 
general had longer patient intervals. Age-related factors may contribute to this difference, 
such as differing life-priorities (e.g. having a job, taking care of children). The distribution 
of diagnoses may play an important role as well: the proportion of participants diagnosed 
with leukemia and lymphoma was larger in the TYA group, whereas carcinomas were 
diagnosed more often in the YA group. Participants who were male or white were more 
at risk of a longer patient interval when aged 25-39, compared to those aged 12-24. 
Furthermore, those diagnosed with lymphoma with a patient interval ≥1 month, or ≥3 
months, were also more likely to be older. This was also true for patients with soft tissue 
sarcoma who had a patient interval ≥3 months. These findings are relevant and call for 
actions to increase awareness among YAs to reduce the patient interval. 
Our findings support those of an American study with patients aged 15-29 that found 
cancer diagnosis was significantly associated with interval length, whereas ethnicity, 
age, and gender were not[28]. Similarly, a National Cancer Intelligence Network report 
found that cancer diagnosis played a major role in determining how TYAs were likely to 
be referred[27].  
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A Danish study amongst AYAs (aged 15-39) reported GP consultations increased several 
months before cancer diagnosis, possibly reflecting low awareness of patients and HCPs 
that symptoms may be due to malignancy[29]. 
Although 68% of participants felt they were taken seriously in their first consultation, 
most suggestions to improve the diagnostic pathway were about taking YAs seriously, 
and not rejecting cancer as a possibility due to age. Additional recommendations were 
made about communication, and reducing passive waiting time, e.g. for additional 
examinations, referrals, or requesting information from other institutions. There were no 
major differences by interval length and most recommendations were not age specific. 
To our knowledge, this is the first study to examine the diagnostic pathway of YA cancer 
patients, with various cancer diagnoses. However, this study has several limitations. First, 
intervals and the number of consultations were self-reported, potentially introducing 
recall bias. A generally consistent finding is that as the recall time increases, the ability 
to recall events degrades[30]. However, significant events, such as a cancer diagnosis, 
are less likely to be forgotten[30]. Furthermore, estimating the duration of an event is 
extremely stable[31]. To minimize the effect of recall bias, patients were asked to report 
the duration of intervals instead of dates, and questions were anchored to a life event (the 
cancer diagnosis). 
Second, the study may be subject to selection bias as only 21% of invited participants 
responded. 
Third, the distribution of tumors does not accurately reflect the incidence of cancers in 
YAs in the population[10]. For males, the most common cancers among YAs in the UK are 
testicular cancer, melanoma, and gastro-intestinal tumors. For females these are breast 
cancer, melanoma, and tumors of the genito-urinary tract. Lymphoma and sarcoma are 
therefore overrepresented in our study, whilst melanoma and gastro-intestinal tumor 
may be underrepresented. We invited patients from hospitals in the South East, East, and 
London regions, who may have relatively more TWW referrals than those diagnosed in the 
North East[27]. Interval length may be underestimated when compared to the whole of 
England. Lastly, as subgroups were small, we were unable to perform adjusted analyses 
and the results should therefore be interpreted with caution.
Our findings highlight that cancer is still seen as a disease of the elderly. We recommend 
increasing awareness and gain better insight in the diagnostic pathway of patients aged 
25-39 and raise awareness in the general public and among health care professionals to 
shorten time to diagnoses. Further research with a larger population is needed to confirm 
our findings with respect to identified risk groups, and to study the impact of a prolonged 
diagnostic pathway on clinical and patient-reported outcomes for YAs. 
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Conclusion
Patient and healthcare interval length is long in a substantial proportion of YA cancer 
patients. Diagnostic intervals were associated with cancer diagnosis, with YAs with 
melanoma or cervical cancer experiencing a long time to diagnosis, and YAs with breast 
cancer and leukemia experiencing a short diagnostic pathway. Compared to the TYA 
population, YA patients who were male, white, or diagnosed with lymphoma or STS, 
were more likely to experience a prolonged patient interval. Participants recommended 
improving the diagnostic pathway by raising awareness, enhancing communication, and 
reducing passive waiting time. The diagnostic pathway of YAs should be studied further 
and awareness about cancer in this age group should be increased.
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Supplementary material A: comparison of patient interval of 
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*Soft tissue sarcoma of YA population contained 1 Ewing sarcoma. **p<0.005.
#Percentages are row percentages. 
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Abstract
Introduction
Sarcomas are rare tumours with considerable heterogeneity. Early and accurate diagnosis 
is important to optimise patient outcomes in terms of local disease control, overall survival 
(OS) and health-related quality of life (HRQoL). Time to diagnosis is variable in bone as well 
as soft tissue sarcoma. Possible factors for a long time from first symptom to diagnosis (the 
total interval) include patient, tumour, and healthcare characteristics, but until now the 
most relevant risk factors and its association with outcomes remain unknown. 
Our study aims to (1) quantify total interval, the time interval from first symptom until 
(histological) diagnosis; (2) identify factors associated with interval length, and (3) 
determine the association between total interval and HRQoL, stage and tumour size at 
diagnosis, progression-free survival (PFS), and OS. 
Methods and analysis
We will conduct a longitudinal, prospective, international, multicentre cohort study 
among patients aged ≥18 with newly diagnosed bone or soft tissue sarcoma at eight 
centres (three in United Kingdom, five in The Netherlands). Patients will be asked to 
complete questionnaires at five points in time; one at diagnosis and at follow-up points 
of 3, 6, 12, and 24 months. Questionnaire data is collected within the PROFILES registry: 
an international data management system for collection of patient-reported outcomes. 
Clinical data will be extracted from patient records. The primary endpoint is HRQoL at 
diagnosis, measured with the EORTC QLQ-C30. Secondary endpoints are stage and 
tumour size at diagnosis, PFS, OS, additional patient-reported outcomes, such as quality-
adjusted life years and psychological distress. 
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Introduction
Sarcomas are a group of solid mesenchymal tumours, which comprise more than 70 
histological subtypes, with considerable heterogeneity with respect to age at diagnosis, 
location, biological behaviour and outcome[1]. Approximately 80% of sarcomas are soft 
tissue sarcomas (STS), the remainder are bone sarcomas (BS). Sarcomas are typical examples 
of so-called rare cancers, with an estimated European incidence of 4-5 per 100 000 per 
year when taken all together[2], accounting for 1% of adult solid malignant cancers[3]. 
Patients with rare cancers have a higher mortality rate than those with common cancers, 
due to delays in diagnosis, suboptimal or inadequate treatment, fewer developments in 
novel therapies and opportunities to participate in clinical trials[4]. 
Early and accurate diagnosis of cancer is important to optimise patient outcomes in terms 
of local disease control, overall survival (OS) and health-related quality of life (HRQoL)[5, 
6]. However, because of the heterogeneity and rarity of sarcomas, there is a lack of public 
awareness, limited experience of primary and secondary healthcare professionals, and 
absence of a typical presentation, resulting in late referrals to specialist sarcoma centres 
and prolonged time to diagnosis[7].
Time to diagnosis can be defined according to the research framework from Olesen et al, 
which we adapted to the situation as applicable for sarcomas[8-10]. The time between 
first symptom and (histological) diagnosis, is known as the total interval. This includes 
a patient and diagnostic interval, defined as time between onset of symptoms until 
consultation of a healthcare professional, and time between consultation of a healthcare 
professional and diagnosis, respectively. The latter can be further divided into a primary, 
secondary, and tertiary care interval, each of which refers to first consultation until referral 
to the next caregiver or diagnosis. 
Possible risk factors for a prolonged total interval could be patient, tumour, or healthcare 
system characteristics. In order to study the latter, it is informative to compare patients 
from different countries. In both the Netherlands and United Kingdom (UK), general 
practitioners (GP) have an important role as healthcare gatekeepers. In general, people 
consult their GP who then decides whether referral is warranted and determines the 
acuteness and location of the referral. In the UK, privately insured patients can also self-
refer to a hospital without seeing a GP. Furthermore, within the UK, a considerable amount 
of cancer patients is diagnosed at an emergency department, associated with worse 
outcomes[11]. Sarcoma care is formally centralized within the UK, whereas the Netherlands 
has bone sarcoma centres, and referral to dedicated STS centres is encouraged, but not 
commissioned. Furthermore, cultural differences may play a role in patient behaviour. 
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Also, longer travel time to a sarcoma centre in the UK compared to the Netherlands, may 
also affect total interval length.
Up to now, only few studies regarding total interval length and clinical outcomes in sarcoma 
have been published, most were retrospective and included mainly children. Some studies 
found that a longer total interval worsened OS, whilst others did not find inferior clinical 
outcomes[10]. Researchers have argued that this lack of an association, often referred to as 
the ‘waiting-time paradox’, may be because the studies have not been able to adequately 
adjust for the aggressiveness of the cancer tumours. The most significant effect of a long 
interval for sarcomas seems to be the increasing size of the lesion[12], with consequent 
decreased chance of uncomplicated resection with clear surgical margins, a greater risk of 
amputation, and increased risk of developing metastases[13]. This may also affect patient-
reported outcomes such as health-related quality of life of sarcoma patients. 
Health-related quality of life (HRQoL) is the patients’ perception of his overall health in 
relation to physical, psychological and social aspects in life[14]. Three systematic reviews 
have been published on HRQoL of sarcoma patients, however, none of these looked at 
the association of total interval length and HRQoL[15-17]. In other cancers and chronic 
diseases, lengthening of total interval was associated with decreased HRQoL[18, 19]. 
HRQoL is an interesting outcome parameter for evaluating consequences of long total 
interval length and provides an insight into the patient’s experience of the consequences 
of diagnostic delay. In addition to using patient-reported outcomes as a measure for 
quality of care, HRQoL can be used to conduct cost-utility analysis to estimate the ratio 
between the cost of a prolonged total interval, and the benefit of earlier diagnosis in 
terms of life-years (QALY). 
Until now, risk factors for a long total interval in adult sarcoma care, as well as its effect 
on clinical and patient-reported outcomes remain unknown. These need to be studied in 
well-designed, large, prospective studies in order to prioritize interventions to optimize 
the total interval. Our study aims to quantify total interval, identify independent variables 
associated with a long interval (such as demographic and clinical factors), and determine 
the association between total interval and other dependent variables, such as HRQoL, 
stage and tumour size at diagnosis, progression-free survival (PFS), and OS (Figure1). 
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Figure 1: Schematic representation of study objectives
Methods and analysis
Study design and setting
We will conduct a longitudinal, prospective, cohort study among adult sarcoma patients, 
newly diagnosed in one of the participating study centres (5 centres in the Netherlands: 
Radboud University Medical Centre Nijmegen, Erasmus Medical Centre Rotterdam, 
University Medical Centre Leiden, University Medical Centre Groningen, Netherlands 
Cancer Institute Amsterdam; 3 centres in the UK: The Royal Marsden London, Christie 
Manchester, Royal Orthopaedic Hospital Birmingham, all NHS Foundation Trusts). The 
study started recruitment at the first centre in the Netherlands in February 2018, and in 
the UK in October 2018, and is currently recruiting.
After informed consent, patients are being asked to complete questionnaires at five 
points in time: the first at baseline, preferably before start of treatment or within four 
weeks thereafter, and at 3, 6, 12, and 24 months follow-up(Table 1). Baseline questionnaire 
completion will take about 45 minutes, follow-up questionnaires will take 20-30 minutes 
each.
Patient and public involvement
The different patient-reported outcome measures (PROMS) were selected in consultation 
with patient advocates. The Sarcoma Patients EuroNet, an international network of 
patient advocacy groups, has formulated research priorities, at least two of which will 
be addressed by our study: (1) earlier diagnosis and (2) patient-reported outcomes such 
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as health-related quality of life[20]. The questionnaire was pilot tested by patients, for 
acceptability and understandability. Study documents were reviewed by the patients 
who are members of the Royal Marsden Hospital Patient and Public involvement panel, 
and the ethics committee of Radboudumc. The panel and committee provided feedback 
on the protocol, questionnaires, patient information sheet and informed consent form, 
regarding content and readability, and changes were incorporated in the final documents. 
Patients have been and will be involved in study related presentations and publications.
Participants
Eligible patients are invited by their treating physician or a member of the research team. 
Inclusion criteria are: (1) aged ≥18; (2) new histological diagnosis of sarcoma as confirmed 
by a sarcoma histopathologist (according to ICD-10-GM codes C40 and C41 for bone 
sarcoma and C49 for soft-tissue sarcoma); (3) able to communicate in English or Dutch 
and to complete questionnaires themselves; (4) mental capacity to provide informed 
consent and participate in the study (as determined by the healthcare professional); and 
(5) diagnosed at or refered to one of the participating hospitals. Exclusion criteria are: 
(1) too ill to complete questionnaires (according to treating physician - patients who 
experience symptoms of are still egligble); (2) desmoid fibromatosis and gastrointestinal 
stromal tumours due to the different nature of the diseases (ICD-10-GM codes C15-20, 
C26, C48 and C80). 
Data collection
Eligible patients receive a patient information sheet, which explains the goals and 
procedure of the study. It includes a link to a secure website (www.profielstudie.nl for both 
English and Dutch patients), a login name, and a password. After logging in, patients can 
provide informed consent and complete questionnaires online. Patients without access to 
internet or preference of written communication, receive a paper version of the informed 
consent form and questionnaire. Questionnaires completed on paper will be entered via 
the data entry option into the PROFILES system (Patient Reported Outcomes Following 
Initial treatment and Long term Evaluation of Survivorship; www.profilesregistry.nl [21]) 
by a member of the study team. The data entry portal has the same format as the online 
questionnaire data, minimizing the chance of errors and enhancing data extraction. Paper 
questionnaires will be stored in a secured room at study coordinating sites (Radboudumc 
and Royal Marsden Hospital). PROFILES is a data management system, set up in 2009 
in the Netherlands for the study of physical and psychosocial impact of cancer and its 
treatment. The data collected in PROFILES is stored on a secure server in the Netherlands. 
In order to retrieve the data, an authorised member of the study team can login and 
download an SPSS or Excel file containing the encoded questionnaire data. PROFILES has 
been developed to the requirements of the higher education and research community 
and allows end to end encryption.
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The research coordinator has access to a password protected file which links patients’ 
study numbers to their electronical patient record number. Clinical data and survival data 
will be retrieved from the patients’ medical record by a member of the study team into the 
electronic case report forms (eCRF) database (MACRO) which is maintained according to 
current norms and ICH-GCP standards, and is password protected. Patient records will not 
leave the hospital. 
Finally, questionnaire data will be linked with the eCRF database (all encoded data) 
using study numbers. The combined dataset will be stored under appropriate password 
protection. Data will be recorded and retained in accordance with the Data Protection Act 
1998.
Case report forms
CRFs will be completed at five time points during the study. The first will be completed 
upon inclusion, the following time points coincide with completion of follow-up 
questionnaires. The last CRF is also the end-of-study CRF which can be completed before 
24 months if a patient withdraws or deceases. The information collected on the CRF will 
be stored on a secure CRF database using anonymous study numbers. Data collected 
includes documentation of eligibility criteria, date of diagnosis, tumour characteristics 
such as histology, TNM stage, tumour size, treatment regiment, re-occurrence of disease 
or metastases, reason for withdrawal of the study, and time of death, if applicable.
Questionnaires
We have combined self-designed questions and several validated questionnaires 
designed by other researchers (details below). For non-commercial scientific use no 
formal licenses are needed for the use of these questionnaires. Self-designed items and 
existent questionnaires not available in both English and Dutch, were translated with 
formal forward-backward translation by bilingual speakers. Table 1 summarizes the time-
points at which each construct is being measured.
Socio-demographics 
The questionnaires contain questions on socio-demographic characteristics of the 
participant at time of questionnaire completion, such as marital status and educational 
level. Co-morbidity is being measured with the self-administered co-morbidity 
questionnaire (SCQ), which is a validated list where patients report their co-morbidity 
during the past year[22]. 
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Total interval
A 42-item list was self-designed to assess the total interval. Examples of questions are: “
With which symptom(s), caused by the sarcoma, did you first go to a doctor?”,  “To which 
doctor did you first talk about your symptoms?”, and “How often did you talk to the 
following doctors about your symptoms belonging to sarcoma, before you heard you had 
a sarcoma?”. At follow-up, a few questions are repeated to complete data collection. We 
will sample survey the reported dates by cross-checking them with the patient’s record. If 
more than 5% of the cross-checked dates deviates more than 1 month from the registered 
dates in the medical record, we will cross-check all dates and use the clinical reported 
dates for statistical analysis.
Health literacy 
Health literacy is being assessed by a Dutch adaptation of Chew’s Set of Brief Screening 
Questions (SBSQ) in a single item question[23-25]. 
Social support 
Social support is being assessed by one single item: “Was the amount of support you 
received from others sufficient?” extracted from the Quality of Life-Cancer Survivors 
questionnaire[26, 27].
Self-efficacy 
Self-efficacy is measured with the general self-efficacy scale (GSE)[28]. This 10-item scale 
assesses a general sense of perceived self-efficacy with the aim to predict coping with 
daily hassles as well as adaptation after experiencing a stressful life event. Self-efficacy is 
the belief that one can perform a novel or difficult task, or cope with adversity. Perceived 
self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and 
recovery from setbacks. Responses are made on a 4-point scale. A higher final composite 
score correlates with higher perceived self-efficacy. 
Coping
Coping is assessed in the 3 months questionnaire with the help of the brief COPE[29]. 
Coping is about emotional and mental reactions, which enable people to activate sources 
of help, needed to cope with stress and problems. This 28-item scale measures 14 positive 
and negative styles of coping on a 5-point Likert-scale. 
Resilience 
Resilience is measured in the 6 months questionnaire using the brief resilience scale (BRS)
[30]. Resilience is a skill which helps people recover from a life event. People with high 
(perceived) resilience can move on faster after a setback. The BRS is a 6-item scale with a 
5-point Likert-scale. 
7
The QUEST study   |   147 
HRQoL
HRQoL is being assessed with the EORTC QLQ-C30, version 3.0, which is validated and 
available in English and Dutch[31].This 30-item HRQoL questionnaire consists of five 
functional scales (physical, role, cognitive, emotional and social), a global quality of life 
scale, 3 symptom scales (fatigue, pain, nausea and vomiting), and a number of single items 
assessing common symptoms (dyspnoea, loss of appetite, sleep disturbance, constipation 
and diarrhoea) and perceived financial impact of the disease. After linear transformation, 
all scales and single item measures have scores ranging from 0-100. A higher score on the 
functional scales and global QoL means better functioning and HRQoL, whereas a higher 
score on the symptom scales means more complaints. 
QALY
QALY is being measured with the EuroQol EQ-5D-5L, which is a descriptive system for the 
measurement of health[32]. It measures HRQoL on five dimensions: mobility, self-care, 
usual activities, pain-discomfort, and anxiety-depression. To make the EQ-5D-5L suitable 
for use in economic evaluations, the health status needs to be valued with a preference-
elicitation method[33]. Both Dutch and English national values were collected and 
subsequently modelled[34, 35]. 
Psychological distress
Psychological distress is being assessed with the Hospital Anxiety and Depression Scale 
(HADS), which is validated in Dutch and English[36]. This 14-item instrument measures 
psychological distress, with 7 items each assessing anxiety and depression. The summed 
total score of the HADS will be used to reflect psychological distress. Higher total scores 
are indicative for more psychological distress.
Financial impact
We self-designed a 20-item questionnaire regarding financial barriers to care. The 
questions were designed based on a literature study of items that are important in health-
seeking behaviour but have not been validated. Topics covered are financial barriers to 
care, financial impact of living with cancer, personal expenses, and potential solutions for 
reducing financial impacts. 
Information provision
Five self-designed questions with multiple items are being asked to identify time-points 
and subjects on which participants would like more information. 
Quality of care
Quality of care is being assessed with the 18-item Patient Satisfaction Questionnaire 
(PSQ-18)[37], available in both English and Dutch[38, 39]. This instrument yields scores 
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for each of seven different subscales: general satisfaction, technical quality, interpersonal 
manner, communication, financial aspects, time spent with doctor and accessibility and 
convenience. High scores reflect satisfaction with medical care. In addition, 3-5 self-
designed single items to assess overall satisfaction of care at the primary doctor’s office, 
hospital and sarcoma centre are being asked. 
Endpoints
The primary endpoint is HRQoL of sarcoma patients at diagnosis (baseline) as measured 
with the EORTC QLQ-C30 (global health status). Secondary endpoints are: QALY, 
psychological distress, stage and tumour size at diagnosis, PFS, and OS. 
If subgroups are large enough, we will conduct these analyses for different clinically 
relevant subgroups, such as different histological subtypes, geographical areas etc. 
Table 1: time points and questionnaire items











Socio-demographic (max 20) X X X X X
Co-morbidity (15) SCQ X X X
Total interval (max 42) Own design X X X X X
Health literacy (1) SBSQ X
Social support (1) QLCS X X X
Self-efficacy (10) GSE X
Coping (28) Brief COPE X
Resilience (6) BRS X
Outcomes
Health-related quality of life (30) EORTC-QLQ-C30 version 3.0 X X X X X
Quality adjusted life years (6) EQ5D5L X X X X X
Psychological distress (14) HADS X X X X X
Financial impact (20) Own design X X X X X
Information provision (max 26) Profiles registry X
Quality of care (max 23) PSQ-18 and 3-5 single items X X X X X
Total number of items 194 158 105 113 114
SCQ: Self-administered co-morbidity questionnaire; SBSQ: Set of Brief Screening Questions; QLCS: 
Quality of Life-Cancer Survivors; GSE: General self- efficacy; BRS: Brief Resilience Scale; HADS: 
Hospital Anxiety and Depression Scale; PSQ: Patient Satisfaction Questionnaire.
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Sample size calculation
We expect a minimum response rate at baseline of 65%, based on rates in other PROFILES 
studies[40]. During follow-up, after completion of the first questionnaire, we expect a 
response rate of 80%. The definition of a long total interval will follow from our statistical 
analysis (see below), however, if the analysis does not provide a clear cut-off point, we will 
use the last quartile to define the population with a long total interval. 
Using the EORTC QLQ‐C30, differences of at least 10 points have been considered as 
clinically meaningful[41]. Based on results from our ongoing PROFILES studies, a 
standard deviation of about 20 points for each scale can be expected. Using an alpha 
of 0.05, a power of 0.90, and a long diagnostic interval of 25% in the total group 
of sarcoma patients, with the expected drop-out, would require 265 patients[42]. 
In order to make country-to-country comparisons, we aim to include 265 Dutch 
and 265 English patients in a timeframe of 18 months with a total follow-up of 24 
months.
Statistical analysis
Descriptive statistics (means, standard deviation, median, range, frequencies) will be used 
to quantify diagnostic intervals and describe the study population.
HRQoL at baseline will be calculated according to the EORTC scoring manual[43]. Missing 
items will be imputed according to these guidelines, after which an available cases analysis 
will be performed. 
The relationship between total interval length and HRQoL at baseline will be investigated 
by plotting HRQoL against total interval length as a continuous variable. Linear regression 
will be used to assess their association. The time point providing a significant difference 
in HRQoL will be used as a cut-off point for further analysis. If this does not provide a clear 
cut-off point, logistic regression will be used to assess an association between baseline 
HRQoL and total interval grouped into suitable categories, such as quartiles. The last 
quartile will then be used to define the population with a long interval. 
Apart from statistical significance, we will look at clinically relevant differences in HRQoL 
scores as determined by Cocks et al[42]. A small effect size will then be considered as an 
appropriate value for a cut-off point.
A series of univariate logistic regression analyses will be conducted to assess the 
relationship between total interval length (grouped by the cut-off point as defined by 
the previous analysis) and independent variables, such as patient, tumour, and healthcare 
system risk factors. All factors with p<0.1 will then be used in multiple logistic regression 
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analysis (forced entry method) to investigate whether these factors are independently 
associated with total interval length.
Apart from total interval length, the association of other patient and tumour characteristics 
(such as self-efficacy, social support, financial difficulties, histology), and HRQoL at baseline 
will be investigated using univariate logistic regression analysis. Using the forced entry 
method, multiple logistic regression analysis will then be performed with all factors with 
p<0.1 to assess what factors are independently associated with baseline HRQoL.
Change in HRQoL during the follow-up period of two years and factors associated with 
changes in HRQoL will be analysed using repeated measures mixed models. This will be 
compared between patients with a short and long total interval, using repeated measures 
analysis of variance, controlling for relevant patient and tumour characteristics, and 
the patient’s baseline score. Clinically relevant differences will be assessed using Cocks’ 
method[41, 42].  
Other patient-reported outcomes such as QALYs and psychological distress will be 
analysed in the same way.
Multivariate analyses will be performed to examine associations between total interval 
length and (1) QALYs, (2) psychological distress, (3) stage at diagnosis, and (4) tumour size. 
These analyses will be corrected for potential confounders including patient and tumour 
characteristics and healthcare system. 
Both unadjusted and adjusted multivariate Cox proportional hazard regression analyses 
will be used to examine whether a long total interval is associated with of PFS or OS. PFS is 
defined as the time interval between diagnosis until clinical or radiological progression, as 
assessed by the treating consultant. OS is defined as the time from diagnosis until death. 
Statistical analyses will be performed using IBM SPSS 25.0; two-sided p-values <0.05 will 
be considered statistically significant.
Missing data
Online questionnaire completion does not allow for missing data, unless participants 
have not completed the entire questionnaire, as patients are unable to proceed to the 
next question until all questions on the current page have been answered. Items missing 
from paper questionnaires will be dealt with as missing at random. The EORTC-QLQ-C30 
allows imputation of missing values according to the EORTC scoring manual guideline[43]. 
Numbers of missing items will be reported.
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Impact of COVID-19 pandemic on QUEST
A national lockdown was introduced across The Netherlands on March 16 and the UK 
on March 23, 2020, as part of the national strategies to flatten the curve of the COVID-19 
pandemic. On March 23 recruitment for QUEST was finished in The Netherlands, while the 
recruitment target was almost reached in the UK. The COVID-19 pandemic forced us to put 
the recruitment on hold in the UK. The negative consequences of the pandemic on cancer 
diagnostic timelines (prolonged), incidence (reduced) and eventually cancer outcomes 
has been shown and modelled  by several studies [44-46]. We will therefor discuss the 
necessity to reopen recruitment in the UK with our statistical department, as patients 
recruited during the pandemic will not be representative for the sarcoma population 
outside COVID times and will bias our results.
Ethics and dissemination
The study was approved by the Health Research Authority and Research Ethics 
Committee of the United Kingdom (18/WA/0096), and by the medical ethical committee 
of Radboudumc for The Netherlands (2017-3881). Under Dutch law, approval for 
observational and questionnaire research by one medical ethical committee is sufficient 
to implement the study at multiple Dutch centres. The study was registered at clinicaltrials.
gov (NCT03441906). 
Results from the QUEST study will be published and disseminated via peer-reviewed 
journals, local, national, and international conferences, and via patient meetings and 
patient advocates. 
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One of the pitfalls in diagnosing sarcoma lays in its rarity. Sarcomas are unknown to many 
patients and healthcare providers, leading to low awareness. This is common for all rare 
cancers. Sarcomas, however, are heterogeneous with respect to age of onset, site, and 
biological behaviour, resulting in the absence of a “typical presentation”. This increases 
the chance that both patients and healthcare providers do not recognize its symptoms 
as a sign of cancer, resulting in prolonged diagnosis and possibly worse outcomes. In this 
thesis, we aimed to investigate the diagnostic pathway, known as the total interval length, 
and its effect on clinical and HRQoL outcomes. 
We found that total interval length is variable and long in a high proportion of sarcoma 
patients. Delay can occur in each of its components: the patient interval, as well as the 
primary, secondary, and tertiary care interval. 
In order to optimize the total interval, cut-off points that discriminate between a short or 
long interval will be helpful to make guidelines more evidence-based, and guide patients 
and healthcare providers. Currently, guidelines that provide a timeline for diagnosis do so 
based on expert opinion, and these timelines are not sarcoma specific. In the Netherlands 
for example, the SONCOS guideline states that the optimal time between referral and 
diagnosis should be 4 weeks[3]. If a patient is being referred to  another hospital, an 
additional 3 weeks may be added. In England, patients suspected of cancer are referred 
under the “two-week-wait rule”: after referral by a general practitioner, patients get a cancer 
specialist appointment within two weeks[4]. For children and young adults suspected of 
bone sarcoma a very urgent referral, meaning an appointment within 48 hours, should be 
considered. The guideline doesn’t provide a timeline for time to diagnosis or treatment 
after referral to the hospital. However, there is a lack of evidence for the relevance of 
these specific cut-off points, apart from the fact that psychological stress may decrease 
if the waiting time from general practitioner to cancer specialist is short. For sarcomas 
specifically, even after symptoms are recognized as caused by sarcoma, pathological 
and molecular diagnosis may add an additional 1-2 weeks to establish a final diagnosis. 
However, getting a specific diagnosis will guard the patient from incorrect treatment 
strategies. Therefore, cut-off points for complex diagnoses, such as sarcomas should 
probably differ from other cancers and could differ between histological subtypes. 
The relevance of cut-off points is currently based on better overall survival (OS) with shorter 
diagnostic pathways in some cancers, such as breast, colorectal, head and neck, testicular, 
and melanoma[5]. For patients with sarcomas, that has never been proven. Historically, 
evaluation of oncologic care has focused on clinical outcomes, such as treatment-related 
toxicities and overall survival. Currently, increasing attention is being given to patient-
reported outcomes (PROs). HRQoL is an example of a PRO and refers to the impact of 
disease and treatment on domains of physical, psychological, and social functioning[6]. 
160   |   Chapter 8
Apart from a cut-off based on clinical outcomes, HRQoL may be an outcome with clinical 
relevance to provide guidance for the length of diagnostic trajectories.
The studies discussed in this thesis were not designed to define a cut-off point and were 
unable to distinguish between a short and a long interval based on outcomes. In all our 
research we have used the term “interval length”, and as long as a clear cut-off point hasn’t 
been identified, researchers should avoid the term “delay”. With this thesis, risk factors for 
longer intervals were identified, and the effect of a longer total interval on health-related 
quality of life was presented. 
Total interval length: contributing factors
To shorten the total interval, it is important to gain insight in factors contributing to a 
short or long interval respectively. These factors can be divided into patient, tumour, and 
healthcare system factors. 
Patient factors
Our systematic review found bone sarcoma (BS) patients with older age to be at risk for a 
long total interval. However, the data studied in this review was heterogeneous regarding 
inclusion criteria and study design and no definite conclusion can be drawn from these 
results. In soft tissue sarcoma (STS), no associated factors could be identified. 
Age was a factor associated with diagnostic interval length in our SURVSARC study: 
patients aged 18-39 had a higher chance of a long diagnostic interval than those aged 
≥40. This trend was also seen in a survey among sarcoma patients in the UK and is a 
known phenomenon among AYAs in other cancer subtypes[7-9]. Furthermore, when 
comparing our YA participants aged 25-39 with a TYA cohort aged 12-24, the YAs had 
longer patient intervals. The difference was significant for YAs diagnosed with STS with a 
patient interval >3 months, compared to TYAs diagnosed with STS. Patients in the YA age 
group are at higher risk for a longer total interval compared to both TYAs and older adults. 
This difference is probably multifactorial and could be related to age-specific events and 
priorities, and low awareness about the occurrence of malignancies at this age. TYAs may 
consult a doctor earlier than YA due to interference of parents (although at a later stage 
than younger children), while  patients aged ≥40 may be more aware that symptoms 
could origin from a cause that does not dissolve by itself have a shorter face of appraisal 
before they seek help. 
Results from the interviews with sarcoma patients showed how diverse diagnostic 
pathways are, and how difficult it is for both patients and healthcare providers to attribute 
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symptoms to a sarcoma diagnosis. Factors leading to a long patient or diagnostic interval 
were not sarcoma specific, e.g. interference with daily life has been known to contribute to 
a long patient interval in other diagnoses as well, but possibly occur in a higher proportion 
of patients compared to common cancers. Low awareness among patients and healthcare 
providers is more specific for rare diseases and cancers occurring at young age but is a 
difficult factor to improve. This is supported by an English study, in which primary care 
data of 10953 patients with 28 types of cancer was collected, and patient and primary 
care intervals were compared[10]. Patients with sarcoma had second longest median pre-
referral time (patient and primary care interval combined) with 52 days, only patients with 
laryngeal cancer had to wait longer before referral (median 58 days).  
Interestingly, in our SURVSARC study, no patient factors were identified to contribute to a 
long patient interval length. This is consistent with other sarcoma and cancer studies, in 
which no association or conflicting results about the association between patient factors 
and patient interval length were found[7, 8]. Macleod et al reviewed patient risk factors 
for delayed presentation for common cancers, using two worldwide systematic reviews 
of the literature[8]. They report conflicting results, e.g. older age was found to be a risk 
factor for breast cancer, but not for colorectal, urological, and lung cancer. Younger et al 
reported age was not related to time to diagnosis among sarcoma patient selected from 
the National Cancer Patient Experience Surveys in the UK[7]. However, again the primary 
aim of these studies was not to study the diagnostic pathway. 
Gender was found to be associated with diagnostic interval length in the SURVSARC 
study: female gender was associated with a long diagnostic interval. This is also found in 
general cancer literature[8, 11], a finding that may be explained by both longer patient 
intervals: females are found to delay seeking help when detecting potential cancer-related 
symptoms, as well as longer diagnostic interval: healthcare professionals may overlook 
symptoms based on patients’ gender only as well[12, 13]. Among our YA population, 
gender was not associated with patient or healthcare interval length.  
The identified associated patient factors, or absence thereof, are thus neither specific for 
the sarcoma population, nor are there any factors specific for the survivorship population. 
This makes it difficult to formulate recommendations that shorten the total interval based 
on patient factors.
Tumour factors
Our systematic review did not identify any tumour factors, such as sarcoma subtype, 
stage at diagnosis etc, associated with interval length; results among included studies 
were conflicting. Researchers have argued that this lack of an association, known as the 
‘waiting-time paradox’, is caused by the biological phenotype of the tumour, which may 
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be more important for survival than a short diagnostic interval. Most studies have not 
been able to adjust for the aggressiveness of the tumour. Furthermore, study designs may 
not have been optimal to detect these associations: most studies included a small number 
of sarcoma patients with heterogeneous diagnoses and used retrospective data.
One may hypothesize that low-grade, indolent tumours do not trigger patients to seek 
help, resulting in a long patient interval. This hypothesis was not only supported by our 
qualitative data as presented in chapter 3, but was also supported by our SURVSARC study, 
where patients with a sarcoma located in the skin or pelvis reported a longer patient 
interval. Sarcomas located in the skin are often indolent, such as dermatofibrosarcoma 
protuberans, whereas pelvic sarcomas often cause nonspecific symptoms. On the other 
hand, liposarcomas, rhabdomyosarcomas, and tumours diagnosed at stage III disease, 
were found to have shorter patient intervals. These tumours often show rapid growth, 
causing patients to seek help. The survivorship selection of the SURVSARC study may 
even underestimate the association, as tumours with aggressive biological behaviour are 
probably underrepresented among our participants. Within our YA study, participants 
diagnosed with sarcoma showed a trend of being more likely to have a long patient 
interval than those diagnosed with breast cancer. However, this was not a unique finding; 
a diagnosis of melanoma and cervical cancer was also associated with a longer patient 
interval in this study.
Histology was also associated with diagnostic interval length in our SURVSARC and YA 
study. In the survivorship population, diagnoses of synovial sarcoma and chordoma were 
associated with a longer interval. This may be caused by the broad differential diagnosis 
of the complaints these patients present with. Among YAs, patients diagnosed with STS 
were also more likely to have a longer healthcare interval. Although this association was 
very strong for sarcomas, it was not specific: participants with lymphoma, melanoma, 
ovarian cancer, thyroid cancer, colorectal cancer, and cervical cancer experienced longer 
healthcare intervals as well. 
Healthcare system factors
Despite the introduction of guidelines for sarcoma diagnostic pathway in the UK, over the 
past 30-50 years there has been no improvement of total interval length[14-17]. Guidelines 
often give advice about location of imaging (e.g. at the local hospital or sarcoma centre), 
timeliness of referral, centralizing care, and use of multidisciplinary teams.
For both STS and BS, studies have shown that investigations prior to referral to a sarcoma 
centre result in longer total intervals, due to incorrect interpretation, delays caused by 
sending the images, re-interpreting them, or performing the investigation again at the 
sarcoma centre[18, 19]. A French study showed that when assessing sarcoma biopsies in 
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a pathology expert panel, 40% of diagnoses were changed, often leading to a change in 
treatment plans[20]. Radiologists and pathologists assessing scans and biopsies may be 
inexperienced in assessing sarcomas, and struggle to formulate the right diagnosis. 
In general, literature has shown that centralizing care at sarcoma centres with a 
multidisciplinary team improves the diagnostic interval because patients (1) do not lose 
time at local hospitals; (2) receive appropriate imaging; and (3) get a higher rate of correct 
pre-operative pathologic diagnosis[18, 21-30]. Improvement of these factors decreases 
tumour size and stage at diagnosis and improves quality of surgery. Centralizing sarcoma 
care to specialist centres with expert teams shortens secondary and tertiary care intervals 
and increases the number of correctly diagnosed and treated patients, hopefully not only 
contributing to a higher standard of care, but also to outcomes for sarcoma patients.
Diagnostic interval length can also vary between geographic regions, especially in 
countries where there is a profound difference between regions in the availability of 
CT-scan equipment and number of hospital beds per inhabitant[31]. These findings 
were supported by our qualitative study, in which diagnostic interval was, among other 
reasons, lengthened by an ineffective process of additional investigations and long 
referral times. Our participants acknowledged centralizing sarcoma care often lead to 
longer travel distances, resulting in difficulties regarding transport, arrangements at work, 
and travel expenses, but this did not withhold them to visit a sarcoma centre or lead to 
longer diagnostic intervals. Specialized care at a sarcoma centre should be available for 
everyone, the diagnostic pathway could be improved if travel expenses would be covered, 
for instance by insurance companies.
These results suggest that diagnostic interval length could be shortened by centralization, 
although no studies with direct comparisons between a country where sarcoma care is 
formally centralized and one where this is not the case have been performed. However, 
referral pathways and imaging and pathology processes need to be optimized to result in 
shortening of diagnostic interval as well. Further research is needed to investigate whether 
countries with large differences between regions, e.g. in access to medical care, will profit 
from centralization as well. Furthermore, most research has been done in countries where 
sarcoma care is publicly financed. In our qualitative study, the English participants thought 
waiting times would have been shorter if they were privately insured. We were unable to 
assess this in a quantitative way, but an American study found that self-pay patients has 
a shorter diagnostic interval than public insurance patients, confirming these results[32]. 
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Effect of total interval length on outcomes
Historically, evaluation of oncologic diagnoses and treatments has focused on clinical 
outcomes, such as overall survival. For sarcomas, it is unknown whether a shorter total 
interval will result in improvement of clinical outcomes, as studies have given contradictory 
results. Apart from the “waiting-time paradox”, this may be due to the heterogeneity of 
the study populations. 
More recently, increasing attention has been given to patient-reported outcomes (PROs), 
which report of the status of a patient’s health condition that comes directly from the 
patient, without interpretation of the patient’s response by a clinician or anyone else[33], 
to evaluate treatment efficacy. Measuring PROs has been shown to improve the patient 
experience of care and induces overall survival benefit in metastatic cancer patients[34]. 
HRQoL is an example of a widely used PRO.
Data about the influence of total interval length on PROs of sarcoma patients were limited. 
We investigated the association between total interval length and HRQoL among 1099 
sarcoma survivors. In this population, HRQoL, as measured with the EORTC-QLQ-C30, 
was not related to patient or diagnostic interval length. However, we also investigated 
the association between perceived impact of diagnostic interval length on HRQoL and 
found that survivors experiencing a negative impact of diagnostic interval length on their 
current HRQoL, had lower scores on both global health status and all functioning scales. 
Diagnostic interval length was long for a larger proportion of patients experiencing 
a negative impact, than for those experiencing a positive or no impact. Participants 
experiencing a negative impact also showed the lowest coping abilities. 
We concluded that the perceived influence of diagnostic interval on HRQoL is more 
important to sarcoma survivors than its actual length, and perception is associated with 
coping abilities. Similar findings were found in other cancer and chronic disease studies. 
Our qualitative analysis supported the findings; many patients experiencing a negative 
impact still described psychological distress, more physical abilities, and a worse prognosis 
due to the diagnostic interval length.       
The discrepancy between diagnostic interval length on HRQoL scores and perceived 
influence on HRQoL, may be more related to coping strategies than the diagnostic 
interval length. Patients with negative feelings regarding their diagnostic pathway 
showing maladaptive coping strategies, should be offered support in order to improve 
their HRQoL.
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Research in rare cancers 
This thesis investigates the diagnostic pathway of sarcoma patients, which is an example 
of a rare group of cancers. Performing research among rare cancer patients distinguishes 
several difficulties. One of the major bottlenecks is the limited number of patients 
affected each year, whilst a large sample size is needed to draw robust conclusions. In 
our qualitative study we interviewed a limited number of patients, when interpreting its 
results this should be considered. However, the study has given us great insight in the 
diversity of sarcoma diagnostic pathways and laid the groundwork for the design of the 
QUEST study. For our quantitative studies, the SURVSARC and QUEST, we took several 
steps to include as many patients as possible. First, for the SURVSARC study, we identified 
patients via the Dutch Cancer Registry, which registers all patients diagnosed with cancer 
in The Netherlands. Second, we invited patients from six sarcoma centres, resulting in 
a high number of eligible patients, representing all Dutch surviving sarcoma patients. 
Treating physicians were involved in the invitation process, which may have increased 
the response rate. Third, we tried to make participation as easy as possible by providing 
the possibility to complete questionnaires online as well as on paper. Fourth, we worked 
with patients and patient advocacies to make sure our study subject was relevant to them 
and get extra attention for recruitment of participants. Finally, eligible patients could 
receive support from both employees of PROFILES as well as from the researcher. With this 
approach, we were able to include 1099 sarcoma survivors, the largest published study 
until now. 
A second limitation of research in rare cancers may be the inaccuracy of pathologic 
diagnosis. As mentioned before, many sarcoma diagnoses are changed when re-assessed 
in an expert panel. We tried to overcome this by recruiting patients diagnosed at sarcoma 
centres, where expert pathologists and multidisciplinary teams are present. Currently, in 
the Netherlands 93% of BS patients and 76% of STS patients are discussed with a sarcoma 
centre[35]. 
Most literature presented in our systematic review was based on retrospective data and 
studies with different inclusion criteria. This limitation, often seen in rare cancer research, 
may be debit to the contradicting results found in these studies as results are both subject 
to recall and selection bias. This is also the case for our SURVSARC study. However, patient-
reported dates regarding cancer diagnosis are often accurate when compared to registry 
data[36]. A prospective design could contribute to minimize these problems.  
Future research should collect prospective data and try to achieve high inclusion numbers 
by multicentre and international designs. This can only be achieved by collaboration. As 
shown in this thesis, by combining forces we’ve recruited a large number of participants. 
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The SURVSARC included patients from all over The Netherlands. However, research 
collaborations should not stop at borders. Recruitment among an international patient 
population will provide reliable results and lead to more valuable conclusions. Regarding 
the diagnostic pathway, healthcare system factors can best be studied in international 
designs. In Europe, institutions that are involved in the management of patients with 
rare cancers form the EURACAN network (https://euracan.ern-net.eu/). Their ambition is 
to establish guidelines, clinical trials, and to develop research projects with international 
partners. This network, in collaboration with the European Organisation for Research and 
Treatment of Cancer (EORTC) and patient advocacy groups, could be the framework for 
future international collaborations.      
Clinical implications and recommendations 
This thesis confirms that a long diagnostic interval is highly undesirable and has a 
negative impact on HRQoL. We have identified several factors and events contributing 
to total interval length which could be optimized. Further research is needed to prioritize 
improvement strategies, and to study the relevance of these events within different 
healthcare systems. 
Changes to the diagnostic pathway should focus on improving relevant outcomes for 
patients, these can be clinical outcomes, as well as patient-reported outcomes. Especially 
for the latter, patient empowerment is important in future approaches to research. In both 
The Netherlands and United Kingdom, as well as in many other European countries, there 
are active patient advocacy groups for patients with sarcoma[37, 38]. Their goals are two-
fold: first, they aim to provide information for sarcoma patients and facilitate contact with 
other patients; second, they want to improve care, research, diagnosis, and treatment for 
sarcoma patients together with external stakeholders. Including patients in new research 
strategies will improve designs, focus on relevant topics, and provide clinically relevant 
outcomes. Furthermore, incorporating advocacy groups in research networks may lead 
to faster research results, as advocacy groups can use their networks for international 
designs and to increase response rates. They can also play a role in increasing awareness 
and communication about research results towards (future) patients. 
Future perspectives
The aim of future research on the diagnostic pathway of sarcoma patients should be to 
study the effect of total interval length on outcomes, to identify risk groups, provide a 
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clinically relevant timeline for the diagnostic pathway, which could differ among sarcoma 
subtypes, and prioritize improvement strategies. 
Strategies to shorten total interval used among other common cancers, such as screening 
programs, are not suitable for rare malignancies. Other strategies, such as increasing 
awareness and improving referral pathways seem more feasible for rare cancers. 
Awareness among the population is difficult to influence, as future patients are not easily 
identifiable. Up until now, no sarcoma specific patient characteristics have been identified. 
Increasing awareness among healthcare providers may contribute faster to shortening 
the diagnostic pathway. A study which showed lumps larger than 5cm and growing 
were more often sarcomas than those smaller than five centimetres, resulted in a British 
national campaign where general practitioners received an awareness pack including golf 
balls[37, 39]. Although there is no report suggesting faster referrals, this playful campaign 
and its message shall not be forgotten quickly.
Attention should be paid to patient-reported outcomes, and relevant tools should be 
designed to be measure these among sarcoma patients. As illustrated in our SURVSARC 
study, the current HRQoL EORTC-QLQ-C30 scale, may not be able to identify relevant 
issues caused by a long diagnostic pathway, for sarcoma patients. The measure may 
be too general, and items specific to tumour site or histological subtype are lacking. A 
possible solution could be to add questions specific for certain subgroups, which have 
already been designed by the EORTC for several other malignancies (https://www.eortc.
be/itemlibrary/). The EORTC is currently performing a study to design new HRQoL tools 
specific for sarcoma subtypes (EORTC-1749; NCT04071704).  
New studies should ideally be designed in a certain way. First, a prospective setting would 
be ideal to limit recall bias and selection bias. Second, designs should enable to include 
large numbers of patients: this can be achieved by using international and multicentre 
designs, but also by making the threshold for participation as low as possible. Third, 
patients should be included in research collaborations. Furthermore, changes made to the 
diagnostic pathway, e.g. new referral strategies, should be evaluated. Both improvement 
in actual interval length and change in outcomes should be monitored. 
For the QUEST study, of which no data have been published yet, we used a multicentre 
design as well. This study is international, recruiting patients from eight sarcoma centres 
in total, in order to include a representable number of all histologic subtypes. All newly 
diagnosed and eligible patients are approached by a member of the research team and 
receive a phone call to answer additional questions and optimize response. Its design 
allows for identification of patient, tumour, and healthcare system factors associated with 
interval length. 
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Conclusion
Despite new insights gained by the different studies on the diagnostic pathway of sarcoma 
patients within this thesis, there are still a lot of challenges and unanswered questions 
that need to be addressed to make clear recommendations for improvement strategies of 
the diagnostic pathway. 
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In this thesis, the diagnostic pathway of sarcoma patients was investigated. This chapter 
summarizes and discusses the different parts of the thesis. Practical implications and 
future research perspectives are formulated. 
Despite efforts to improve survival outcomes of sarcoma patients with novel imaging and 
treatment strategies, only limited progress has been made. Another approach to improve 
survival is to improve the diagnostic pathway. Due to the rarity of the disease and the 
heterogenous presentation, the diagnostic pathway may be difficult and prolonged, 
resulting in larger tumours at diagnosis and possibly worse outcomes.
The diagnostic pathway encompasses time from first symptom to histological diagnosis, 
which is defined as the total interval. This can be divided in a patient interval (time from 
first symptom until first consultation with a doctor) and diagnostic interval (time from first 
consultation until diagnosis). The diagnostic interval can be further divided into a primary 
care, secondary care, and tertiary care interval. 
A systematic review was performed in chapter 2. The objectives were to quantify total 
interval length and its components, to identify factors associated with its length, and 
to determine the impact on patients’ outcomes. Both clinical outcomes, such as overall 
survival, as well as patient-reported outcomes, such as health-related quality of life 
(HRQoL) were subject of investigation. 
Our search resulted in 2310 articles, of which 76 met the inclusion criteria. Total intervals 
varied broadly; 9-120.4 weeks for bone sarcoma (BS) and 4.3-614.9 weeks for soft tissue 
sarcoma (STS). Factors associated with a long interval in BS were older age and the lack of 
performing radiologic examinations upon presentation. In STS, results were conflicting, 
and no associated factors could be identified. 
The influence of total interval length on clinical outcomes remains unclear. One might 
hypothesize that sarcomas with more aggressive behaviour have a shorter total interval 
and worse survival outcomes, whilst sarcomas with indolent behaviour have a longer 
total interval and improved survival. Alternatively, it may be expected that shorter total 
intervals lead to earlier treatment and better outcomes. Neither of these hypotheses 
could be supported by our review, as results from individual studies were conflicting. This 
was possibly the case due to the heterogeneity in design and included sarcoma subtypes. 
No study examined the impact on HRQoL.
In neither bone or soft tissue sarcoma did we identify a clear cut-off point for appropriate 
versus inappropriate length of total interval or its components.
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In chapter 3 we investigated the diagnostic pathway in more detail, as experienced 
by adult sarcoma patients. Fifteen sarcoma patients from the Netherlands and United 
Kingdom were interviewed, followed by qualitative content analysis. The interviews 
focussed on the route to diagnosis, factors contributing to total interval length from a 
patients’ perspective, the impact of the route to diagnosis on HRQoL and care satisfaction, 
and differences in experiences between Dutch and English patients. 
Participants had a total interval varying between 10-145 weeks. Both patient and 
diagnostic interval contributed to total interval length: patient interval ranged from 0-119 
weeks, diagnostic interval from 3-140 weeks. Qualitative analysis resulted in four main 
themes: patient interval, diagnostic interval, reflection on the route to diagnosis, and 
recommendations for improvement. 
The patient interval could be divided into two stages: appraisal and help-seeking. If 
symptoms were attributed as benign, did not interfere with daily life, or were expected to 
cease by themselves, appraisal, the time period of assessing symptoms, could last long. 
The main trigger of help-seeking was interference of symptoms with daily life. 
The diagnostic interval was prolonged by six factors: incorrect working diagnosis, 
ineffective process of additional investigations (e.g. passive waiting time), long referral 
times, course of disease progression different than expected, long time for histological 
diagnosis, and lack of lead clinician. English patients perceived their waiting times to be 
longer than Dutch patients and perceived healthcare providers to be under pressure.
When patients reflected on their route to diagnosis, they commented on subjects related 
to care satisfaction, impact of receiving the diagnosis, and impact of a perceived diagnostic 
delay. Long waiting times, false reassurance and inadequate information provision led to 
dissatisfaction and a high emotional burden. 
Factors for improvement of care included increasing awareness of patients and healthcare 
providers to consider sarcoma diagnosis, empowering patients, and having a lead clinician.
The study confirmed the findings of our review; the diagnostic pathway of sarcoma 
patients is variable, and its length is influenced by patient and healthcare system factors. 
Furthermore, the route to diagnosis influences patients’ care satisfaction and emotional 
status. It showed the need for adequately designed quantitative research to confirm its 
findings. This thesis describes three such studies: the SURVSARC, about the diagnostic 
pathway among sarcoma survivors; the QUEST, a prospective study among newly 
diagnosed patients with sarcoma; and a study among young adults, comparing their 
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diagnostic pathway with patients with other cancer diagnosis, and comparing it with 
younger patients with cancer. These studies will now be described in more detail. 
First, the SURVSARC study. Since no data were available on the diagnostic pathway of 
sarcoma survivors, we conducted a cross-sectional cohort study among Dutch sarcoma 
patients, diagnosed 2-10 years prior to the study in one of the six participating sarcoma 
centres. Participants were selected from the Dutch Cancer Registry. Our efforts resulted in 
the inclusion of 1099 participants (response rate 58%) who completed one questionnaire 
on the diagnostic pathway and quality of life. Additional clinical data was extracted from 
the Dutch Cancer Registry. In chapter 4, the first report of this SURVSARC study described 
the total interval length and its components, and identified factors associated with 
prolonged intervals. 
The patient interval lasted ≥1 month in 60%, and ≥3 months in 36% of participants. 
Factors associated with a patient interval ≥3 months were sarcoma of skin and pelvis. 
Liposarcoma, rhabdomyosarcoma, or stage III disease were associated with a shorter 
patient interval. Diagnostic interval length was ≥1 month in 55%, ≥3 months in 28%. 
Factors associated with a diagnostic interval ≥3 months were being female, aged <40, or 
having a synovial sarcoma or chordoma. 
In chapter 5 we investigated the relationship between time to diagnosis and HRQoL 
among participants of the SURVSARC study. We showed that HRQoL scores were not 
influenced by time to diagnosis, but patients’ perception of the impact of diagnostic 
pathway length did influence HRQoL scores. Participants perceiving a negative impact 
had lower HRQoL scores than those perceiving a positive or no impact, and more often 
showed maladaptive coping strategies. In addition, we analyzed the answers given in the 
open text field of the question “Why do you think your diagnostic interval influenced your 
HRQoL negatively?”. The qualitative analyses showed that many participants reported 
psychological distress, physical disabilities, and worse prognosis due to their diagnostic 
interval length. 
Second, we describe the study among young adults. Many patients diagnosed with 
sarcoma are adolescents and young adults (AYA), forming a distinct group within the 
heterogeneous sarcoma population. Unique within this group of patients are their 
developmental issues and the life events they go through (e.g. becoming financially 
independent, caring for small children). Furthermore, the distribution of cancers and 
sarcoma histological subtypes differs from those diagnosed at older age. The characteristics 
of this specific group of patients may contribute to a prolonged diagnostic pathway. 
Since decades much attention has gone to researching factors for improvement among 
teenagers and young adults (TYAs), aged 12-24, but evidence regarding the diagnostic 
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pathway of young adults aged 25-39 is lacking. We conducted secondary analyses on 
a cross-sectional study in the United Kingdom about the diagnostic pathway of young 
adults aged 25-39 at cancer diagnosis in chapter 6. 
We analyzed data of 341 participants, including 22 sarcoma patients. The patient interval 
lasted >1 month in 53% of sarcoma patients, and >3months in 42%. When compared to 
breast cancer (reference group), there was a trend for a longer patient interval for sarcoma 
patients (OR=2.1 (95%CI 0.9-5.3)). The healthcare interval lasted >1month in 73%, which 
was significantly longer than for breast cancer patients (OR=14.1 (95%CI 4.9-40.8)). Nearly 
half of sarcoma patients (46%) had a healthcare interval >3 months. The patient interval 
was compared to a TYA cohort from the BRIGHTLIGHT study, which is a research program 
assessing specialist care for TYA with cancer in England[1, 2]. Its cohort is the largest study 
among TYA patients looking at diagnostic timeliness. The patient interval was >1 month 
in 32% of TYAs, compared to 53% in YAs. At a cut-off of 3 months, the difference was 
significant: 4% of TYAs compared to 13% of YAs. Participants identified themes to improve 
the diagnostic pathway, such as raising awareness, adequate information provision, and 
reducing passive waiting time. These advices were generally not age-specific and did not 
differ among sarcoma or rare cancers compared to the entire included YA population. 
Third, the design of the QUEST study is described in chapter 7. The QUEST study 
(QUality of life and Experiences of Sarcoma Trajectories) is a longitudinal, prospective, 
and international study, which aims to quantify total interval, identify factors associated 
with interval length, and determine the association between total interval and HRQoL, 
stage and tumour size at diagnosis, progression-free survival, and overall survival. Its 
prospective design will minimize recall and selection bias, generating reliable results. Its 
international design enables us to compare healthcare systems and identify healthcare 
system factors contributing to total interval length. All patients newly diagnosed with 
sarcoma at one of five Dutch or three English sarcoma centres between 2018-2020 were 
invited to participate. Participants completed a questionnaire as soon as possible after 
diagnosis, and were asked to complete four more questionnaires during the follow-up 
period of two years. Questions include the diagnostic pathway, HRQoL, quality of care, 
and impact of having a rare disease. Additional clinical data was extracted from electronic 
patient records. The study has included 311 Dutch patients and 228 English patients. 
The first results will be available early 2021 and will, hopefully lead to advices on how to 
improve quality of life and outcomes for patients with sarcoma. 
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De overleving van patiënten met sarcomen – een zeldzame groep van tumoren uitgaande van 
bot en steunweefsel – is helaas beperkt. In dit proefschrift onderzoek ik hoe het diagnostische 
traject van patiënten met sarcomen eruit ziet en of dit aanknopingspunten ter verbetering van 
overleving en kwaliteit van leven biedt. 
Sarcomen
Sarcomen zijn kwaadaardige tumoren die ontstaan in de botten of wekedelen, zoals 
de spieren of bindweefsel. Zij behoren tot de groep van zeldzame tumoren: ze vormen 
slechts 1,5% van alle soorten kanker die op volwassen leeftijd voorkomen. In Nederland 
worden per jaar ongeveer 200 patiënten met kwaadaardige bottumoren en 800 patiënten 
met kwaadaardige tumoren in de wekedelen gediagnosticeerd. Een huisarts zal tijdens 
zijn carrière waarschijnlijk slechts één of twee patiënten met een sarcoom in zijn praktijk 
hebben. Er zijn meer dan 100 verschillende soorten sarcomen geïdentificeerd, die zich 
stuk voor stuk anders gedragen met betrekking tot de specifieke diagnose, plaats in 
het lichaam waar zij voorkomen, de leeftijd van de patiënt waarop zij meestal ontstaan, 
agressiviteit van de tumor en overlevingskansen. Naast bot- en wekedelen sarcomen, 
krijgen in Nederland jaarlijks 400 patiënten een gastrointestinale stromatumor (GIST). Dit 
subtype sarcoom maakt geen onderdeel uit van dit proefschrift. 
Sarcomen die niet verspreid zijn naar andere plaatsen in het lichaam – dus niet zijn 
uitgezaaid -  worden in principe behandeld met een operatie. Het doel van deze 
behandeling is genezing. Afhankelijk van de agressiviteit van de tumor is aanvullende 
behandeling met radiotherapie noodzakelijk. Dat gebeurt toenemend vooraf aan een 
operatie. Voor sommige subtypes sarcomen maakt ook chemotherapie voor en/of na de 
operatie onderdeel uit van de primaire behandeling. 
Bij wekedelen sarcomen wordt zelden als onderdeel van de primaire behandeling 
chemotherapie gegeven. De indicatie wordt bepaald door het subtype sarcoom en bij 
extremiteitssarcomen met een hoog risico op uitzaaiingen, wordt chemotherapie ook 
overwogen voorafgaand aan de lokale behandeling. 
De behandeling van botsarcomen verschilt per subtype. De meest voorkomende 
subtypes zijn osteosarcomen, Ewing sarcomen en chondrosarcomen. De behandeling van 
(hooggradige) osteosarcomen bestaat uit een operatie in combinatie met chemotherapie 
vooraf en na de operatie. Ewing sarcomen worden behandeld met een combinatie van 
chemotherapie en een lokale behandeling die bestaat uit opereren, vaak in combinatie 
met bestraling. Als er niet geopereerd kan worden, bestaat de lokale behandeling alleen 
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uit bestraling. Chondrosarcomen zijn veel minder gevoelig voor chemotherapie; zij 
worden in het algemeen behandeld met alleen een operatie. 
Wanneer er uitzaaiingen zijn van een sarcoom wordt er gekeken of er nog een kans 
bestaat op genezing. Voor de meeste patiënten bij wie een sarcoom is uitgezaaid zijn de 
kansen op uiteindelijke overleving van de ziekte echter beperkt en richt de behandeling 
zich niet meer op genezing, maar op het verlichten van klachten en verlenging van 
leven. Afhankelijk van de hoeveelheid en plaats van de uitzaaiingen, de klachten die een 
patiënt hiervan ondervindt en de tijd die er zit tussen de diagnose en het ontstaan van 
de uitzaaiingen, wordt er gekozen voor een bepaalde behandeling. Dit kan een lokale 
behandeling zijn, zoals operatie of bestraling, of een systemische behandeling met 
(veelal) chemotherapie.
De overlevingskansen van patiënten met een sarcoom variëren sterk tussen de 
verschillende subtypes en het stadium bij diagnose. In het IKNL rapport “sarcomenzorg 
in Nederland” wordt een overzicht van de epidemiologie, aspecten en uitkomsten 
van zorg van volwassen patiënten met een sarcoom gegeven die zijn geregistreerd in 
de Nederlandse Kankerregistratie in  de periode 2009-2018. Dit rapport laat zien dat 
na 5 jaar 81% van patiënten met een laaggradig wekedelen sarcoom nog in leven is, 
terwijl dit slechts 46% is voor patiënten met een hooggradig wekedelen sarcoom[1]. 
Bij botsarcomen zijn deze percentages 93% en 60% respectievelijk, waarbij er nog een 
aanzienlijke variatie per subtype is. Ongeveer 7% van patiënten met een botsarcoom 
en 14% van patiënten met een wekedelen sarcoom hebben uitzaaiingen bij diagnose, 
maar ook hierbij is de variatie per subtype heel groot[1]. Bij botsarcomen had 42% van 
de patiënten met een Ewing sarcoom uitgezaaide ziekte bij diagnose, tegenover 2% bij 
chordomen. Bij wekedelensarcomen was de kans op uitzaaiing bij diagnose het grootst 
bij leiomyosarcoom: 25%, en het kleinst bij dermatofibrosarcoom: <1%[1]. 
Het diagnostisch traject
In het IKNL rapport “Kankerzorg in beeld: zeldzame kanker” uit 2018 wordt benoemd dat het 
diagnostische traject van zeldzame kankers vaak moeilijker is, langer duurt en leidt tot een 
slechtere uitgangssituatie[2]. Deze slechtere uitgangssituatie leidt mogelijk tot slechtere 
overleving of kwaliteit van leven. Doordat sarcomen zeldzaam zijn, op alle leeftijden 
voorkomen en geen typische klachten of symptomen hebben, is de diagnose sarcoom 
vaak moeilijk te stellen. Bovendien is er expertise nodig om tot de juiste histologische 
sarcoom diagnose te komen. Hierdoor is er na huisarts en perifeer specialist vaak nog een 
doorverwijzing naar een expertisecentrum nodig voor aanvullende diagnostiek.
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De tijd tot diagnose wordt gedefinieerd als het tijdsinterval tussen het moment waarop 
de patiënt voor het eerst een klacht ervaart die veroorzaakt wordt door een sarcoom, tot 
het moment van definitieve diagnose. Dit tijdsinterval noemen we het totale interval en 
kan worden onderverdeeld in een patiënt interval en diagnostisch interval. Het patiënt 
interval is de tijd tussen het ervaren van de eerste klacht en het moment waarop het 
eerste consult met een (huis)arts plaatsvindt. Het diagnostisch interval is de tijd tussen 
het eerste consult en het stellen van de diagnose sarcoom. Het diagnostisch interval 
kan verder worden onderverdeeld in een eerstelijns interval (de tijd dat een patiënt bij 
de huisarts is voor zijn klachten gerelateerd aan sarcoom), een tweedelijns interval (de 
tijd dat een patiënt door een medisch specialist in een algemeen ziekenhuis onderzocht 
wordt voor zijn klachten gerelateerd aan sarcoom) en een derdelijns interval (de tijd dat 
een patiënt door een medisch specialist in een sarcoom expertisecentrum onderzocht 
wordt).
Eerdere onderzoeken hebben laten zien dat de tijd tot diagnose heel variabel en lang is 
bij een groot deel van de patiënten met een sarcoom[3]. De tijd tot diagnose kan variëren 
van enkele weken tot jaren. Verschillende factoren zouden van invloed kunnen zijn op 
de duur van het totale interval. Deze kunnen worden onderverdeeld in patiënt factoren 
(bijvoorbeeld sociodemografische karakteristieken), tumor factoren (zoals histologisch 
subtype) en zorgsysteem factoren (bijvoorbeeld routes van verwijzing). 
Bij sommige vormen van kanker, zoals borstkanker, darmkanker of melanoom, is 
aangetoond dat een kortere tijd tot diagnose leidt tot een betere prognose[4]. Bij 
sarcomen is vooral onderzocht of een langere tijd tot diagnose leidt tot een grotere 
tumor, met een kleinere kans op een complete resectie en groter risico voor het krijgen 
van uitzaaiingen[5]. Onderzoek naar de relatie tussen tijd tot diagnose en overleving voor 
patiënten met sarcoom ontbreekt. 
Van oudsher zijn artsen vooral geïnteresseerd in klinische uitkomstmaten, zoals overleving. 
Patiënt gerapporteerde uitkomstmaten zijn nieuwere manieren om artsen en patiënten 
te informeren. Met behulp van patiënt-gerapporteerde uitkomsten geeft de patiënt zijn 
of haar mening en waardering over de eigen gezondheid. Kwaliteit van leven is een goed 
voorbeeld van een patiënt gerapporteerde uitkomstmaat. Kwaliteit van leven zegt iets 
over hoe de patiënt zijn functioneren ervaart op fysiek, psychisch en sociaal gebied. Tot 
dusver is er geen onderzoek gepubliceerd waarin gekeken is naar het effect van tijd tot 
diagnose op de kwaliteit van leven van patiënten met een sarcoom. 
186   |   Chapter 10
Doel van dit proefschrift
Het doel van dit proefschrift is om inzicht te krijgen in het diagnostisch traject van 
volwassen patiënten met een sarcoom, om risicofactoren van een lange tijd tot diagnose 
te vinden en het effect van een lange tijd tot diagnose op zowel klinische als patiënt 
gerapporteerde uitkomstmaten te bestuderen. 
De onderzoeken in dit proefschrift zijn uitgevoerd onder Nederlandse en Engelse 
sarcoompatiënten. In Nederland krijgen jaarlijks ongeveer 1200 en in Engeland 5000 
mensen de diagnose sarcoom. Deze twee landen hebben zowel een ander zorgsysteem, 
als ook verschillen ze in de organisatie van sarcoomzorg. Om deze reden is het mogelijk 
de invloed van zorgsysteemfactoren op het diagnostisch traject te bestuderen. In beide 
landen speelt de huisarts een grote rol: in het algemeen is dit de eerste dokter die 
mensen spreken over hun klachten, en deze bepaalt of een verwijzing naar het ziekenhuis 
noodzakelijk is. Indien er sprake is van een sarcoom, wordt de patiënt doorverwezen naar 
een sarcoom expertisecentrum. In Nederland is dit formeel geregeld voor patiënten 
met een botsarcoom, voor patiënten met een wekedelen sarcoom is dit een advies. In 
Engeland is zorg voor alle patiënten met een sarcoom formeel gecentraliseerd; in principe 
worden alle patiënten doorverwezen naar een expertisecentrum. 
Hieronder volgt een overzicht van de belangrijkste resultaten van dit proefschrift. Ten 
slotte volgen aanbevelingen voor toekomstig onderzoek. 
Resultaten van onderzoek beschreven in dit proefschrift
Hoofdstuk 2 geeft een overzicht van de huidige literatuur over het totale interval van 
sarcoompatiënten. Dit systematische literatuuronderzoek beschrijft 76 artikelen, die een 
zeer gevarieerde lengte van het totale interval laten zien: voor botsarcomen gemiddeld 
tussen de 9-120 weken en voor wekedelen sarcomen tussen de 4-615 weken. Patiënten 
met een botsarcoom die ouder zijn of bij wie geen radiologisch onderzoek wordt ingezet 
door de eerste arts, hebben een groter risico om een langere tijd tot diagnose te hebben. 
Voor patiënten met wekedelen sarcomen kunnen geen eenduidige resultaten met 
betrekking tot risicofactoren worden geformuleerd. 
Het effect van een langere tijd tot diagnose op klinische uitkomstmaten zoals overleving 
blijft onduidelijk omdat de studies tegenstrijdige resultaten laten zien. Er was geen enkel 
onderzoek dat het effect van langere tijd tot diagnose op kwaliteit van leven bekeek. 
Op basis hiervan kan geen tijdsduur geformuleerd worden die kan gelden als relevant 
afkappunt voor een kort versus lang interval. 
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Hoofdstuk 3 beschrijft de tijd tot diagnose zoals die ervaren wordt door volwassen 
sarcoompatiënten uit Engeland en Nederland. Voor deze studie werden vijftien patiënten 
geïnterviewd over hun tijd tot diagnose, factoren die ertoe geleid hadden dat ze snel of 
langzaam hulp van een dokter inschakelden, factoren die in hun ogen hadden bijgedragen 
tot een snelle of langzame verwijzing en het effect van tijd tot diagnose op hun kwaliteit 
van leven en tevredenheid over de zorg. 
Het totale interval van deze deelnemers varieerde tussen de 10 en 145 weken. Zowel 
patiënt als diagnostisch interval droegen bij aan de lengte van het totale interval: het 
patiënt interval wisselde tussen de 0 en 119 weken, het diagnostisch interval tussen de 
3 en 140 weken. Analyse van de interviews leverde inzichten op met betrekking tot vier 
thema’s: het patiënt interval, het diagnostisch interval, reflectie op tijd tot diagnose en 
aanbevelingen ter verbetering van het diagnostisch traject.
Ten eerste het patiënt interval, waarbij onderscheid kan worden gemaakt tussen het 
proces van beoordeling van de klachten en hulpzoekend gedrag. Op het moment dat 
een patiënt zijn/haar klachten ervoer als goedaardig, de klachten niet in de weg stonden 
van zijn dagelijkse bezigheden, of wanneer een persoon verwachtte dat de klachten 
vanzelf verdwenen, duurde het langer voordat iemand vond dat hulp noodzakelijk was. 
De belangrijkste aanleiding om hulp te zoeken was wanneer de klachten dagelijkse 
bezigheden belemmerden. 
Ten tweede het diagnostisch interval. Dit was lang door een zestal factoren: (1) het stellen 
van een verkeerde werkdiagnose, (2) een inefficiënt proces van aanvullende onderzoeken, 
(3) lange duur van periode van verwijzing(en), (4) ontwikkeling van de klachten anders 
dan verwacht, (5) een lange tijd tot pathologische diagnose en (6) het gebrek aan een 
hoofdbehandelaar. Engelse patiënten noemden vaker dan Nederlandse patiënten dat zij 
lang moesten wachten op onderzoeken en afspraken en dat hun artsen onder grote (tijds)
druk stonden. 
Het derde thema was reflectie op de tijd tot diagnose. Lange wachttijden, het krijgen 
van onterechte zekerheid en onjuiste informatie leidden tot ontevredenheid en een grote 
emotionele last. 
Tenslotte  benoemden patiënten factoren die het diagnostisch traject zouden kunnen 
verbeteren, zoals het vergroten van de bekendheid van sarcomen onder patiënten 
en artsen, het vergroten van de regie door de patiënt en het toekennen van één 
hoofdbehandelaar. 
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De resultaten bevestigden de bevindingen die beschreven zijn in het literatuuronderzoek, 
en legden de basis voor twee vervolgstudies, de SURVSARC en de QUEST. Daarnaast wordt 
in dit proefschrift een subanalyse van een derde studie onder Engelse jong volwassenen 
met kanker beschreven. 
Hoofdstuk 4 en hoofdstuk 5 beschrijven resultaten van de Survivorship Sarcoma 
(SURVSARC) studie. Het primaire doel van deze studie was het in kaart brengen van de 
kwaliteit van leven van sarcoompatiënten 2-10 jaar na diagnose.
Voor deze studie werden vanuit de Nederlandse Kanker Registratie patiënten geselecteerd 
die tussen 2008-2016 de diagnose sarcoom kregen en behandeld werden in een van de 
zes deelnemende sarcoom centra. 1099 (ex-)patiënten vulden eenmalig een uitgebreide 
vragenlijst in met vragen over hun diagnostisch traject, kwaliteit van leven, symptomen, 
ervaren kwaliteit van zorg, informatievoorziening en leven met een zeldzame ziekte. 
Aanvullende klinische informatie werd uit de Nederlandse Kanker Registratie gehaald. 
Voor dit onderzoek heb ik mij gefocust op de vragen met betrekking tot risicofactoren 
van een lang diagnostisch traject en gevolgen van de tijd tot diagnose voor de kwaliteit 
van leven. Hoofdstuk 4 beschrijft het diagnostisch traject van deze sarcoompatiënten. 
Uit deze gegevens blijkt dat het patiënt interval bij 60% ≥1 maand duurde, en bij 36% zelfs 
≥3 maanden. Patiënten met een sarcoom van de huid of in het bekken bleken langer te 
wachten voor zij hulp zochten, terwijl patiënten met een liposarcoom, rhabdomyosarcoom 
of stadium III ziekte eerder hulp zochten. Het diagnostisch interval duurde ≥1 maand 
bij 55% van de patiënten, en ≥3 maanden bij 28%. Vrouwen en patiënten jonger dan 
40 jaar en patiënten met een synoviaal sarcoom of chordoom, hadden vaker een lang 
diagnostisch interval. 
In hoofdstuk 5 wordt bekeken of de tijd tot diagnose effect had op de kwaliteit van 
leven van de patiënten die deelnamen aan de SURVSARC studie. Verondersteld werd 
dat mensen die een langere tijd tot diagnose hadden een slechtere kwaliteit van 
leven zouden hebben. Enerzijds door het psychische aspect van het lange wachten, 
anderzijds doordat de kanker mogelijk groter was, met een uitgebreidere behandeling 
en complicaties hiervan tot gevolg. De tijd tot diagnose bleek echter niet gerelateerd 
aan de gemeten kwaliteit van leven. Er werd ook gevraagd aan patiënten of zij dachten 
dat hun huidige kwaliteit van leven beïnvloed werd door de duur van het diagnostisch 
traject. Deze subjectieve beleving van de duur van het diagnostisch traject bleek wel 
geassocieerd met hun huidige kwaliteit van leven. Patiënten die vonden dat de tijd tot 
diagnose hun kwaliteit van leven negatief beïnvloedt, scoorden ook lager op de gemeten 
kwaliteit van leven schaal. Deze patiënten gebruikten vaker minder goede strategieën om 
met hun ziekte om te gaan dan de patiënten die geen of een positieve invloed ervoeren. 
Zij ervoeren bijvoorbeeld meer hulpeloosheid en waren minder geneigd om hulp te 
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zoeken of een probleem op te lossen. Daarnaast benoemden patiënten die een negatieve 
invloed van de duur van het diagnostisch traject ervoeren dat zij nog steeds last hadden 
van psychologische stress, lichamelijke beperkingen, en een slechtere prognose door de 
lengte van hun diagnostisch interval. Vroegtijdige begeleiding van deze groep patiënten, 
waarbij aandacht besteed wordt aan het diagnostisch traject en de manier waarop zij met 
hun ziekte omgaan, kan mogelijk bijdragen tot een verbetering in kwaliteit van leven. 
Veel patiënten die een sarcoom krijgen zijn relatief jong en vallen onder de groep 
adolescenten en jongvolwassenen (15-39 jaar op het moment van eerste kankerdiagnose). 
Deze groep patiënten onderscheidt zich van oudere volwassenen doordat zij in een andere 
levensfase zitten, die wordt gekenmerkt door een snel veranderende psychosociale 
ontwikkeling en levensgebeurtenissen zoals het afronden van een opleiding, het krijgen 
van een eerste baan, het aangaan van relaties  en het zorg dragen voor jonge kinderen. 
Deze karakteristieken kunnen leiden tot een langere tijd tot diagnose. Er is veel onderzoek 
gedaan naar het verbeteren van de diagnose voor jonge kinderen en adolescenten tot 24 
jaar, maar de groep 25-39 jaar is nauwelijks onderzocht. 
Om de kwaliteit van leven te bestuderen van jong volwassenen in de leeftijd van 25-
39 jaar met kanker werd een vragenlijst onderzoek gedaan onder Engelse patiënten. 
Deelnemende patiënten hadden in de afgelopen vijf jaar kanker gekregen en werden 
behandeld in een van de zes deelnemende ziekenhuizen. In de vragenlijst werden 
onder andere vragen gesteld over de diagnose, het diagnostisch traject, de kwaliteit van 
leven en ervaren kwaliteit van zorg. Voor dit onderzoek richtte ik mij op de vragen met 
betrekking tot het diagnostisch traject. Hoofdstuk 6 beschrijft het diagnostisch traject 
van deze 341 patiënten, waarvan er 22 een sarcoom hadden. Het patiënt interval van de 
341 respondenten duurde >1 maand in 53%, en >3 maanden in 42% van de gevallen. In 
vergelijking met de groep borstkanker patiënten hadden de patiënten met een sarcoom 
een langer patiënt en diagnostisch interval. Het patiënt interval van borstkanker patiënten 
duurde >1 maand in 34% van de gevallen, terwijl dit 53% was voor sarcoom patiënten. 
Het diagnostisch interval duurde >1 maand voor 16% van de borstkanker patiënten en 
voor 73% van de sarcoom patiënten. Het patiënt interval van de gehele groep deelnemers 
werd ook vergeleken met een groep tieners en adolescenten in de leeftijd van 12-24 jaar. 
De data van deze tieners kwam uit reeds gepubliceerde data van een ander onderzoek, 
waarin vergelijkbare vragen werden gesteld[6]. Het patiënt interval bleek langer te zijn 
voor de jongvolwassenen: 32% van de jongeren had een patiënt interval >1 maand, in 
vergelijking met 53% van de jongvolwassenen. Bij drie maanden was het verschil 4% 
versus 13% voor tieners versus jongvolwassenen. 
De jongvolwassenen gaven adviezen ter verbetering van het diagnostisch traject op 
een open antwoord vraag. Deze adviezen werden kwalitatief geanalyseerd en betroffen 
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het vergroten van de bekendheid van het voorkomen van kanker op deze leeftijd, het 
aanbieden van goede informatie aan de patiënt en het verminderen van wachttijden. 
De adviezen die gegeven werden door jongvolwassen patiënten met een zeldzame 
kanker verschilden niet van die gegeven door patiënten met een vaker voorkomende 
kankersoort. 
De onderzoeksmethode van de derde studie, de QUEST (QUality of life and Experiences 
of Sarcoma Trajectories) wordt beschreven in hoofdstuk 7. Het doel van deze studie is 
om zo nauwkeurig mogelijk de tijd tot diagnose te bepalen en factoren te vinden die 
leiden tot een kort of lang diagnostisch traject. Daarnaast heeft de studie tot doel om 
vast te stellen of er een relatie bestaat tussen tijd tot diagnose en uitkomstmaten zoals 
kwaliteit van leven, stadium en grootte van de tumor bij diagnose en overleving. Dit is 
een prospectieve studie waar patiënten uit vijf sarcoomcentra in Nederland en drie 
sarcoomcentra in Engeland aan deelnemen. Patiënten vullen een vragenlijst in direct 
na de diagnose, en vervolgens nog vier keer gedurende een periode van twee jaar. 
De vragenlijst bevat onder andere vragen over het diagnostisch traject, kwaliteit van 
leven, kwaliteit van zorg en het hebben van een zeldzame ziekte. Aanvullende klinische 
gegevens, zoals precieze diagnose, worden uit het elektronisch patiëntendossier gehaald. 
De opzet van deze studie zorgt er enerzijds voor dat patiënt- en tumorkarakteristieken 
bestudeerd kunnen worden die een risico vormen voor een lang diagnostisch traject. 
Anderzijds biedt deze studie ook de mogelijkheid om twee zorgsystemen met elkaar te 
vergelijken en gezondheidszorgsysteem specifieke factoren als ook eventuele culturele 
verschillen te onderzoeken. De studie heeft het benodigde aantal patiënten inmiddels 
geïncludeerd (311 Nederlandse en 228 Engelse patiënten).
Toekomstig onderzoek en aanbevelingen
Dit proefschrift heeft geleid tot meer inzicht in het diagnostisch traject van sarcoom 
patiënten, maar roept tegelijkertijd ook weer nieuwe vragen op. Nieuwe studies zouden 
een opzet moeten hebben die er zorg voor draagt dat de bias veroorzaakt door selectie 
(patiënten die al meer dan 2 jaar overleefd hebben zoals in de SURVSARC studie) en 
herinnering zo klein mogelijk gemaakt wordt. Deze bias kan tegen gegaan worden door 
een prospectieve opzet en het ontwerpen van grote, internationale studies. De QUEST-
studie is een goed voorbeeld van een dergelijke studie. Wij hopen dat de eerste resultaten 
van deze studie in 2021/2022 gepubliceerd kunnen worden, en dat deze leiden tot concrete 
adviezen voor het verkorten van het diagnostisch traject of verbeteren van kwaliteit 
van leven en andere uitkomstmaten. Behulpzaam hierbij zou zijn wanneer de data een 
klinisch relevante afkapwaarde voor een kort versus lang traject zou opleveren, welke zou 
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kunnen verschillen per subgroep sarcoom, zodat er gerichte verbeterstrategieën kunnen 
worden ingezet. 
Strategieën voor verbetering die gebuikt worden bij veel voorkomende kankers, zoals 
screeningprogramma’s, zijn niet geschikt voor zeldzame tumoren. Strategieën die zich 
richten op het vergroten van de bekendheid en het verbeteren van verwijzingen naar 
expertisecentra lijken meer effect te kunnen hebben voor patiënten met zeldzame 
kankersoorten, zoals sarcomen. 
Voor het meten van patiënt-gerapporteerde uitkomsten, zoals kwaliteit van leven, lijken 
schalen ontwikkeld voor patiënten met een veel voorkomende kankersoort minder 
geschikt om de verscheidenheid aan problemen bij sarcoom patiënten op te sporen. 
Dit kwam ook uit de SURVSARC-studie naar voren. Een mogelijke oplossing kan zijn om 
locatie-specifieke items toe te voegen aan een bestaande (algemene) vragenlijst, of om 
bijvoorbeeld locatie-specifieke sarcoomvragenlijsten te ontwikkelen. Een reeds lopende 
studie van de EORTC is erop gericht om een meetstrategie te ontwikkelen om kwaliteit 
van leven zo precies mogelijk te meten bij patiënten met een sarcoom.  
Conclusie
In dit proefschrift zijn de resultaten van onderzoeken beschreven bij patiënten met 
een sarcoom, waarvan het doel was om het diagnostisch traject te beschrijven en 
aanbevelingen te kunnen doen ter verbetering van de tijd tot diagnose. De onderzoeken 
in dit proefschrift laten zien dat sarcomen een groep vormen waarin veel variatie zit en 
dit maakt het lastig om te zeggen welke exacte duur van het diagnostisch traject een 
negatieve invloed heeft op overleving of kwaliteit van leven. Uit de SURVSARC studie 
blijkt dat patiënt gerapporteerde uitkomsten belangrijk zijn: zelfs jaren na diagnose gaven 
patiënten aan dat hun kwaliteit van leven negatief beïnvloed werd door de ervaren duur 
van het diagnostisch traject. 
De in dit proefschrift verworven inzichten dragen bij aan vooruitgang van zorg voor 
patiënten met een sarcoom. Er zijn echter nog veel uitdagingen om de zorg voor deze 
patiënten te verbeteren. Het is van belang om te bepalen welke patiënten een groot risico 
hebben op een lange tijd tot diagnose en welke gevolgen dit heeft voor hun overleving 
en kwaliteit van leven. Waarschijnlijk zal dit verschillen per subtype sarcoom, daarom zijn 
studies met grote aantallen patiënten noodzakelijk. De resultaten van de prospectieve 
QUEST studie zullen hier naar verwachting de eerste antwoorden op geven.
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Vicky Soomers werd geboren op 17 mei 1988 in Kerkrade. In 2005 voltooide zij de 
middelbare school aan het Eijkhagen college te Landgraaf (tweetalig VWO, cum laude) 
en in datzelfde jaar begon zij aan de studie geneeskunde aan de Radboud Universiteit 
te Nijmegen. Zij behaalde in 2012 haar artsexamen en kreeg direct een opleidingsplaats 
Interne geneeskunde in het Radboudumc, onder hoofdopleider prof. Dr. Jos van der Meer, 
en later prof. Dr. Jacqueline de Graaf en Dr. Gerald Vervoort. 
Van 2012-2015 werkte zij in het TweeSteden Ziekenhuis te Tilburg (thans Elisabeth-
TweeSteden Ziekenhuis) met als opleider Dr. Thomas Wierema, waar haar interesse in 
wetenschappelijk onderzoek werd gewekt. In 2014 besprak zij de mogelijkheden hiertoe 
binnen de afdeling Medische Oncologie van het Radboudumc met Prof. Dr. Winette van 
der Graaf. 
In 2015 zette zij haar opleiding voort in het Radboudumc, alwaar zij in 2016 begon met de 
differentiatie Medische Oncologie met als opleiders Prof. Dr. Koos van der Hoeven en Dr. 
Ingrid Desar. Met een subsidie voor een junioronderzoeker die door het Radboud Institute 
for Health Sciences was toegekend betreffende ‘The impact of the diagnostic trajectory in 
sarcoma patients on stage at diagnosis, primary treatment, clinical outcome and quality 
of life’ kon zij in 2017 haar promotie-onderzoek starten onder leiding van Prof. Dr. Winette 
van der Graaf, Prof. Dr. Lonneke van de Poll-Franse, Dr. Ingrid Desar en Dr. Olga Husson. 
Tussen mei en november 2019 werd het promotie-onderzoek part-time voortgezet, en 
verrichte zij tevens stageonderdelen van de opleiding tot internist-oncoloog. Sinds medio 
mei 2020 richt zij zich weer op haar opleiding tot internist-oncoloog, welke ze in augustus 
2021 hoopt af te ronden. 
Vicky is getrouwd met Joep van Dijk. Samen hebben zij een zoon (Arthur, 2020). Joep 
heeft twee dochters (Meike, 2012; Jasmijn, 2014). 
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Research data management
The data obtained during my PhD at the Radboud university medical center (Radboudumc) 
have been captured and stored via the PROFILES database (www.profilesregistry.nl). 
Coded data was additionally backed-up on university servers in “Statistical Package for 
the Social Sciences” (SPSS) files. These files did not contain information regarding the 
identity of the patient (such as name or social security number), and only contained 
coded-anonymous data. 
Data were stored on both my digital personal Radboud workplace environment and a 
communal Radboud drive. Only researchers within the study team have access to this 
drive. In this manner, the data can be used for future research.
Transcribed interviews used in my qualitative study were stored on servers of the 
Radboudumc in “Atlas.ti” files. These were password protected and do not contain 
information regarding the identity of the patient. 
The medical and ethical review board committee of the Radboudumc in the Netherlands 
or The Research Ethics Committee in the United Kingdom have given approval to conduct 
the studies within this thesis in which patients were involved. All studies comply with the 
standards of the Declaration of Helsinki. 
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Dankwoord
Dit proefschrift was nooit tot stand gekomen zonder de inzet van vele anderen, die ik 
hiervoor graag zou willen bedanken. Allereerst wil ik alle patiënten bedanken die hebben 
deelgenomen aan de studies in dit proefschrift. Door hun deelname in een moeilijke 
periode in hun leven, zijn wij in staat om de zorg voor sarcoompatiënten te verbeteren. 
Daarnaast ben ik veel dank verschuldigd aan mijn promotieteam. 
Prof. Dr. van der Graaf, beste Winette, bedankt dat je me de mogelijkheid gegeven hebt 
om mijzelf op wetenschappelijk gebied verder te ontwikkelen. Je legt de lat hoog, dat 
heeft mij altijd gestimuleerd om het goed te willen doen. Ik heb veel geleerd van je kennis 
en ervaring, en je netwerk heeft voor mij vele deuren geopend. De inkijk in het Engelse 
zorgstelsel heeft mijn blik verder verbreed en daar zal ik de rest van mijn carrière gebruik 
van maken. Daarnaast was er ruimte om andere dingen met je te delen. Dank daarvoor! 
Prof. Dr. van de Poll-Franse, beste Lonneke, jouw kennis over met name de methodologie 
heeft de kwaliteit van onze studies enorm geholpen. Ondanks ons laagfrequente contact 
had jij altijd oog voor  de dingen die buiten het promotieonderzoek speelden. Bedankt 
voor de prettige samenwerking! 
Dr. Desar, beste Ingrid, na onze kennismaking in 2014 werd mij duidelijk dat een 
promotieonderzoek kunnen doen niet vanzelfsprekend was. Toen ik in 2016 startte 
met mijn differentiatie was dit nog steeds onzeker. Dank voor je inzet om mij dit 
promotieonderzoek te kunnen laten combineren met de opleiding tot internist-
oncoloog. De afgelopen jaren hebben we intensief samengewerkt en is mij gebleken dat 
ik op veel vlakken op je lijk. Ik waardeer je kritische blik, directe communicatie en kennis 
enorm. Je gaf (en geeft als opleider nog steeds!) mij kaders, maar laat me daarbinnen 
mijn eigen keuzes maken. Dank voor je begeleiding en inzet om van mij een betere arts(-
onderzoeker) te maken!
Dr Husson, beste Olga, het begon op een koude maar zonnige dag in het AvL, voerde 
ons vele malen langs Londen en Nijmegen, en een enkele keer naar Strijbeek, Rome, 
Barcelona, Milaan en Birmingham. Mijn promotietijd eindigt op zomerse dagen achter 
mijn computer op zolder, met jou aan de telefoon aan de eettafel in Strijbeek. Zonder jouw 
gastvrijheid, lach, en wekelijks contact waren de afgelopen jaren een stuk saaier geweest. 
Je wist mij niet alleen wegwijs te maken in het Britse zorgsysteem en de Londense metro, 
zonder jouw kennis en daadkracht was dit proefschrift nu niet afgerond. Je ‘pure’ kijk op 
statistiek en mogelijkheid om dit samen te koppelen aan de kliniek heeft de kwaliteit van 
de studies en publicaties bepaald. Ik hoop dat er nog veel wijntjes volgen op terrassen 
of – wie zal het zeggen – in de KLM lounge! 
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De leden van de manuscriptcommissie, professor Verheij, professor Merkx en professor 
Muris, wil ik hartelijk danken voor het beoordelen van dit proefschrift. 
Alle co-auteurs en leden van de sarcoomketens van alle deelnemende centra wil ik 
bedanken voor de bijdrage aan deze studies, van opzet en inclusie, tot toevoegingen aan 
de manuscripten. Zonder jullie vertrouwen in mij en onze samenwerking zou gedegen 
sarcoomonderzoek onmogelijk geweest zijn. 
Dank aan de collega’s van IKNL en profielstudies voor jullie ondersteuning bij de 
uitvoering van de studies in dit proefschrift. Sommigen van jullie zetten je nog steeds in 
voor de QUEST, dank daarvoor! 
A special thanks to our British team members! Eugenie, thank you for the work you’ve 
put in the QUEST UK study the past year! Emma, thanks for sharing the YA database with 
me, your practical help, and Christmas drinks! Helena, thanks for your stories and help 
with running the QUEST and doing the data management. Dr. Robin Jones and staff 
of the sarcoma unit, thank you for welcoming me to the Royal Marsden and providing 
me with an insight in sarcoma care in London. Doing research in two countries gave me 
experiences valuable for the rest of my career. 
Prof. Dr. Burger, beste David, als mentor heb ik je gelukkig niet vaak nodig gehad. 
Bedankt voor je beschikbaarheid en adviezen de afgelopen jaren. 
Er zijn een aantal mensen die een belangrijke bijdrage geleverd hebben en mij gemotiveerd 
hebben om de stap te nemen om promotieonderzoek te gaan doen. Een paar van hen 
wil ik persoonlijk bedanken. Dr. Wierema, beste Thomas, jij was het die vond dat ik toe 
was aan wetenschappelijke verrijking en mij stimuleerde tot dat eerste gesprek in het 
Radboudumc. Bedankt dat je mij destijds gestimuleerd hebt! Dr. Faes, beste Miriam, als 
enige gepromoveerde collega-aios in Tilburg enthousiasmeerde jij mij ook om deze kans 
te grijpen. Jij bent voor mij een voorbeeld als mens, dokter, en moeder.
Beste collega’s uit de dungeon; Minke, Eline, Martine, Wim, Maarten, Mark, Karin, 
Wouter, Sarah, Janneke, Annelieke, Dide, Gerben, Kim, Maike, Marije, Sandra, Sophie, 
Lotte, Jorien en Iris, wat fijn om voor alles bij jullie binnen te mogen lopen. Beste Minke, 
mijn all-time roomie, bedankt voor alle theetjes, wandelingen, verjaardagslunches en het 
helpen vullen van de enveloppen! 
Mijn opleiders, Prof. Dr. Jacqueline de Graaf, Prof. Dr. Jan Smit, Dr. Gerald Vervoort, 
Prof. Dr. Ir. Koos van der Hoeven, Dr. Ingrid Desar, Prof. Dr. Carla van Herpen, 
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Dr. Anja Timmer-Bonte, bedankt dat jullie mij in staat gesteld hebben om mijn opleiding 
tot internist te combineren met mijn promotieonderzoek. 
Dank aan alle collega’s van de afdeling medische oncologie voor de fijne werksfeer 
de afgelopen jaren, in het bijzonder mijn mede (oud-)fellows die ook dit bijzondere 
pandemie-jaar zorgen voor persoonlijk contact.  
Mijn lieve vriendinnen en jullie partners, jullie geven kleur aan mijn leven! Sanne, Josanne, 
Laura, Simone, Rebecca, Lianne, Anne, Iris, Ingrid, Carlijn, met elk van jullie heb ik een 
bijzondere vriendschap die mij heel dierbaar is. Ondanks vaak hetzelfde antwoord bleven 
jullie mij vragen hoe het ervoor stond met mijn promotieonderzoek. Het is af! 
Mijn paranimfen. Sanne, onze vriendschap hoeft niet in woorden uitgedrukt te worden. 
Dank dat jij al meer dan 20 jaar aan mijn zijde staat en nooit meer dan één telefoontje ver 
weg bent. Rebecca, mijn partner in crime. Onze sparringmomenten en de spiegel die jij 
mij voorhoudt zijn onbetaalbaar. 
De letter D, mijn schoonfamilie, Kees en Thea, Lieneke en Bart, Bram en Tessa, 
Marlijn, jullie leerden mij kennen toen ik net gestart was met mijn promotieonderzoek, 
en hoewel het soms misschien moeilijk te volgen was waar ik nou eigenlijk mee bezig was, 
bleven jullie informeren hoe het ervoor stond. Lieve Kees en Thea, bedankt dat jullie mij 
op deze manier in jullie gezin hebben opgenomen! 
Mijn familie, waarin flink gediscussieerd kan worden maar we altijd het beste met elkaar 
voor hebben. Lieve Luc, Alette, Melissa en Guido, bedankt dat jullie er altijd voor mij zijn! 
Lieve papa en mama, jullie hebben mij altijd gestimuleerd om te doen wat ik leuk vond, 
en daarin het beste naar boven te halen. Al kon ik zo slecht leren dat ik wel internist moest 
worden ☺, jullie hebben mij altijd gesteund. Ik hou van jullie!   
Meike en Jasmijn, een onverwachte toevoeging aan mijn leven. Jullie zijn twee slimme 
en bijdehante tantes, het is genieten om jullie bezig te zien met een knutselwerk of jullie 
broertje. 
Lieve Arthur, ik kan nu zeggen: een proefschrift afronden is niets vergeleken met een 
bevalling. Wat houd ik veel van jou! 
Lieve Joep, in korte tijd hebben we al veel beleefd! De naam ‘QUEST’ is aan jou te danken. 
Bedankt voor het luisteren naar mijn gemopper en het geven van je (on)gevraagde advies. 











































voor het bijwonen van de 
(digitale) openbare verdediging 
van mijn proefschrift getiteld
Op maandag 14 juni 2021
om 14:30 uur precies in de Aula van 
de Radboud Universiteit Nijmegen
Gezien de geldende corona 
maatregelen, wordt er beperkt 
publiek toegang toegelaten
tot de aula. Genodigden 
ontvangen voor de plechtigheid 
een persoonlijke uitnodiging
De verdediging is digitaal te volgen 
via onderstaande livestreamlink:
www.ru.nl/aula/livestream
Paranimfen
Sanne Alleleijn
sannealleleijn@live.nl
Rebecca Verheggen 
rebecca_verheggen@hotmail.com
